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OBJECTIVES OF THE THESIS
The recurring theme of this thesis is the assessment in daily practice (i.e. after approval) 
of the value of lamotrigine, a relatively new drug in the treatment of epilepsy. The case 
of lamotrigine illustrates the need for effectiveness data in addition to the efficacy data 
obtained in randomised clinical trials. In addition, lamotrigine was the first drug in the 
Netherlands for which a prescription guideline aiming at cost containment was applied.
The main objectives of this thesis are to gain insight in: 
• the positioning of new antiepileptic drugs;
• the outcomes in patients using lamotrigine;
• clinical and health policy decision making.
Research principles and methods from pharmacoepidemiology and pharmaco-
economics will be applied to attain these objectives. The remainder of this introductory 
chapter provides information on epilepsy and its drug treatment, the learn-confirm 
cycle of drug evaluation and the differences between randomised controlled trials and 
observational studies. At the end of this chapter the outline of the thesis is given.
EPILEPSY
Epilepsy is a neurological disorder characterised by recurrent, unprovoked seizures 
(1). Epilepsy is not a uniform condition, but comprises many different seizure types and 
epilepsy syndromes. An epileptic seizure is the clinical manifestation of an abnormal 
and excessive synchronised discharge of a set of cerebral neurones (2). These clinical 
manifestations are sudden and transient and can include a wide variety of movement, 
feeling or psychic disturbances, with or without alteration in consciousness. Seizures are 
broadly divided into two categories: partial and generalised. Partial seizures arise in a so-
called epileptogenic region in one hemisphere of the cerebral cortex. They are subdivided 
into simple partial seizures, which occur without alteration of consciousness, and 
complex partial seizures, in which consciousness is impaired or lost. These seizures may 
generalise into a secondary generalised tonic clonic seizure. Primary generalised seizures 
are characterised by more diffuse neuronal discharges involving both hemispheres of 
the brain at once and always result in loss of consciousness.
Epilepsy is one of the most common neurological disorders. The prevalence is around 
0.5% - 1%; it is assumed that there are about 100,000 individuals with epilepsy in the 
Netherlands (3). The incidence in industrialised countries has been estimated to be 
around 50 cases per 100,000 persons per annum (range 40 - 70/100,000 people per 
annum) (3,4). The incidence varies greatly with age with peak rates occurring in early 
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childhood and in those aged over 65. Epilepsy has a great impact on patients’ lives. 
Restrictions of work or schooling are among the most frequently stated impacts in all 
age groups and severity groups (5). In adults, driving restrictions were also frequently 
stated as a far-reaching consequence. People with epilepsy are more often unemployed 
and experience limited choice and advancement in the workplace. It has been found that 
the quality of life, particularly in psychological and psychosocial domains, is markedly 
diminished in patients with active epilepsy, which may be partly drug-induced (5).
GENERAL PRINCIPLES OF TREATMENT
Drug therapy is the mainstay of epilepsy management, although resective surgery 
has become a realistic option for patients with certain types of difficult-to-treat epilepsy. 
The field of antiepileptic drug therapy has been an unusual one, being dominated for 
decennia by older drugs such as carbamazepine, phenobarbital, phenytoin and valproate 
(figure 1) (6). Several limitations of these conventional antiepileptic drugs restrict their 
use. First, the adverse effects of these antiepileptic drugs are troublesome. Monotherapy 
trials show that a majority of patients can expect to experience adverse effects related 
to their medication (7,8). These adverse effects may vary from mild feelings of fatigue to 
life-threatening hypersensitivity reactions. 
Second, some of the conventional antiepileptic drugs have complex pharmacokinetic 
properties and considerable potential for drug interactions with numerous other drugs. 
A third limitation of the conventional antiepileptic drugs is that they are associated with 
an increased risk for major foetal malformations
The decision to initiate drug therapy therefore depends on a difficult-to-define 
balance between the likelihood of further seizures versus the possible drawbacks of 
therapy (9). The aim of treatment is to abolish seizures completely, while keeping the 
adverse effects of treatment to a minimum. Treatment with a single drug is generally 
PB: phenobarbital. PHT: phenytoin. ESM: ethosuximide. CBZ: carbamazepine. VPA: valproate. CLZP: clonazepam. VGB: 
vigabatrin. OXC: oxcarbazepine. LTG: lamotrigine. FBM: felbamate. TPM: topiramate. GBP: gabapentin. LEV: levetiracetam
Figure 1. Approval dates of antiepileptic drugs in the Netherlands
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preferred, because monotherapy is associated with less-intrusive regimens, better 
tolerability and absence of interactions with other antiepileptic drugs. Monotherapy is 
initiated by gradually increasing the dose until seizures are controlled or adverse effects 
become unacceptable.
The outcome of therapy in newly-diagnosed patients with epilepsy is reasonably 
good. Around 60% of new epilepsy patients will be satisfactorily controlled with 
the first or second antiepileptic drug (figure 2) (10). The most powerful predictor of 
refractory epilepsy is response to the first or first two antiepileptic drugs. This supports 
the hypothesis that patients with newly-diagnosed epilepsy comprise two distinct 
populations. The aforementioned 60 to 70% have a good prognosis, and become seizure 
free on a modest dose of the first- or second-line antiepileptic drug without developing 
intolerable adverse effects. The remaining 30 to 40% of the patients have refractory 
epilepsy and despite combination therapy will not become seizure free (11,12). The 
aim of therapy for these patients should be a balance between seizure control and an 
optimal quality of life. With over ten different antiepileptic drugs currently available, 
there are more than 80 possible two- and three-drug combinations. A point of criticism 
on current practice has been that most of the combinations used are based on empirical 
decisions rather than on rational choices (13). Recently, however, more information on 
rational polytherapy has become available (11). 
Rational polytherapy Surgical assessment
Seizure free
Seizure free
Seizure free
Newly diagnosed epilepsy
First drug
Second drug
Third drug
47%
13%
1%
Adapted from Kwan et al. (10).
Figure 2. Staged approach to epilepsy management
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NEW ANTIEPILEPTIC DRUGS
A number of new antiepileptic drugs has become available in the Netherlands from 
1990 onwards (figure 1). In the comparative trials to date, the newer drugs have not 
yet demonstrated better efficacy compared to conventional drugs, but the newer drugs 
are claimed to lead to a better quality of life. This improvement has been attributed to 
various factors, but mainly to more acceptable adverse effect profiles. It is likely that 
there will be a substantial market for any antiepileptic drug that has proven to address 
the limitations of the conventional antiepileptic drugs. The acquisition cost of the new 
antiepileptic drugs are, however, a factor 5 – 20 higher than that of the older generation 
of drugs. Because epilepsy represents one of the most common neurologic disorders, an 
indiscriminate switching from old to new antiepileptic drugs would have considerable 
health economic implications (6). The crucial issue for new antiepileptic drugs is, however, 
not their cost, but their cost-effectiveness. Rational drug use taking cost into account 
can be seen as the end phase of the learn-confirm cycle of drug evaluation (figure 3). 
Evaluation can be achieved in four successive steps; efficacy, accessibility, effectiveness 
and cost-effectiveness. In each step both therapeutic and financial aspects are taken 
into account, the different steps are addressed below (14). 
Cost effectiveness Effectiveness
New drug
Efficacy
Accessibility
Figure 3. Learning-cycle in drug development
Adapted from Pronk et al. (14).
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EFFICACY OF NEW ANTIEPILEPTIC DRUGS 
The Netherlands has a strict programme for the evaluation of new drugs (15). 
The registration authority requires proof of efficacy and safety before the drug can 
be introduced to the market. It is an established fact that evidence for demonstrating 
efficacy can best be obtained through randomised controlled trials, in which eligible 
patients are randomly assigned to either a group using the new drug or to a comparison 
group (16). New antiepileptic drugs receive regulatory approval as a result of placebo-
controlled, add-on randomised controlled trials, in patients with refractory epilepsy. The 
primary efficacy parameter is usually a 50% or more reduction in seizure frequency in 
the trial period, compared to the baseline seizure frequency. Attempts have been made 
to provide a comprehensive systematic quantitative review of antiepileptic drug efficacy 
by combining the results of all available data from the placebo-controlled clinical trials 
(17,18). These meta-analyses showed a trend towards a better efficacy with drugs such 
as topiramate and vigabatrin than with drugs such as gabapentin and lamotrigine 
(figure 4). These reviews have been criticised on various counts, and the consensus is 
that different results would have been obtained if different dosages had been used for 
the various drugs (2,19). 
Mean (95% confi dence interval) number needed to treat to get one responder (defi ned as a patient with at least 50% 
seizure reduction) with each of six drugs. Adopted from Marson et al. (17) and Elferink et al. (40).
Figure 4. Efficacy of new antiepileptic drugs
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Regulatory approval efficacy studies provide information that only scratches the 
surface of potentially available information about a new drug (20). Regulatory trials 
are designed primarily to prove that a drug works (compared to placebo) in patients 
to whom it is given. These randomised controlled trials typically take place in highly 
selected populations in standardised situations, in order to make the statistical 
evaluation of efficacy more efficient (21). Patients with multiple diseases, compliance 
problems and other complex health problems are often excluded (20,22). Moreover, 
the regulatory trials of new antiepileptic drugs examine efficacy over a short duration, 
typically only 3-6 months. It is taken on faith that the effect will not wane over a longer 
period. Whenever new antiepileptic drugs have reached the market, there have been on 
average 3,000 patient exposures over several years’ duration (20). This limits the amount 
of safety data available from randomised controlled trials, as detection of rare adverse 
drug effects requires a longer follow-up of large groups of patients.
ACCESSIBILITY OF NEW ANTIEPILEPTIC DRUGS
In an insurance-based healthcare system, like the Dutch one, crucial to the accessibility 
of care is the decision made on reimbursement (23). In this stage it is decided whether a 
regulatory approved drug is included in the benefit package and under which conditions. 
As far as social health insurance is concerned, in the Netherlands the reimbursement 
decision is made by the government with an important advisory and implementation 
role for the Health Care Insurance Board (College voor zorgverzekeringen). Private 
insurance companies have full autonomy in deciding what to include in their insurance 
policies. In practice, however, they tend to follow the corresponding packages in the 
social health insurances.
The case of lamotrigine illustrates that registration and reimbursement decisions 
have become clearly distinct processes. Market approval was obtained from the Dutch 
Medicines Evaluation Board in 1995. A reimbursement decision, however, was not taken 
until almost two years later by the Health Care Insurance Board. The late reimbursement 
decision was a consequence of the high acquisition cost of lamotrigine and the relative 
lack of information about actual clinical (added) value at the moment of approval. This 
deadlock was ended when the Health Care Insurance Board imposed restrictions on the 
claim made for the drug. These restrictions were included in a prescribing guideline 
that was subsequently published. The Lamotrigine Prescription Guideline restricted 
the use of lamotrigine to patients with refractory epilepsy who failed three consecutive 
drug treatments, i.e. a patient population rather similar to that in the regulatory trials. 
The Lamotrigine Prescription Guideline was the first prescription guideline in the 
Netherlands aiming at cost containment and is also used for the antiepileptic drugs 
introduced after lamotrigine. 
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EFFECTIVENESS OF NEW ANTIEPILEPTIC DRUGS
Effectiveness studies focus on the net benefit of a drug therapy applied in daily 
clinical practice. Figure 5 shows a prototypical description of the distribution of several 
patient populations along the dimension of disease severity (22). For regulatory trials of 
new antiepileptic drugs, patients are recruited who have refractory epilepsy, i.e. patients 
tend to be positioned at the right side of the figure. Once an antiepileptic drug is on the 
market and physicians have become familiar with its use and safety, it is often used for 
patients with less severe epilepsy and for patients excluded from the trials because of 
age, co-morbidity et cetera (24). Thus, daily clinical practice results in drug exposure to 
patients from mild to moderate regions of disease severity, as is shown in figure 5. The 
applicability of trial results to clinical practice is limited, as a result of the large variations 
in patient characteristics in real life (21,25).
Pharmacoepidemiological research is concerned with the describing and explaining 
of the dynamics of drug exposure, as well as with the detecting and unravelling of 
drug-effect relations in large populations. These studies often are observational in 
nature. Inherent to the non-experimental design of such studies is that the findings are 
more susceptible to bias than clinical trials and are therefore judged as a lower degree 
of evidence than trials. For example, if a drug is perceived as highly effective, patients 
with more severe disease activity may be more likely to receive it. Patients with mild 
disease activity may be given a drug perceived as “safe”. Confounding by indication, due 
to the non-random assignment, may bias the outcome of observational studies. After 
their introduction, new antiepileptic drugs have to compete with the drugs already on 
the market. This can result in selective prescribing of the new drugs, e.g. for patients not 
Theoretical distribution of disease severity in a “normal” patient population, in a randomised controlled trial (RCT), 
and in patients receiving drugs in daily clinical practice (Drug A). Adopted from Leufkens et al. (22).
Figure 5. Theoretical distribution patient populations
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responding to previous therapy or suffering from adverse effects. Selective prescribing, 
or channelling, may hamper valid observational comparisons between different 
antiepileptic drugs (26,27). For example, figure 6 appears to suggest that lamotrigine 
is more effective than gabapentin, when assessed by the cumulative persistence rate. It 
may well be, however, that the gabapentin group of patients was not comparable to the 
lamotrigine group with respect to disease severity, due to the fact that both drugs were 
introduced at two distinctive points in time. 
Although observational studies have lower internal validity than randomised 
controlled trials, they have better external validity as observational studies often 
represent daily clinical practice patients, whereas trials often include a highly selected 
study population for a limited period of time. Observational drug evaluation in daily 
clinical practice is therefore complementary to experimental research. Observational 
research can offer a clearer picture of the actual value of new antiepileptic drugs in 
terms of effectiveness and safety. Observational studies with new antiepileptic drugs 
have shown that the long-term effectiveness in patients with refractory epilepsy was 
modest. A long-term persistence (i.e. the number of patients that continue drug use) of 
as low as 15% over six years has been reported in these patients (figure 6) (28-30). 
As mentioned above, safety issues are rarely explored within the context of clinical 
trials. Observational studies with some of the new antiepileptic drugs confirm the need 
for continued vigilance in this area (31). Vigabatrin, for instance, may cause severe and 
Adopted from Wong et al. (41).
Figure 6. Estimated persistence rate of new antiepileptic drugs in patients 
                   with refractory epilepsy
Vigabatrin
Lamotrigine
Gabapentin
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irreversible visual-field constriction (32). This case illustrates the differences between 
efficacy and effectiveness. Vigabatrin was assumed to be relatively highly efficacious, 
when assessed with pooled short-term randomised controlled trial data (figure 4). 
However, in long-term observational studies the value of vigabatrin proved to be limited 
due to insufficient effectiveness and severe adverse events (figure 6).
There is ongoing controversy in medical literature between scientists who adopt 
the outcome of randomised controlled trials solely, and those who advocate the use 
of observational studies to evaluate the effectiveness of health care (33-35). Instead 
of advocates of each approach criticising the other method, an attempt should be 
made to integrate results from both methods, as they both contribute relevant and 
complementary information upon which the value of drug therapy can reliably be 
based.
COST EFFECTIVENESS OF NEW ANTIEPILEPTIC DRUGS
All modern, regulated healthcare environments struggle with such problems as 
ensuring the quality of care and equity, macro-economic cost control and micro-
economic efficiency (36). An area of ongoing concern for policy makers in Western 
countries is the rapid increase of pharmaceutical expenditures, which is due to factors 
like ageing of the population and the introduction of new, expensive drugs. In most 
Western countries pharmaceutical expenditures has reached 10 - 20% of the total 
healthcare budget. As in many other countries, in the Netherlands there is a growing 
tension between rising demand for health care and political pressure to contain its costs 
(23). This tension has led to the insight that new health technologies (e.g. new drugs) 
should not be incorporated without an evaluation of their added value compared to 
current standards or acceptable options. This added value must be established in order 
to gain widespread reimbursement from payers, broad acceptance from providers and 
patients, and approval from society at large. 
The interest in economic evaluations of epilepsy therapy is related to the high 
prevalence and chronicity of the illness. Economic evaluations involve the comparative 
assessment of all courses of action in terms of their clinical consequences and resource 
costs (37). By making all relevant costs and consequences explicit, cost-effectiveness 
analysis aims to provide information on rational drug use for decision makers on both a 
macro and a micro level. On a macro level, policy makers like the Health Care Insurance 
Board has taken the initiative to introduce economic appraisal in the reimbursement 
procedures (23). On a micro level, information on cost-effectiveness can be very helpful 
in defining standards or clinical guidelines for good medical practice. Holloway held a 
survey among a random selection of United States neurologists on the topic of allocating 
finite resources with an emphasis of decisions on costly drugs (38). Most neurologists 
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acknowledged the need to ration health care, and they believed that cost-effectiveness 
research is one method to achieve efficient distribution of resources.
Decision-analytic models are the most commonly used approach for economic 
assessment in epilepsy research to date. This technique attempts to synthesise the best 
data available from both randomised clinical trials and observational studies. These 
models compare alternative treatments by combining available data into a “simulated 
experiment”. Each possible outcome or complication of treatment is assigned both a 
probability and a utility (clinical, functional or economic), based on the best available 
data. The validity of this process is based on the assumption that the consequences of 
treatment decisions can be composed into a finite set of discrete events and well-defined 
probabilities (39). Cost-effectiveness analyses of new antiepileptic drugs in patients with 
refractory epilepsy are presented in table 1. However, the studies are not comparable, as 
different approaches were used and the results were not expressed uniformly.
OUTLINE OF THE THESIS
This thesis contains five chapters. In this introductory chapter (chapter 1) the 
scope, objective and outline are described. Next, the individual research projects of 
the thesis are addressed in three chapters: the positioning of new antiepileptic drugs 
in general and lamotrigine in particular (chapter 2); the outcomes in patients using 
lamotrigine (chapter 3); and clinical and health policy decision making (chapter 4). The 
methodological framework and future perspectives are discussed in chapter 5.
Positioning of new antiepileptic drugs (Chapter 2)
Chapter 2.1 reviews clinically relevant selection criteria for new antiepileptic drugs. 
In chapters 2.2 and 2.3 data is used of the Dutch Information Project database, which 
contains dispensing information from over 5 million compulsorily insured patients. 
Chapter 2.2 describes the utilisation of antiepileptic drugs on a macro level, with an 
emphasis on the cost implications of newly-introduced drugs. Chapter 2.3 compares the 
prescription patterns of lamotrigine with those of three conventional antiepileptic drugs. 
This study specifically addresses the diffusion of lamotrigine in clinical practice, with a 
focus on selective prescribing and changes therein over time. Chapter 2.4 describes the 
patterns of lamotrigine use during the first years after introduction in the Netherlands, 
using prescription data of almost 3,600 lamotrigine-using patients identified from over 
1,000 community pharmacies.
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Outcomes in patients using lamotrigine (Chapter 3)
Chapter 3 is about the evaluation of the effectiveness of lamotrigine in daily practice. 
This assessment uses a phased approach, and key elements of this approach are: the 
recruitment of a sample of patients from the lamotrigine database and the evaluation 
of the differences between patients who gave informed consent and those who did 
not (chapter 3.1); the evaluation of the effectiveness of lamotrigine by means of a 
retrospective chart study (chapter 3.2); and the linking of data on clinical outcome with 
resources used in a cost-effectiveness study of lamotrigine (chapter 3.3). Finally, chapter 
3.4 describes the validation of several prescription patterns; by comparing information 
from the pharmacy records with information obtained from medical charts. 
Clinical and health policy decision making (Chapter 4)
Chapter 4.1 describes a survey into the awareness and acceptance among Dutch 
neurologists of the Lamotrigine Prescription Guideline that followed the reimbursement 
decision. Based on the results of this survey, interviews with several stakeholders were 
held by us to gain a better understanding of their perception of policy measures like 
prescription guidelines (chapter 4.2). Chapter 4.3 presents a decision analytic model on 
the use of lamotrigine as a first-line antiepileptic drug. In this chapter costs and effects 
of lamotrigine treatment are compared with those of the conventional antiepileptic 
drugs carbamazepine and valproate.
General discussion and future perspectives (Chapter 5)
Finally, in chapter 5 the theoretical framework and the generic issues from the 
research projects are discussed and a future perspective on the value assessment of 
new drugs in daily practice is presented. 
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ABSTRACT
Objective
In recent years, several new antiepileptic drugs have been licensed: felbamate, 
gabapentin, lamotrigine, levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin 
and zonisamide. This article gives an overview of the available pharmacological 
information on these new antiepileptic drugs. This article aims to give detailed 
background information on the new antiepileptic drugs, in order to enable physicians to 
make a rational choice out of the available drugs for individual patients. Data is provided 
for the different new antiepileptic drugs on mechanisms of action, efficacy in refractory 
partial epilepsy, efficacy in newly-diagnosed epilepsy in adults, efficacy in generalised 
seizure types, adverse effects, pharmacokinetics and special patient categories. 
Methods
This article reviews the available pharmacological information on these new 
antiepileptic drugs. 
Results
The new drugs have a proven efficacy as add-on drugs in patients with difficult-
to-treat partial epilepsy, as 20-50% of patients treated in so-called add-on trials 
experience a seizure reduction of 50% or more. Relatively few trials have been conducted 
to evaluate them as monotherapy drugs for patients with newly diagnosed epilepsy. 
In the monotherapy trials that have been done, new drugs are often as efficacious 
as conventional drugs, but their tolerability is often better. However, methodological 
comments can be made about these trials. 
Discussion
The conventional drugs have thus far maintained their status as first-line 
monotherapy drugs. However, when first-line monotherapy fails, an alternative has to 
be chosen out of the available conventional and new drugs. 
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INTRODUCTION
In the last decade, several new antiepileptic drugs have been introduced. This was a 
very welcome development, as no significant new antiepileptic drugs had been marketed 
for over ten to twenty years (this varied among countries). The conventional drugs are 
efficacious, but about 30% of patients with epilepsy are not adequately controlled with 
these drugs. Furthermore, conventional antiepileptic drugs can have serious adverse 
effects, such as cognitive impairment and severe idiosyncratic reactions (e.g. rash and 
hepatotoxicity). 
The compounds that were licensed are felbamate, gabapentin, lamotrigine, 
levetiracetam, oxcarbazepine, tiagabine, topiramate, vigabatrin and zonisamide. In order 
to be licensed, these drugs had to demonstrate their efficacy in clinical trials involving 
adult patients with difficult-to-treat partial epilepsy. In these so-called add-on trials, 
the new compound is added to the existing antiepileptic medication of patients. When 
these studies are compared with each other, the parameter chosen for comparison is 
most often the proportion of patients with a decrease in seizure frequency greater 
than 50%. These new antiepileptic drugs accomplish such a reduction in 20-50% of 
the patients; representative trials are cited in the reference list (1-9). Different authors 
of relevant review papers have used different add-on studies to compare the new 
antiepileptic drugs (10,11). The selection of trials cited here is based on our opinion 
of the appropriateness of the titration schedules and the maintenance dosages that 
were used. New antiepileptic drugs are always tested in add-on trials first, because it 
is considered unethical to administer these drugs in monotherapy when their efficacy 
has not yet been established. The disadvantage of add-on trials is that they give only a 
rough idea of the efficacy and the adverse effects of a specific compound, as the effects 
seen in these trials are effects of combinations of drugs. Furthermore, unexpected or 
idiosyncratic adverse effects may become apparent only after licensing, as registration 
files typically contain data of at most 2,000 patient years, and many idiosyncratic 
reactions have a lower incidence. This was the case for felbamate and vigabatrin (12). 
Felbamate is associated with a relatively high incidence of aplastic anaemia (± 0.5 to 
1 per 10,000 patients treated) and hepatic failure (± 1 per 10,000 patients treated) and 
vigabatrin is associated with a high incidence of irreversible visual field defects after 
chronic use (20-40%) (13,14). The use of these compounds has been restricted to severe 
refractory partial epilepsy and to the syndromes of Lennox-Gastaut (felbamate) and 
West (vigabatrin). 
Most of the new antiepileptic drugs have not been evaluated extensively as 
monotherapy drugs in adult patients with newly diagnosed partial epilepsy. There are 
even less studies which have evaluated new antiepileptic drugs in patients who failed 
to respond to their first antiepileptic drug. Currently, such conventional antiepileptic 
drugs as carbamazepine, phenytoin and valproate maintain their first-line status. 
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When carbamazepine, phenytoin or valproate fail because of a lack of seizure control 
and/or because of adverse effects, another drug must be chosen out of the other 
conventional drugs or out of the new ones. This article gives an overview of the available 
pharmacological information on these new antiepileptic drugs. This information should 
assist physicians in the choice between the available antiepileptic drugs for each 
individual adult patient. We have focused on mechanisms of action, efficacy, specific 
adverse effects, pharmacokinetic properties and patient characteristics.
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Table 1.   Mechanisms of action of antiepileptic drugs
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* Phenobarbital is the major active metabolite of primidon.
It is uncertain to which extent primidon itself contributes to effi cacy and to toxicity.
+++ Well-documented action believed to account for a major part of the drug’s anticonvulsant effect;
++ Effect probably of clinical signifi cance;
+ Effect only tentatively characterized or seen only in supratherapeutic concentrations.
Antiepileptic drug 
  
Sodium channel blockers    
Carbamazepine (CBZ) 
Phenytoin (PHT) 
Lamotrigine (LTG) 
Oxcarbazepine (OXC) 
Multiple mechanisms 
of action        
Phenobarbital (PB)/
Primidon (PRM) *
Gabapentin (GBP) 
Topiramate (TPM) 
Valproate (VPA) 
GABAergic drugs       
Clonazepam (CLZP)/
Diazepam (DZP) 
Tiagabine (TGB) 
Vigabatrin (VGB) 
Other       
Ethosuximide (ESM) 
Felbamate (FBM) 
Levetiracetam (LEV) 
Zonisamide (ZSM) 
State-
dependent 
blockade of 
sodium 
channel 
T-type 
calcium 
channel
blockers 
Non-T-type
calcium 
channel
blockers 
Enhancing 
GABAergic 
inhibition
Reduction of 
glutamate-
mediated 
excitation
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MECHANISMS OF ACTION
Knowledge of the pathophysiology of epilepsy and the mechanisms of action of 
antiepileptic drugs is still incomplete. The main mechanisms of action of the available 
antiepileptic drugs are thought to be: blocking voltage-dependent ion channels 
(sodium, potassium and calcium channels), increasing the activity of the inhibitory GABA 
(gamma-aminobutyric acid)-ergic system and decreasing the activity of the excitatory 
glutamatergic system (15,16). The mechanisms of action of the new antiepileptic drugs 
show some overlap with the longer existing compounds, as is shown in table 1 (16-19). 
The potentially most important mechanisms of action of certain antiepileptic drugs are 
not shown in the table. Gabapentin, for example, binds to a protein subunit of voltage-
gated calcium channels and the mechanism of action of levetiracetam is largely unknown 
(20). Selective blockade of N-type calcium channels by levetiracetam has recently been 
described (21). A review of clinical studies suggested that a combination of a sodium 
channel blocker with a drug that increases the GABA-ergic neurotransmission or that 
has multiple mechanisms is generally more effective than a combination of two sodium 
channel blockers (22). However, as the relative contribution of different mechanisms 
of action to the anticonvulsant effect is controversial for many of these drugs, it is 
currently more appropriate to judge each individual combination on its own merits. In 
agreement with the aforementioned review (22), Stephen and Brodie have found that 
the most effectual combinations in their epilepsy unit were valproate+lamotrigine, 
valproate+carbamazepine, carbamazepine+gabapentin and phenytoin+phenobarbital 
(23). Wong has found that among lamotrigine users, patients who were not taking 
concurrent carbamazepine were three times more likely to become seizure-free than 
those who were (24). 
EFFICACY
The efficacy of antiepileptic drugs is usually assessed in two subpopulations of 
epilepsy patients: patients with difficult-to-treat partial epilepsy and patients with 
newly-diagnosed epilepsy.
Refractory partial epilepsy
Marson et al. have evaluated the efficacy of several new antiepileptic drugs 
(gabapentin, lamotrigine, tiagabine, topiramate, vigabatrin, zonisamide) in a meta-
analysis of add-on trials (10). In this analysis, these antiepileptic drugs showed efficacy 
in 20-40% of patients with refractory partial epilepsy (i.e. more than 50% seizure 
reduction). The efficacy and/or adverse drug reactions did not differ statistically between 
the compounds. A trend was noted in which topiramate and vigabatrin show higher 
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efficacy than the other compounds, but they also tended to be associated with more 
adverse effects. Marson et al. have also reviewed add-on studies involving levetiracetam, 
oxcarbazepine, remacemide and zonisamide (25). 
In recent years it has become clear that several compounds were not administered 
optimally in the add-on studies that were reviewed. Gabapentin, for example, can be 
given in higher dosages than were used during the trials reviewed, while lamotrigine 
and topiramate are presently given at slower dose titration schedules to avoid or limit 
the adverse drug reactions. Also, patients who used valproate were excluded from a 
large lamotrigine add-on trial, while lamotrigine/valproate is an effective combination 
(3). Therefore the results of this meta-analysis are of limited use. The calculation of 
the ‘number needed to be treated’ for each compound based on this meta-analysis 
therefore also has only limited validity (26). Cramer et al. reviewed only “key” add-
on trials of new antiepileptic drugs, but found that comparison was difficult due to 
differences in methodology, in baseline characteristics of patients and in reporting of 
data between trials (11). 
Recently, a number of papers have been published which report the retention time 
of several new antiepileptic drugs in patients with difficult-to-treat partial epilepsy 
(27-32). Retention time is the period of time that a patient continues to use a drug. It is 
considered to be a global means of measuring effectiveness, as it expresses both efficacy 
and tolerability (33). Lamotrigine was less likely to be discontinued than gabapentin and 
vigabatrin in some of these studies. These studies may suffer from survival bias: the new 
antiepileptic drugs were not licensed simultaneously, which means that persons who 
reacted favorably to a previously licensed antiepileptic drug were no longer available for 
trials with drugs introduced afterwards. These drugs may also have been administered 
with titration rates and maintenance doses which are no longer recommended. It should 
be mentioned that topiramate performed better than lamotrigine and gabapentin in 
one study and that the recently licensed levetiracetam achieved better seizure-free rates 
in a “continuation study” than previously licensed antiepileptic drugs had done (32). 
Czapinski has evaluated the effectiveness of the first new antiepileptic drug given 
to patients with drug-resistant partial epilepsy (34). The percentages of seizure-free 
patients were 31% for tiagabine; 28% for gabapentin; 27% for topiramate; 21% for 
lamotrigine and 16% for vigabatrin. Topiramate led to the most withdrawals (18%, 
compared with 2-7% for the other drugs). It must be noted that drug-resistance was 
defined as a failure for one or two conventional drugs; this appears to be a less refractory 
population than patients usually included in add-on trials. 
Newly-diagnosed epilepsy
A number of monotherapy studies have been performed in which a new drug has 
been compared with one of the conventional compounds (table 2) (35-44). The main 
means of expressing the outcome in most of the studies was by the percentage of 
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seizure-free patients during a pre-determined evaluation period. As can be seen in the 
table, some trials only included patients with newly-diagnosed partial epilepsy, whereas 
in other trials patients with newly-diagnosed primary generalised tonic-clonic seizures 
were also included. 
Comparative monotherapy studies enable a more straightforward comparison of the 
effectiveness of drugs. Alas, differences in titration schedules, in maintenance dosages 
and in study scheme make it difficult to compare the results of these studies. Table 2
shows that none of the newer antiepileptic drugs has superior efficacy compared with 
the older compounds. The trials listed in table 2 do suggest that fewer patients using 
gabapentin, lamotrigine or oxcarbazepine withdraw from treatment than patients using 
carbamazepine or phenytoin. The tolerability of valproate appears to be comparable 
to that of the new compounds. However, it is doubtful whether carbamazepine in 
particular was given the same “chance” of success in these studies. The dose increases 
for carbamazepine occurred fairly rapidly in most of these trials, while the titration 
schedules of the newer drugs have been adjusted to reduce treatment failure due to 
adverse effects (45). Furthermore, carbamazepine was not applied in currently available 
slow-release or long-acting forms. This may have increased its number of adverse 
effect-related treatment failures. 
Kwan and Brodie have recently reported about their experiences with first-line drugs 
in their epilepsy unit (46): 61.5% of the 78 de novo patients treated with lamotrigine 
became seizure free (10% of the withdrawals due to adverse effects), whereas only 
41.5% of the 212 patients treated with carbamazepine became seizure free (with 27% 
withdrawing because of adverse effects). Valproate performed similarly to lamotrigine, 
with 57% of the 101 patients becoming seizure free and 13% withdrawing because 
of adverse effects. 26%, 25% and 26% respectively withdrew because of inadequate 
seizure control. However, an unknown proportion of these patients participated in two 
of the aforementioned trials. It is possible that a more conservative titration schedule 
and use of controlled-release formulations would have lowered the withdrawal rate of 
carbamazepine. 
In the only head-to-head comparison between two new antiepileptic drugs 
published to date, lamotrigine and gabapentin showed similar effectiveness in 
previously untreated patients (36).
Generalised epilepsy
Felbamate may be effective in a range of generalised seizure types, but due to 
the risk of serious adverse effects, felbamate is only used for patients with malignant 
epilepsies, such as West and Lennox-Gastaut syndrome, who have continued seizures 
on other drugs. Gabapentin has no effect on absence or myoclonic seizures (47,48). It 
did reduce primary generalised seizures more than placebo; however this difference was 
not statistically significant (47). 
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Lamotrigine is efficacious for all generalised seizure types (49-51). The best responses 
have been noted in typical and atypical absence seizures and in atonic seizures. It is not 
administered as a first-line drug, but may be given as an add-on when valproate or 
another first-line drug fails. When the combination with lamotrigine is successful, an 
attempt may be made to withdraw the first-line drug. Although lamotrigine has been 
reported to be efficacious in juvenile myoclonic epilepsy (52), it seems less efficacious 
than valproate (53). Biraben and colleagues treated 7 juvenile myoclonic epilepsy 
patients with lamotrigine, and all 7 patients worsened (54). As lamotrigine can worsen 
myoclonic seizures, it should not be used in severe myoclonic epilepsy. Patients with 
photosensitivity may benefit from lamotrigine, especially when it is used in combination 
with valproate. 
Levetiracetam has shown promise in several generalised seizure types, but data is 
limited (55-57). Oxcarbazepine may be given to patients who have idiopathic generalised 
tonic-clonic seizures, but it may worsen absence and myoclonic seizures (58). Tiagabine 
has no indication for patients with primary generalised epilepsy. It has been reported to 
induce absence status epilepticus in these patients. 
Topiramate is efficacious against generalised tonic-clonic seizures, myoclonic 
seizures and in Lennox-Gastaut and West syndromes (59-61). It is a drug that may be 
helpful after first-line drugs have failed (58). Dooley et al. have warned that, although 
topiramate may be efficacious in intractable childhood epilepsy, the associated adverse 
effects were considerable (62). A recent study has shown that topiramate may also be 
efficacious for absence seizures (63). 
Some experts consider vigabatrin, which is administered primarily for tuberous 
sclerosis, also to be a first-line drug for West syndrome (64,65). It may also be used in 
patients with idiopathic infantile spasms refractory to ACTH or valproate (65). However, 
the steering committee of the United Kingdom Infantile Spasm study claims that 
there is no evidence that vigabatrin is a better treatment for infantile spasms than 
ACTH (66). The steering committee challenges the claim that vigabatrin is the drug 
of choice for infantile spasms because vigabatrin has also been reported to lead to 
concentric visual field defects in children. As visual field testing is not feasible in small 
children, one has to rely on less appropriate tests in these patients (visually evoked 
potentials and electroretinography) (67). Irrespective of the use of vigabatrin in West 
syndrome, vigabatrin has been reported to worsen absence and myoclonic seizures (58). 
Zonisamide seems to be efficacious in most generalised seizure types; the evidence is 
however limited (68,69). It may be used as a third line drug for generalised epilepsy. It 
appears to be particularly potent in progressive myoclonic epilepsy (69). 
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ADVERSE EFFECTS
Neurotoxicity
Dose-related neurotoxic adverse effects, such as cognitive impairments, diplopia, 
headache, fatigue and sedation, characterize the use of the older generation of 
antiepileptic drugs. Neurotoxicity is also the most frequently occurring type of adverse 
effect for the new compounds, although the frequency of these adverse effects differs 
between the compounds. In addition to these general neurotoxic adverse effects, each of 
the new compounds has its own specific adverse effects, which can be either neurotoxic 
or systemic. 
Felbamate was associated with dizziness in more than 5% of the patients that 
received the drug as adjunctive therapy (70). Gabapentin is tolerated well by most 
patients, as was shown by the monotherapy trials (35,36). It may lead to adverse effects, 
such as somnolence, dizziness and ataxia quickly after the start of treatment (71), and 
therefore we recommend a more conservative titration schedule than the manufacturer 
does. Ramsay and Pryor have reported the occurrence of oscillopsia and diplopia when 
gabapentin is administered to patients with high plasma levels of carbamazepine (71). 
An increase in fatigue may also occur when using this combination. 
Lamotrigine is well tolerated by most patients (36-40,46,72). It can lead to dosage-
related neurotoxic adverse effects (e.g. dizziness and ataxia) when used in combination 
with carbamazepine of phenytoin. Lowering the dosage of the conventional drug may 
reverse these adverse effects (73). Comparative studies (table 2) show less cognitive 
side effects for gabapentin and lamotrigine compared with conventional antiepileptic 
drugs.
Levetiracetam has not yet been evaluated as monotherapy for newly diagnosed 
patients, but appears to have little detrimental effect on cognitive abilities. Somnolence, 
headache and dizziness can be encountered in patients who start with levetiracetam 
(74). A pharmacodynamic interaction may cause or increase adverse effects when 
levetiracetam is added to carbamazepine (75). 
Oxcarbazepine is structurally related to carbamazepine, and these drugs have a same 
range of neurotoxic adverse effects (41). Due to the methodological limitations of the 
monotherapy trials comparing new to old compounds, superior effectiveness has not 
(yet) been demonstrated for oxcarbazepine compared to carbamazepine (41). Dizziness 
and asthenia are the most frequently encountered neurotoxic adverse effects associated 
with the use of tiagabine, but this drug has a favorable cognitive profile (76). 
Topiramate is known for neurotoxic adverse effects such as paresthesias and 
psychomotor slowing, and these can be serious handicaps for patients. The current 
slower titration rate and lower daily dosages may reduce these adverse effects (77). In 
a study with a limited number of adult volunteers the cognitive effects of gabapentin, 
lamotrigine and topiramate have been compared directly (78). Gabapentin and 
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lamotrigine seem to have a more favorable profile when compared with topiramate. 
It is likely that the use of vigabatrin may lead to psychosis (67). Zonisamide may have 
detrimental effects on verbal learning, but a slower titration rate may help decrease 
this. The use of zonisamide may lead to irritability, depression, anxiety or psychosis. 
This may be related to its effects on the synthesis and degradation of monoamine 
neurotransmitters (79).
Besag has reviewed the behavioral effects of new antiepileptic drugs (80). Epilepsy 
patients seem to be at greater risk of behavioral adverse effects than patients with 
other CNS conditions. Gabapentin, oxcarbazepine and especially lamotrigine can induce 
mood improvement, although insomnia and aggressive behavior have been reported 
as well (80). Topiramate is associated with a higher frequency of psychosis. Tiagabine 
may induce depressions in some patients, but, as for levetiracetam, experience is limited 
(80). 
Ketter et al. have proposed to select antiepileptic drugs based on their ‘sedatory’ 
or ‘stimulating’ effects (81): a patient who is rather inactive should be prescribed a 
‘stimulating’ antiepileptic drug and vice versa. 
Systemic side effects 
Currently 36 cases of aplastic anemia and 18 cases of hepatic failure have been 
reported in patients receiving felbamate (82). Rash is a well-known idiosyncratic adverse 
effect of the old generation of antiepileptic drugs. Rash can occur with lamotrigine and 
oxcarbazepine; it seldom occurs with zonisamide and very seldom with gabapentin. A 
low starting dose and slow titration are factors that reduce the incidence of rash. Severe 
lamotrigine-induced rashes (even fatal Stevens-Johnson and Lyell syndromes) still occur 
despite of these measures. Rash does not seem to occur with levetiracetam, tiagabine, 
topiramate or vigabatrin. 
The risk of gabapentin and vigabatrin is that they may cause body weight gain (83). 
Mild infections have been reported for levetiracetam, mostly upper respiratory tract 
infections, such as rhinitis and flu- like symptoms (74). The underlying cause is unclear 
and these symptoms are not related to changes in white blood cell or neutrophil counts 
(84). This is generally not an adverse effect that necessitates treatment withdrawal (77). 
Oxcarbazepine is associated with hyponatremia, an adverse effect that usually does not 
lead to clinical symptoms. In the elderly however, it may lead to an encephalopathic 
syndrome. 
Diarrhea has been reported as a result of the use of tiagabine (76). Recently, a case 
report was published of asymptomatic visual field defects associated with tiagabine; 
the defects reversed upon discontinuation of tiagabine (85). However, tiagabine was not 
associated with visual field effects in larger patient series (86). Sills et al. have reported 
that tiagabine does not increase GABA levels in the retina and does not accumulate in 
the retina; vigabatrin does both these things (87). 
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Well-known systemic adverse effects of topiramate are weight loss and the risk of the 
development of renal stones. In a pooled analysis of add-on trials, weight loss ranged from 
1.6 to 5.6 kilograms (88). Weight loss appears to be greatest in patients who are heavier 
at onset and patients who use higher dosages, while it is most commonly seen in female 
patients (88, 89). Weight loss may be very severe. There have been several case reports of 
angle-closure glaucoma associated with topiramate use; one example is included in the 
reference list (90). 
Vigabatrin is associated with the development of concentric visual field defects after 
chronic use in up to 20 - 40% of the patients. The use of zonisamide is associated with 
weight loss (in 3 - 21% of the patients) and sporadically with hematogical disorders (such 
as leukopenia) and renal calculi (79). The risk of renal calculi seems to be higher in patients 
from Europe and the United States than in patients from Japan, where the drug has been 
licensed since 1989 (79). 
Dose titration and side effects 
The experiences from the large add-on trials have led to changes in the titration 
schedules for lamotrigine, tiagabine and topiramate, because of the occurrence of rash 
(lamotrigine) and dose-related side effects in general (tiagabine, topiramate). It therefore 
now takes six weeks or more before these drugs can be administered in therapeutic doses 
(91). This may limit the use of these drugs in patients with low seizure frequencies. The 
manufacturers of gabapentin and levetiracetam recommend titration schedules of only 
a few days before reaching the first maintenance dose (900 mg/day and 1000 mg/day 
respectively); clinical experience leads us to believe that a more conservative approach is 
to be preferred (this is the authors’ personal experience).
PHARMACOKINETICS
The complex pharmacokinetics of the old generation antiepileptic drugs hamper the use 
of these drugs. Disadvantages are a high protein binding (phenytoin, valproate), non-linear 
kinetic profile (phenytoin) and a high potential for interactions (phenobarbital, phenytoin, 
carbamazepine) (92). This high interaction potential is due to the fact that these drugs 
induce and are metabolised by the cytochrome P450 system. The new antiepileptic drugs 
generally have a more favorable pharmacokinetic profile, which is shown in table 3 (82,92). 
Bioavailability is generally high, with the only exception for gabapentin in higher dosages, 
caused by saturation of the absorption. Nutrition hardly interferes with the absorption of 
these compounds (92). Protein binding is low, with the exception of tiagabine, so there is 
generally no risk for changes in the free fraction through interaction with co-medication. 
Most of the drugs have relatively short elimination half-life times; only gabapentin and 
tiagabine need more then two daily dosing caused by short half-life times (92). 
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The new compounds have fewer interactions with concurrent medication then 
conventional antiepileptic drugs do, with the possible exception of felbamate. Tiagabine 
and lamotrigine do show interactions with other antiepileptic drugs. Enzyme-inducing 
antiepileptic drugs such as carbamazepine and phenytoin reduce the half-life times 
of these drugs considerably. The concentration of tiagabine or lamotrigine is reduced 
by approximately 50% when compared with monotherapy. In cases where lamotrigine 
is used together with valproate, lamotrigine levels are about twice as high as in 
lamotrigine monotherapy. There is uncertainty whether the high effectiveness of the 
valproate /lamotrigine combination is due to this pharmacokinetic interaction alone; 
there might very well also be a pharmacodynamic interaction (93). 
Oxcarbazepine and topiramate show some enzyme-inducing activity, and in cases 
when these drugs are combined with oral contraceptives or oral anticoagulants, doses 
need to be adjusted. Oxcarbazepine, because of its lesser enzyme induction, is an 
appropriate alternative for carbamazepine when co-medication makes this relevant. 
The available therapeutic ranges for the new antiepileptic drugs should be 
interpreted with care, as these values are based on patients with severe epilepsy 
treated with several antiepileptic drugs (94). There is considerable overlap between 
responders and non-responders and between patients with and without adverse 
effects for felbamate, lamotrigine, oxcarbazepine and zonisamide. The serum levels vary 
greatly between patients responding to gabapentin. For levetiracetam and tiagabine 
there is little information. As vigabatrin’s mechanism of action is irreversible GABA-
transaminase inhibition, its serum levels give no indication for its effect. 
SPECIAL PATIENT POPULATIONS
The risk of certain adverse effects may be higher in certain sub-populations. One 
will want to avoid tiagabine in patients with a history of psychosis, and topiramate in 
patients with a history of renal stones. 
Several conventional drugs have the advantage of different formulations. An 
intravenous formulation is important during surgery. The availability of a drug in a 
solution can be necessary for children and patients with a mental or physical handicap. 
Elderly: The adverse effects of the new drugs on the elderly still awaits extensive 
evaluation. The elderly appear to have relatively good tolerability for gabapentin and 
lamotrigine, which, together with valproate and carbamazepine, are deemed first-line 
anticonvulsants in these patients (95). Oxcarbazepine has the risk of hyponatremia and 
topiramate may cause cognitive problems in the elderly (95). Data on levetiracetam, 
tiagabine and zonisamide is incomplete in this respect. 
Decreasing organ functions will influence the clearance of drugs and must be taken 
into account. A number of drugs have a relative contra-indication for patients with a 
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decreased renal function. Dosage adjustments and extra attention are necessary for 
gabapentin, levetiracetam, oxcarbazepine, topiramate and vigabatrin in these patients. 
Concerning liver function, the metabolisation of a drug will usually be influenced 
only when that function is in an advanced state of impairment. In those cases, it is 
better to use a drug that is not or hardly metabolised by the liver (such as gabapentin, 
levetiracetam or topiramate). 
Women in childbearing age: There is controversy regarding the question whether use 
of valproate is associated with a higher incidence of polycystic ovary syndrome (PCOS) 
(96, 97). Herzog and Schacter conclude that, despite limitations in studies reporting an 
association between use of valproate and occurrence of PCOS, the evidence cannot be 
entirely dismissed (98). As valproate also has teratogenic effects, it may be concluded 
that it is less suitable for women of childbearing age. Lamotrigine has been positioned 
as a better alternative for this group. It does have certain advantages, such as its relative 
lack of adverse effects and its lack of enzyme induction. It may cause a worsening of 
acne. Based on limited pregnancy data, lamotrigine does not seem to have a major 
teratogenic effect (99). There is no good reason for avoiding lamotrigine in women who 
wish to get pregnant, given the known effects of the conventional antiepileptic drugs.
The problem with lamotrigine and [even more with] the other new antiepileptic 
drugs is that only limited data is available regarding their teratogenic effects. 
Retrospective data is available, but should be treated with caution and take its selection 
bias into account. Women with epilepsy who become pregnant should be encouraged 
to enroll in prospective pregnancy registries (such as the Antiepileptic Drug Pregnancy 
Registry in North America and EURAP in Europe). 
Two different attitudes can be taken towards the problem of possible teratogenic 
effects of new antiepileptic drugs. One is that the new antiepileptic drugs should be 
avoided in women who wish to become pregnant, since the risks for birth defects are 
not known. The other is that the conventional antiepileptic drugs should be avoided 
in these patients, because their risks are known to be relatively high. Whatever the 
compound used, recommendations are still valid for the use of drugs in monotherapy, 
in low doses, and divided over the day. It is known that topiramate and zonisamide are 
teratogenic in animals, whereas other drugs are less or not teratogenic in animals (82). 
Oxcarbazepine and topiramate are enzyme-inducers, which is important in women 
using oral anticonception. 
Children: For efficacy in partial seizure and generalised seizure types see the relevant 
paragraph. Young children in particular have a higher clearance than adults and 
therefore they may need higher dosages per kilogram. 
Lamotrigine has few cognitive effects and it is efficacious in children with partial 
epilepsy and in children with generalised epilepsy. The slow titration rate and the 
risk of severe rashes (which seems to be higher in children) are disadvantages. There 
is sufficient evidence for the effectiveness of oxcarbazepine in children with partial 
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epilepsy (100). Topiramate may provoke metabolic acidosis and central hyperventilation 
in small children (101). There is insufficient data for the other new compounds. 
The mentally handicapped: Recent studies in this population suggest that gabapentin, 
lamotrigine and topiramate are effective in this population (102,103). Oxcarbazepine 
is also an effective drug for this type of patient (104). There is insufficient data for 
levetiracetam, tiagabine and zonisamide. The agitation sometimes caused by certain 
antiepileptic drugs merits extra caution in this population (105). 
CONCLUSIONS
The choice for second-line antiepileptic drugs depends on individual patient 
characteristics and on the characteristics of the individual drugs. The data presented in 
this article, which is summarised in table 4, should assist physicians in making a rational 
choice. Please note that licensed indications can vary per country. 
Some general conclusions may be drawn
1. Effectiveness in refractory partial epilepsy: The 9 new antiepileptic drugs have proven 
efficacy in patients with intractable epilepsy. FBM and vigabatrin are no longer 
routinely used because of their idiosyncratic adverse effects. 
2. Effectiveness in newly diagnosed epilepsy: The only new compounds, which have 
been evaluated extensively as monotherapy drugs for partial seizures and generalised 
tonic-clonic seizures, are lamotrigine and oxcarbazepine. These drugs seem to have 
comparable efficacy to carbamazepine and phenytoin, but more favorable tolerability. 
Efficacy and tolerability are comparable to valproate. As there are methodological 
limitations to these studies, there is no conclusive data to prefer these drugs as first-
line drugs, except when there are specific reasons to choose them. 
3. Some new antiepileptic drugs are very useful second-line drugs for generalised 
seizure types, whereas other new drugs have no use or are contra-indicated. It is 
currently being debated whether vigabatrin is the best first-line treatment of infantile 
spasms. 
4. Tolerability: The new drugs seem to be tolerated well, but they all have specific adverse 
effects which may make them less suited for individual patients. Slower titration rates 
seem to improve the tolerability of many of these drugs. Physicians should realise 
that the severe adverse drug reactions of vigabatrin became apparent only after these 
drugs had been available for several years. 
5. Most new drugs have a straightforward pharmacokinetic profile and a low potential 
for interactions. 
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ABSTRACT
Objective
In the past decade, several new antiepileptic drugs (AEDs) were introduced in the 
Netherlands. These new drugs, one of which is lamotrigine, are 5 to 20 times more 
expensive than conventional anticonvulsants. In 1997, the high cost of lamotrigine, 
together with a lack of clinical data supporting its superiority over conventional drugs, 
prompted the Dutch Health Insurance Board to release a guideline in which the use 
of lamotrigine was restricted to difficult-to-treat patients. Other new drugs that were 
marketed after 1997 also became subject to this guideline. The utilisation of new 
antiepileptic drugs and the consequences for the cost of pharmaceutical care are the 
subject of this paper.
Methods
Data from extramurally prescribed antiepileptic drugs was obtained from the Dutch 
Drug Information Project, which is a database containing prescriptions for about 5.5
million inhabitants of the Netherlands. This data was used to study the impact of new 
antiepileptic drugs on volume and costs of pharmaceutical care in the period from 1995
to 2001 in the Netherlands.
Results
Between 1995 and 2001, the total volume of antiepileptic drugs increased by 
130%, 60% of which consisted of new antiepileptic drugs. Gabapentin, lamotrigine 
and oxcarbazepine were the most frequently prescribed new compounds. The volume 
share of new antiepileptic drugs increased from 5% in 1995 to 18% in 2001. The cost of 
pharmaceutical care amounted to 1 21.5 million in 1995 and rose to 1 47 million in 2001; 
80% of this increase was due to the introduction of new antiepileptic drugs. 
Discussion
Although in 2001 the volume share of new antiepileptic drugs was still modest, their 
introduction has led to a strong increase in the cost of pharmaceutical care. New data 
is emerging on the effectiveness and cost-benefit sum of the new antiepileptic drugs; 
this may change the place in therapy of these drugs. Because of their strong potential to 
force up cost, the positioning of new antiepileptic drugs requires further attention.
INTRODUCTION
Pharmacotherapy represents the first-line option in the management of epilepsy, a 
common, heterogeneous neurological disorder. For 25 years, four drugs have dominated 
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the pharmacotherapeutic arsenal: carbamazepine, phenobarbital, phenytoin and 
valproate. However, 30 to 40% of the patients do not become seizure-free with 
these conventional drugs. Furthermore, their usefulness is limited by a relatively high 
frequency of side effects (1,2).
The introduction of several new antiepileptic drugs in the last decade has therefore 
been a welcome expansion of the treatment options. The new antiepileptic drugs are 5
to 20 times more expensive than the conventional antiepileptic drugs (table 1). This is 
worth noting, as the cost of pharmacotherapy represents a main cost-increasing factor 
in epilepsy care (3). Even in studies initiated before the arrival of new antiepileptic drugs, 
drug costs accounted up to 40% of the immediate medical costs (3,4). 
Lamotrigine was registered in the Netherlands in 1995. The introduction of 
lamotrigine was followed by a period of prolonged compassionate use, as it became 
fully reimbursed only after the establishment of a guideline for restrictive use by the 
Dutch Health Care Insurance Board in August 1997 (5). The relatively high acquisition 
cost of lamotrigine, and a lack of clinical documentation in favour of lamotrigine in 
treating epilepsy, were the main criteria for the Health Care Insurance Board to issue this 
prescribing guideline. The Lamotrigine Prescription Guideline allows full reimbursement 
of lamotrigine only for patients diagnosed with epilepsy with whom at least three 
treatment strategies with conventional antiepileptic drugs had failed. This guideline 
also applies to new antiepileptic drugs introduced after lamotrigine. These drugs were 
therefore reimbursed shortly after their introduction. The aim of the present study is to 
estimate the impact new antiepileptic drugs have on volume and cost of antiepileptic 
Year of introduction          Name                                                    ATC                       DDD (mg)           Drug costB
1912                                        Phenobarbital          (PB)                  N03AA02            100                       2.41
1938                                        Phenytoin                  (PHT)               N03AB02            300                      2.73
1958                                        Ethosuximide          (ESM)              N03AD01           1250                    15.45
1964                                        Carbamazepine       (CBZ)               N03AF01            1000                    14.73
1971                                        Valproate                   (VPA)               N03AG01            1500                    23.88
1975                                        Clonazepam             (CLZP)             N03AE01            8                            12.13
1990C                                       Vigabatrin                 (VGB)              NO3AG04           2000                    78.55
1991                                        Oxcarbazepine        (OXC)               N03AF02            1000                    37.43
1995                                        Lamotrigine              (LTG)                N03AX09            300                       100.12
1996                                        Felbamate                 (FBM)              N03AX10            2400                    198.43
1999                                        Topiramate               (TPM)              N03AX11            300                       125.72
1999                                        Gabapentin              (GBP)               N03AX12            1800                    109.13
2001                                        Levetiracetam          (LVT)                N03AX14            2000                    143
Table 1.   Antiepileptic drugs in the Netherlands
B Cost in Euros for 30 DDD (monthly total cost for average adult dose based on most frequently used oral dosage form). 
Source: GIP database
C In this article, antiepileptic drugs introduced from 1990 onwards are regarded as new AEDs.
52
drugs in the Netherlands. In order to study the utilisation of antiepileptic drugs in the 
Netherlands, data were obtained from the Dutch Drug Information Project (GIP). 
METHODS
Data on drug utilisation
The GIP is a unit of the Dutch Health Care Insurance Board, whose goal is to collect 
and interpret information on drug use in the Netherlands. The GIP database contains 
complete information on extramurally prescribed, reimbursed drugs dispensed by 
pharmacists and general practitioners with in-house pharmacies. Ten selected health 
insurance companies provide the data. This data refers to the 5.6 million inhabitants 
who are covered by the Dutch National Health Service, which amounts to about 55% of 
all inhabitants thus covered. The data is extrapolated to the entire insured population, 
i.e. those either with National Health Service or with private health insurance. For this 
extrapolation, coefficients have been ascribed to each collaborating health insurance 
company, based on patient characteristics and consumption differences between those 
covered under the compulsory National Health Scheme and privately insured patients. 
Each prescription in the GIP database contains information on the number of filled drug 
units, the number of dispensed defined daily doses, gender and age of the patients 
and the type of prescribing physician. All prescription drugs are coded according to the 
Anatomical Therapeutic Chemical (ATC) classification (6).
Information was obtained from the GIP database on all dispensed antiepileptic drugs 
(ATC-code: N03, table 1) in the period from 1995 to 2001. The following drugs marketed 
in the Netherlands after 1990 were classified as new antiepileptic drugs: felbamate, 
gabapentin, lamotrigine, oxcarbazepine, topiramate and vigabatrin. All other drugs with 
ATC-code NO3 were classified as conventional antiepileptic drugs.
Statistics and definitions
The statistics on drug consumption and cost are presented as an average of the 
total insured population. Drug consumption is expressed as the number of defined 
daily doses (DDD) per 1,000 insured persons per day. The DDD is a technical unit of 
measurement, usually based on the average dosage per day for the main indication in 
adult patients (6).
The cost of pharmaceutical care is presented as a total cost. The total cost can be 
broken down into two major components: the prescription drug cost and the dispensing 
fee. The cost is expressed in euros (1; exchange rate on 4 November 2003: EUR 1 = USD 
1.15 or GBP 0.69).
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RESULTS 
Consumption
Table 2 presents the utilisation data of antiepileptic drugs in the Netherlands during 
the period 1995 to 2001 in DDD per 1,000 insured persons per day. The consumption of 
antiepileptic drugs increased from 5.4 DDD per 1,000 insured persons per day in 1995
to 7.0 DDD in 2001. The conventional antiepileptic drugs carbamazepine, phenytoin and 
valproate were the most commonly prescribed drugs throughout the study period. The 
use of phenytoin decreased, however, from 1.28 DDD per 1,000 insured persons per day 
in 1995 to 0.96 in 2001.
New antiepileptic drugs account for 60% of this increase, with 0.96 DDD per 1,000
insured persons per day. The volume share of new antiepileptic drugs increased from 
0.27 DDD per 1,000 insured persons per day (5%) in 1995 to 1.2 DDD (17.5%) in 2001.
For the first years after the introduction of lamotrigine, its volume of consumption 
remained low, at 0.04 DDD per 1,000 insured persons per day in 1997. After 1998, 
lamotrigine started to gain market share; in 2001, the volume share was 6%. Another 
strong volume increase in antiepileptic drugs was seen when gabapentin reached 0.25
DDD per 1,000 insured persons per day in the second year after its introduction. 
In 2001, gabapentin, lamotrigine and oxcarbazepine were the most frequently used 
new antiepileptic drugs, and their consumption is still increasing. Compared with these 
three drugs, the consumption of topiramate remained relatively low at 0.08 DDD per 
1,000 insured persons per day in 2001. The use of vigabatrin decreased from 0.18 DDD 
per 1,000 insured persons per day in 1995 to 0.05 in 2001. After the introduction of 
felbamate in 1996, its consumption volume remained below 0.01 DDD per 1,000 insured 
persons per day.
Cost
In 1995, the total cost of pharmaceutical care amounted to 1 21.5 million, of 
which conventional antiepileptic drugs accounted for 83% (1 17.8 million). In 2001, 
the total cost more than doubled when 1 47 million was spent on antiepileptic drugs 
in pharmaceutical care. A major share (80%) of this 1 25.5 million cost increase is 
accounted for by the introduction of new antiepileptic drugs. The market share of the 
new antiepileptic drugs increased from 1 3.8 million in 1995 (17%) to 1 24.2 million 
(52%) in 2001. During the study period, the cost per DDD went up from 1 0.7 per DDD in 
the period 1995-1997 to 1 1.2 per DDD in 2000, a 63% increase. As figure 1 shows, until 
1997 the development in costs trailed behind the volume development; after 1997, the 
cost of antiepileptic drugs increased strongly in relation to consumption. Both 1998 and 
2001 showed peak increases in the cost of pharmaceutical care, with relative increases of 
123% in both years. The first peak increase coincided with the changed reimbursement 
policy regarding lamotrigine. In 1998, when 1 4.1 million were spent on lamotrigine, 
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that drug accounted for 74% of the increase costs. The strong rise in gabapentin use 
is the major factor for the peak increase seen in 2001. The cost for gabapentin rose by 
1 5 million in 2001, which accounted for 56% of the total increase in pharmaceutical 
costs in that year. The volume and cost shares of individual antiepileptic drugs in 2001
are presented in figure 2. The overall picture is that new antiepileptic drugs have a 
relatively small volume share, but a comparatively high share of pharmaceutical costs. 
Lamotrigine, for instance, had a volume share of 6% in 2001 whereas its contribution to 
total pharmaceutical costs, 24%, was the highest of all antiepileptic drugs.
DISCUSSION
Drug utilisation data provides useful information to health care professionals and 
policy makers on different areas of interest (7). Several other researchers have also 
studied antiepileptic drug utilisation (8-13). Our study shares two limitations with 
some other studies. First, we used DDD data to determine utilisation. This does not 
provide insight into the percentage of people who are exposed to antiepileptic drugs, nor 
does it give insight into the number of new cases. Shackleton et al. and Lammers et al. 
collected drug-dispensing information on an individual patient level, i.e. they knew how 
Figure 1. Patterns in cost and volume of AEDs in the Netherlands
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Figure 2. Comparison of volume and cost of AEDs in 2001
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many patients used antiepileptic drugs, in which dosages these antiepileptic drugs were 
used and whether patients used more than one antiepileptic drug (10,11). The counting 
method undoubtedly supplies more specifically epidemiological information than an 
aggregated measure of analysis like the DDD used in this study (7).
 The other limitation of this study is that the indication for which the antiepileptic 
drugs are prescribed is unknown. Carbamazepine and clonazepam especially are 
often prescribed for other indications than epilepsy. Carbamazepine and valproate are 
increasingly being used in the field of psychiatry. Shackleton et al. demonstrated that 
for almost 50% of the patients on carbamazepine monotherapy, the indication was 
not epilepsy (11). In several of the epidemiological studies, corrections were made for 
off-label use by applying a correction factor of 0.68 (8,14). For new antiepileptic drugs, 
the correction factor is not yet known, but it is likely that there is off-label use of these 
compounds as well. The effectiveness of gabapentin and lamotrigine is being assessed 
for several other diseases, mainly bipolar disorder and neuralgic pain (15-19). Despite 
these limitations, the present study still allows a comparison to be made between the 
prescribing of different drugs within one class and the related cost consequences. The 
GIP database is based on the computerised registration of prescription drugs by several 
health maintenance organisations. This has the advantage of being a relatively easy, 
inexpensive and rapid way to collect information on drug use for a large number of 
patients (20). Our study uses a much larger database than other studies did. 
The Lamotrigine Prescription Guideline confined the use of the drug to the treatment 
of patients with refractory epilepsy only. This guideline was issued almost two years 
after the registration of lamotrigine in the Netherlands, which explains the low volume 
share of lamotrigine in the first years after registration. Only after the reimbursement 
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settlement in August 1997 did the volume share start to increase. Nowadays, lamotrigine 
is the most frequently prescribed new AED in the Netherlands.
The conventional antiepileptic drugs, in particular carbamazepine and valproate, 
are still the most frequently prescribed drugs. Their volume share continues to increase, 
which may also be due to off-label use. In 2001, the new antiepileptic drugs accounted 
for 18% of the use in antiepileptic drugs. Despite this still modest volume share, the 
impact of the new antiepileptic drugs on the development of costs of pharmaceutical 
care seems large. Over the study period, the cost of pharmaceutical care more than 
doubled, to 1 47 million in 2001. The market share of new antiepileptic drugs soared 
from 17% in 1995 to 52% in 2001. Lamotrigine has the highest share of pharmaceutical 
care costs at 1 11 million in 2001 (24%). A similar pattern in drug sales was seen in the 
United Kingdom, where the introduction of new antiepileptic drugs led to a twofold 
increase in costs of AED prescriptions in the period 1992 to 1997 (3).
At present, the utilisation of new antiepileptic drugs can still be described as modest, 
considering that around a third of the patients have refractory epilepsy (11). This may 
be due to an effective implementation of the Lamotrigine Prescription Guideline among 
prescribing physicians, but this has not been assessed. There are also other factors that 
probably contribute to the modest utilisation volume of new antiepileptic drugs. Petri 
and Urquhart described a so-called channelling phenomenon, which means prescribing 
new drugs to a selected group of patients (21). In epilepsy treatment, channelling would 
consist of using new antiepileptic drugs for intractable patients only, irrespective of a 
guideline. Furthermore, physicians may hesitate to prescribe new antiepileptic drugs 
soon after registration because not all relevant data on safety is available at the moment. 
Felbamate and vigabatrin are cases in point. Both drugs were introduced as promising 
new antiepileptic drugs, but as table 2 shows, these drugs are now seldom prescribed. 
These two drugs are associated with severe, idiosyncratic adverse effects that became 
apparent only several years after the drugs had been registered (22,23). 
When considering the cost consequences presented in this paper, it is important 
to ask whether the present positioning of the new antiepileptic drugs will be subject 
to change in the near future. Data is emerging on the efficacy and tolerability of 
new antiepileptic drugs in patients with newly diagnosed epilepsy (24-29). The main 
advantage of the new antiepileptic drugs over conventional drugs like carbamazepine 
and phenytoin seems to be a favourable tolerability profile, which leads to fewer 
treatment failures. In the case of lamotrigine, its better tolerability profile resulted in 
a higher quality of life for patients treated with the drug, compared with those treated 
with carbamazepine or phenytoin (27,30). The results of these monotherapy trials may 
contribute to a more widespread use of new antiepileptic drugs earlier in the treatment 
and thus to their being employed as first-line treatment for newly diagnosed epilepsy. 
Physicians may decide to switch from conventional antiepileptic drugs as first-line 
treatment options to the new alternatives based on the lower number of treatment 
58
failures. The utilisation of phenytoin is decreasing (table 2), possibly because physicians 
are changing their treatment preference towards new antiepileptic drugs with fewer 
side-effects.
Conclusion
Unbridled use of new antiepileptic drugs will inevitably impose a tremendous burden 
on the healthcare budget. A well-regulated healthcare environment will increasingly 
mandate a demonstration of value for money, defined in terms of measurable health 
and/or financial outcome for a given pharmacotherapeutic option. Selection criteria for 
the rational use and positioning of new antiepileptic drugs are needed, criteria which 
should be based on effectiveness and cost-benefit data derived from real-life use. 
Without data on population-based effectiveness of new antiepileptic drugs, plan payers, 
like the Dutch Health Care Insurance Board, will remain wary about paying for new 
drugs or reconsidering the positioning of these drugs. Drug utilisation studies should 
be included in the ways of finding criteria that attribute to a rational positioning of the 
new antiepileptics and in demonstrating that new antiepileptic drugs, when effective, 
will almost always justify their cost.
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1 1 0 0 1 1 0 0 1 1 1 0 0 1 0 1 0 1 1 1 1 0
1 0 1 0 1 1 0 0 1 0 1 0 1 0 1 0 1 0 1 0 0 0
0 0 1 1 1 0 0 1 0 1 0 1 1 0 1 1 0 0 0 1 1 0
1 1 0 1 1 0 1 0 0 1 1 1 0 1 0 1 0 1 1 0 1 1
2.DDiffusion of the new antiepileptic drug lamotrigine in Dutch clinical practice
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ABSTRACT
Objective
Lamotrigine is one of the recently introduced antiepileptic drugs licensed in the 
Netherlands in 1995. The objective of this study was to examine the diffusion of 
lamotrigine into clinical practice. Three different aspects of this diffusion process were 
examined: incidence of use, patient characteristics and changes in prescription patterns 
in the first 5 years following its introduction. 
Methods
A retrospective follow-up study has been conducted using drug prescription data 
from the database of the Dutch Drug Information Project (GIP-database). Patients 
were included who started with lamotrigine, carbamazepine, phenytoin or valproate 
in the period of January 1996 to December 2000. Incidence of use was calculated for 
the four drugs. Multiple logistic regression analysis was used to determine differences 
in baseline characteristics. Chi-square test was used to analyse changes in the usage 
patterns of lamotrigine.
Results
The study population consisted of a total of 29,718 patients who were prescribed 
carbamazepine, phenytoin, valproate or lamotrigine for the first time in the study period. 
Carbamazepine and valproate accounted for the majority of all new prescriptions; the 
incidence of lamotrigine use remained stable with 4.4 patients per 100,000 per year. 
Baseline characteristics of lamotrigine differed, depending on the patient’s age and 
gender compared to the conventional antiepileptic drugs. In a large majority of cases 
lamotrigine was used as a second-line or third-line antiepileptic drug. Physicians 
prescribing lamotrigine were predominantly neurologists, in contrast to prescribers 
of conventional antiepileptic drugs. The prevalence of psychotropic medication and 
migraine-abortive drugs was significantly lower in users of lamotrigine compared to 
users of conventional antiepileptic drugs. During follow-up several significant trends 
were noticed in the prescribing of lamotrigine with regard to age groups, gender, 
antiepileptic history and off-label use.
Discussion
Lamotrigine is prescribed to a population different from that using conventional 
antiepileptic drugs. The uptake of lamotrigine in clinical practice is slow, for reasons 
probably related to characteristics of the drug itself and the prescribers. During the 
observation period, lamotrigine diffused gradually towards more first-line use as an 
antiepileptic drug and more off-label use.
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INTRODUCTION
The field of antiepileptic drug therapy is dominated by conventional drugs, such 
as phenytoin (introduced in 1938), carbamazepine (1964) and valproate (1971) (1). 
As a substantial proportion of the patients is not controlled optimally or suffers from 
bothersome or clinically severe side-effects while using conventional antiepileptic drugs 
(2), there remains a clear need for new drugs. Lamotrigine is one of the new treatment 
options that has been introduced in the past decade. On the basis of results from 
placebo-controlled trials, lamotrigine received regulatory approval in the Netherlands 
for indication in 1995 as an add-on drug in patients with refractory, localisation-related 
epilepsy. The reimbursement of the drug was not immediately approved by the Dutch 
Health Care Insurance Board because of its relatively high cost compared to conventional 
antiepileptic drugs, and also because of a lack of favourable clinical documentation on 
lamotrigine (as head-to-head comparisons with other antiepileptic drugs were lacking). 
In August 1997, the Health Care Insurance Board decided that the reimbursement of 
lamotrigine should be restricted to the initial indication, i.e. add-on therapy for patients 
with refractory epilepsy. A prescription guideline, the first in the Netherlands, was issued 
by the Health Care Insurance Board and distributed among Dutch neurologists (but 
not other physicians) to ensure the restricted use of lamotrigine. It is to be expected, 
however, that once physicians become familiar with the use and safety of a new 
antiepileptic drug, the drug will be prescribed for a broader range of indications, e.g. 
to patients with less severe epilepsy or to patients from other age groups than those 
included in the initial trials. Still little is known about this process of diffusion of new 
drugs in daily practice. Most available theoretical frameworks rely on Rogers’ diffusion of 
innovations theory (3-5). Rogers defined diffusion as the process by which an innovation 
disseminates through certain channels over time among members of a social system 
(3). In the decision to prescribe a new drug, doctors have to strike a balance between 
possible benefits and risks. Because new drugs are generally more expensive than 
established drugs, doctors also have to make this judgement in the wider context of a 
health service with a limited budget (6). Within this context, health care providers and 
formulary decision-makers, too, often evaluate newly introduced drugs. Knowledge of 
the diffusion process would help doctors as well as policy makers in the interpretation 
of aspects such as effectiveness and economic outcomes of new drugs. The objective of 
this study was to examine the diffusion of lamotrigine after it became reimbursed in 
the Netherlands, using a large prescription database over the period from 1996 – 2000. 
Prescribing trends, usage patterns, and baseline characteristics of patients in a cohort 
of lamotrigine patients were compared with those of a cohort of patients using the 
conventional antiepileptic drugs carbamazepine, phenytoin and valproate.
64
METHODS
Setting
The prescription data for this study was obtained from the GIP-database. This is a 
project run by the Dutch Health Care Insurance Board, an independent advisory and 
supervisory body in the field of social health insurance. The GIP-database contains data 
from all extramurally prescribed drugs that are dispensed by pharmacists and general 
practitioners with an in-house pharmacy and are reimbursed by the health insurance 
funds under the Health Insurance Act. The data was provided by ten health insurance 
funds and concerns 5.6 million compulsorily insured in 2000, which is about 55% of all 
compulsorily insured Dutch persons. This sample is representative for the distribution by 
age and gender of all persons compulsorily insured in the Netherlands. 
For each prescription in the GIP-database, retrievable information covers the 
following domains: patient (gender, age and unique anonymous identification number); 
prescription (trade name, ATC code, dispensing date, dispensed amount and prescribed 
dose); and prescriber (general practitioner or specialist). The GIP-database does not 
provide information concerning indications for use of the medicines nor the complete 
registration of non-prescription medicines.
Study population
We collected prescription data from the GIP database of all patients who received at 
least one prescription in the period January 1 1996 – December 31 2000 for lamotrigine 
and/or one of the three most frequently prescribed antiepileptic drugs in the Netherlands 
(i.e. carbamazepine, phenytoin or valproate; n = 98,043). Other antiepileptic drugs in the 
Netherlands (i.e. clonazepam, ethosuximide, felbamate, oxcarbazepine, phenobarbital 
and vigabatrin) represent a combined market share of less than 15% and were not 
considered in this study. The date of first prescription of one of the four antiepileptic 
drugs was defined as the index date. First-time use was defined as a prescription for one 
of these four antiepileptic drugs written during the study period, with no prescription 
for the same drug having been during the twelve months before the index date. Only 
first-time users were included in this study (n = 37,695). Due to the selection criteria, 
these were only first-time users from January 1997 onwards. 
In the Netherlands drugs are dispensed for a maximum of three months. In order to 
prevent the occurrence of information gaps, patients were included only if the period 
between two subsequent prescriptions (any drug) was less than 180 days (n = 32,206). 
Thus, the final study population included only new users of one of the four 
antiepileptic drugs: either patients who did not receive any antiepileptic drug during 
the twelve months before the index date, or patients who received one or more other 
antiepileptic drugs before the index date (figure 1).
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Analysis of the diffusion process
The diffusion process of lamotrigine was characterised by analysing different aspects 
of the prescription pattern. First, the market share of lamotrigine was compared to that 
of the three conventional antiepileptic drugs. Market share of the four antiepileptic 
drugs was calculated as the number of first-time users of the antiepileptic drug during 
the study period divided by the source population in the GIP database. 
As a second aspect of the diffusion process, differences in the prevalence of baseline 
characteristics in the lamotrigine cohort and the cohort of patients receiving the 
conventional antiepileptic drugs (reference group) were compared. Crude prevalence 
odds ratios were calculated using multiple logistic regression and were presented with 
a 95% CI. The whole group of users of conventional antiepileptic drugs was taken as 
reference, instead of users of separate conventional antiepileptic drugs, because the 
combined group was considered to be more representative of the entire population 
using antiepileptic drugs. In the comparisons between new users of lamotrigine and 
the reference group the following characteristics were evaluated: 
• age (on the index date) and gender;
• type of prescriber: general practitioner, neurologist, psychiatrist or other;
• prescription of different antiepileptic drugs during the twelve months before the 
index date. The prior use of antiepileptic drugs, and especially that of vigabatrin, was 
used as a marker for refractory epilepsy;
• prescription of psychotropic agents (antidepressants, antipsychotics, lithium salts) 
and abortive migraine medication during the twelve months before the index 
History before index date
AED A
no AED
AED A
AED A
no AED
Pattern Inclusion?
continuation of therapy NO
start of therapy YES (AED A)
switch of therapy YES (AED B)
add-on therapy YES (AED B)
start of therapy & YES
add-on therapy (AED A & B)
Start of analysis
AED A
AED A
AED B
AED A AED B
AED A AED B
The study population included only new users of a specific AED (e.g. AED A or AED B) during January 1996
until December 2000. As a consequence of the long time-frame one patient could be a new user of more 
than one AED.
Figure 1. Study population
01.01.1996 index date 12.31.2000index date
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date. The use of these drugs was used as a marker for off-label use (e.g. for bipolar 
depression, migraine) of lamotrigine. 
As a consequence of the long follow-up period, patients could be a first-time 
user of more than one antiepileptic drug (as shown in figure 1). For the statistical 
methods used, independent observations are required, which is not the case if a patient 
contributed more than one observation. Therefore, an analysis was also performed that 
was restricted to only one new use (chosen randomly) for each user with multiple new 
uses. This did not change the estimates. 
A third aspect of the diffusion process was the analysis of any changes in the 
population that used lamotrigine throughout the study period. In order to find out 
if lamotrigine treatment reached a more heterogeneous population than the one 
considered for inclusion in the initial add-on randomised controlled trials (7,8), trends in 
the following baseline characteristics were evaluated:
• increased prevalence of lamotrigine in patients outside the age category 18 – 65;
• increased prevalence of lamotrigine in patients without a history of antiepileptic drug 
use;
• increased prevalence of lamotrigine in patients with either lithium or abortive 
migraine medication in their history.
The trend analyses also evaluated if the prescription patterns regarding gender 
changed through time. For these analyses the relative risks (RR) per period of three 
months were calculated using the first three months after the start of reimbursement 
of lamotrigine as reference. The Chi-square test was applied to statistically describe 
trends in prescribing from 1997 to 2000.
RESULTS
A total of 29,718 patients were identified who received a prescription of 
carbamazepine, phenytoin, valproate or lamotrigine for the first time during the study 
period. These patients accounted for a total of 32,206 new uses of antiepileptic drugs. 
The development in market share is presented in figure 2. Carbamazepine and valproate 
accounted for the majority of all new prescriptions (52% and 29%, respectively). After 
reimbursement settlement (August 1997), the market share of lamotrigine rose quickly 
to approximately 9 patients per 100,000 persons insured per year. Initially, the market 
share of lamotrigine exceeded that of phenytoin (approximately 7 patients per 100,000), 
but from 1998 onwards the market share of lamotrigine levelled off to approximately 
4.4 patients per 100,000 per year. On average, the market share of lamotrigine was less 
than 10%; within the group of neurologists, the market share reached 16%.
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Table 1 shows the characteristics of the patients stratified according to the 
antiepileptic drug treatment started with at the index date. Overall, 60% of the patients 
were women, the median age was 52. A majority of patients (76%) had no history of 
antiepileptic drugs in the year before the index date. A high prevalence of psychotropic 
drugs was registered, especially benzodiazepines (47%) and antidepressants (24%). 
Differences in baseline characteristics of the lamotrigine group and the reference group 
are presented in table 2. Lamotrigine users were significantly younger than users of one 
of the conventional antiepileptic drugs (OR0-17 years 2.8; 95%CI 2.5 – 3.1), and more often 
male than female (OR 1.4; 95%CI 1.3 – 1.5). Lamotrigine patients had more frequently 
used one or more antiepileptic drug prior to the index date when compared to users 
of one of the conventional antiepileptic drugs (OR 35.5; 95%CI 31.6 – 39.9). Prior use of 
vigabatrin was significantly more prevalent in the lamotrigine group (OR 25.5; 95%CI 
21.9 – 29.7). Prescribers of lamotrigine were more often neurologists (OR 2.8; 95%CI 2.6
– 3.0). In addition, the prevalence of psychotropic medication and migraine-aborting 
drugs was significantly lower with users of lamotrigine than with users of conventional 
antiepileptic drugs.
Several significant changes were observed in the type of patients receiving 
lamotrigine during the first years after its introduction (figure 3). The ratio of age 
categories changed; the RR for patients outside of the age category 18-65 (included in 
the initial randomised controlled trials) increased to 3.0 at the end of the study period 
(p-value for trend < 0.01). The number of patients in the age category 18-65 fell from 
86% in 1997 to 68% in 2000. The RR for patients without a history of use of another 
antiepileptic drug increased to 5.2 (p-value for trend < 0.01). The number of patients 
Figure 2. Incidence of antiepileptic drugs in the Netherlands
CBZ
VPA
PHT
LTG
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using lamotrigine without prior use of any antiepileptic drug increased from 3% in 
1997 to 16% in 2000. Overall, the mean number of antiepileptic drugs prior to the index 
date of lamotrigine dropped from 2.2 in 1997 to 1.5 in 2000. The RR for markers of off-
label use increased to 5.0 (p-value for trend < 0.01). Over the study period, a significant 
increase in the number of prescriptions for women was noticed: the RR increased to 1.5
(p-value for trend < 0.01). Differences in the prescription patterns of the conventional 
antiepileptic drugs were analysed in a similar way; however, no significant changes 
were observed for any of the baseline characteristics. The same analyses were applied 
for the reference group; the RRs for the characteristics mentioned above did not change 
significantly.
Gender
Male
Female
Age
0-17 years
18-64 years
≥ 65 years
Prior use of antiepileptic drugs
None
One
Two
Three or more
Vigabatrin
Prescriber
General Practitioner
Neurologist
Psychiatrist
Other
Prior use of comedication
Antidepressants
Antipsychotics
Benzodiazepines
Lithium
Migraine abortive drugs
1,377 (46.8)
1,567 (53.2)
483 (16.4)
2,164 (73.5)
297 (10.1)
341 (11.6)
855 (29.0)
1,069 (36.3)
679 (23.1)
555 (18.9)
506 (17.2)
1,456 (49.4)
70 (2.4)
912 (31.0)
312 (10.6)
188 (6.4)
1,146 (38.9)
65 (2.2)
85 (2.9)
6,249 (37.1)
10,596(62.9)
497 (2.9)
10,304(61.2)
6,044 (35.9)
14,779(87.7)
1,679 (10.0)
304 (1.8)
83 (0.5)
77 (0.5)
9,489 (56.3)
2,899 (17.2)
704 (4.2)
3,753 (22.3)
4,599 (27.3)
1,427 (8.5)
8,227 (48.8)
591 (3.5)
734 (4.4)
3,748 (40.4)
5,519 (59.6)
907 (9.8)
6,123 (66.1)
2,237 (24.1)
7,094 (76.6)
1,631 (17.6)
400 (4.3)
142 (1.5)
120 (1.3)
2,241 (24.2)
3,422 (36.9)
818 (8.8)
2,786 (30.1)
2,273 (24.5)
1,538 (16.6)
4,235 (45.7)
735 (7.9)
1,256 (13.6)
1,433 (45.5)
1,717 (54.5)
58 (1.8)
1,665 (52.9)
1,427 (45.3)
2,210 (70.2)
637 (20.2)
206 (6.5)
97 (3.1)
67 (2.1)
1,051 (33.4)
1,283 (40.7)
15 (0.5)
801 (25.4)
535 (17.0)
188 (6.0)
1,443 (45.8)
11 (0.3)
89 (2.8)
Characteristics, N(%) LTG 
(n = 2,944)
CBZ 
(n = 16,845)
VPA 
(n = 9,267)
PHT 
(n = 3,150)
Comparator group (n = 29,262)
Table 1.   Baseline characteristics of the study population
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Age
0-17 years
18-64 years
≥ 65 years
Prior use of antiepileptic drugs
None
One
Two
Three or more
VigabatrinB
Prescriber 
General Practitioner
Neurologist
Psychiatrist
Others
Prior use of comedicationB
Antidepressants
Antipsychotics
Benzodiazepines
Lithium
Migraine abortive drugs
2.76 (2.47 – 3.09)
reference
0.26 (0.23 – 0.29)
reference
15.30 (13.43 – 17.42)
82.96 (72.22 – 95.31)
148.92 (125.60 - 176.58)
25.50 (21.91 – 29.71)
0.21 (0.19 – 0.23)
reference
0.24 (0.19 – 0.30)
0.65 (0.59 – 0.71)
0.35 (0.31 – 0.39)
0.57 (0.49 – 0.66)
0.70 (0.65 – 0.76)
0.47 (0.37 – 0.61)
0.39 (0.31 – 0.49)
Table 2.   Characteristics of patients starting with lamotrigine compared to those starting 
                   with conventional antiepileptic drugs
Reference group =combined group of patients starting with carbamazepine, phenytoin or valproate. 
OR = odds ratio. B(presence vs. absence).
Characteristics OR (95% CI)
Gender; male 1.40 (1.27 – 1.48)
Figure 3. Trends in lamotrigine utilisation throughout the study period
marker ‘off label use’
age outside 18-65 yrs.
no history of AED use
female : male
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DISCUSSION
Having access to a large prescription database allowed us to follow the diffusion 
of lamotrigine in a population-based cohort. The results of our study have shown that 
the uptake of lamotrigine was rather slow. After its introduction in the Netherlands, 
lamotrigine was prescribed to patients who had previously received other antiepileptic 
drugs, suggesting that it was introduced as a second-line or third-line treatment. 
Subsequently, the diffusion process of lamotrigine resulted in a more heterogeneous 
population being reached. According to Rogers, new ideas are adopted very slowly during 
the early stages of the diffusion process, the rate of adoption, however, increases steadily 
(3,4). Remarkably, after the diffusion process for lamotrigine had passed the early stages, 
a further increase in market share has yet to take place. Several possible barriers can be 
characterised that probably slowed down the uptake of lamotrigine.
a. Characteristics of the drug itself affect use. Rogers’ theory states that the rate 
of diffusion is inversely proportional to the perceived complexity of the innovation (3). 
Lamotrigine is not simple to use (9). The use is hampered by a relative high incidence 
of idiosyncratic adverse events, predominantly rash (10,11). Review of trial data showed 
that severe rashes occur more often with rapid titration in pediatric patients. Valproate 
inhibits the metabolism of lamotrigine, and this has major clinical impact on the risk 
of skin reactions (9). The metabolism of lamotrigine is accelerated by enzyme-inducing 
antiepileptic drugs such as carbamazepine and phenytoin, necessitating higher dosage 
with these co-medications. The complexity of lamotrigine, i.e. the slow titration schedule 
and its interaction potential, will probably have caused slower diffusion, expressed in the 
numbers of new patients. This may possibly have been worsened by the introduction 
since 2000 of other new antiepileptic drugs, like gabapentin and levetiracetam, with 
less interaction potential and faster titration schedules than lamotrigine. It would be 
interesting to see whether the diffusion process of these new antiepileptic drugs was 
different compared to that of lamotrigine. Both gabapentin and levetiracetam, however, 
were not registered in the Netherlands until after 2000, so follow-up data of these drugs 
are absent from our database.
b. Prescriber characteristics. Individuals do not all adopt an innovation at the same 
time, and they can be divided into several adopter categories (innovators, early adopters, 
early majority, late majority and laggards) (3). The majority of physicians is considered to 
be conservative (late majority and laggards) regarding drug choice (6). In our study, we 
conclude from the differences in baseline characteristics that selective prescribing of 
lamotrigine to patients with more severe epilepsy has occurred. We believe that prior use 
of other antiepileptic drugs, and the use of vigabatrin especially, can be seen as markers 
for refractory epilepsy. Selective prescribing, or “channelling”, is likely to occur for new 
representatives of a therapeutic class for which alternatives existed, as is the case for 
antiepileptic drugs. This is a general phenomenon, which has been demonstrated for 
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various drug classes, e.g. NSAIDs, antidepressants or spasmolytics (12-14). The peak in 
incidence noticed shortly after reimbursement approval could possibly be related to 
the backlog of patients with refractory epilepsy. About the introduction of lamotrigine, 
safety issues regarding two other new antiepileptic drugs played a part. One year after 
approval of felbamate, reports of aplastic anaemia began to emerge (11). Several years 
after the introduction of vigabatrin, evidence was produced that prolonged high-dose 
treatment may cause severe and symptomatic irreversible visual field constriction (9,15). 
The detection of such safety risks may have withheld many physician’s from prescribing 
antiepileptic drugs that had been registered after felbamate and vigabatrin.
c. Economic aspects. The pharmaceutical cost of lamotrigine is at least a fivefold of 
that of conventional antiepileptic drugs. Indiscriminate switching from conventional to 
new antiepileptic drugs would have considerable economic implications (9). A survey 
among U.S. neurologists showed that neurologists recognise the need to rationalise 
health care and that they are willing to accept the notion that individual sacrifices can 
and should be made because of the finite healthcare resources (16). Increasing pressure 
on drug budgets will make physicians more reluctant to prescribe new drugs.What’s 
more, the Dutch National Health Care Insurance tried, by issuing the prescription 
guideline for lamotrigine, to contain the cost of the drug by restricting its prescription 
to patients with refractory epilepsy. This may also have reduced the “trialability” of 
lamotrigine. “Potential adopters” want the opportunity to “test” a drug before adopting 
(3). The prescription guideline could have prevented this testing, although we were not 
able to evaluate how the guideline was adhered to in the present study. 
Despite the barriers mentioned above, the diffusion of lamotrigine is still ongoing. 
This study shows that the cohort of lamotrigine users is subject to change. Gradually, the 
baseline characteristics of the patients start to drift away from those of the patients in 
the initial, add-on regulatory trials. From 1997 to 2000, lamotrigine gradually became an 
antiepileptic drug of first and second choice, and was increasingly being given to children 
and elderly persons. It is well-known that the publication of new, high-level evidence 
(i.e. randomised controlled trials) influences prescription patterns (17). Randomised 
trials comparing lamotrigine to carbamazepine, phenytoin and valproate in patients 
with newly diagnosed epilepsy are available in medical literature (18-21). Broadly 
speaking, these trials showed that lamotrigine cannot claim greater efficacy than the 
conventional antiepileptic drugs but that the drug seemed to be tolerated better than 
its comparators, with fewer withdrawals due to adverse events. A similar result emerged 
from a trial comparing lamotrigine and carbamazepine in elderly patients (over 65 years 
of age) with newly-diagnosed epilepsy (22). Trials and observational studies assessing 
lamotrigine in the treatment of childhood epilepsy syndromes also became available. 
This is likely to be an important factor explaining the overall trend towards more use 
of lamotrigine for the young, as carbamazepine and phenytoin are not indicated in 
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the treatment of the idiopathic generalised epilepsy syndromes. Trial data on the 
effectiveness of lamotrigine in the treatment of other diseases than epilepsy has also 
started to emerge (23-26). We noticed a strong increase in markers for off-label use. Our 
data suggests that there is an increased use of lamotrigine for second-line treatment 
of bipolar disorder (markers: lithium and antidepressants); neuropathic pain (marker: 
antidepressants) and migraine (marker: abortive migraine drugs).
Compared to the conventional antiepileptic drugs, lamotrigine has been positioned 
as a better alternative for women of childbearing age, which may explain the increased 
prevalence in women. There are several aspects that make lamotrigine favourable for 
this group of patients. First, pregnancy data on lamotrigine increases and the drug 
does not seem to have major teratogenic effects (27). Given the known effects of the 
conventional antiepileptic drugs, this may possibly explain the increase seen. Second, 
there is a controversy regarding the question whether the use of valproate is associated 
with a higher incidence of polycystic ovary syndrome (PCOS) (28,29). Herzog and Schacter 
conclude that, despite limitations in studies reporting an association between the use 
of valproate and occurrence of PCOS, the evidence cannot be entirely dismissed (30). 
As valproate also has teratogenic effects, it may be concluded that it is less suitable for 
women of childbearing age. Lamotrigine has been positioned as a better alternative for 
this group. Third, lamotrigine lacks an enzyme-inducing capacity and does not reduce 
the effect of oral contraceptives (whereas carbamazepine and phenytoin do). More 
recently, however, a relevant interaction between lamotrigine and oral contraceptives 
became known (31).
The changing baseline characteristics shown in figure 3 make it clear that there is a 
gap between the information available from the initial randomised controlled trials and 
the use of lamotrigine in the real world of medicine. These changes are relevant to issues 
like rational drug therapy, effectiveness and safety in a population-based setting. This 
supports post-marketing surveillance studies addressing these issues (32). The results 
of this study should be interpreted in the light of its limitations. A first limitation of our 
study is the lack of additional medical information, most importantly the indications 
of use. It is common knowledge that antiepileptic drugs are used for other indications 
than epilepsy. However, to what extent, depends on the individual antiepileptic drug 
(33). Using a Dutch prescription database (PHARMO), Shackleton et al. demonstrated 
that epilepsy was present in 58% of patients using a single antiepileptic drug, and 
epilepsy prevalence was 93% in patients using more than one antiepileptic drug (33). 
Carbamazepine was more often used for other indications than the other conventional 
antiepileptic drugs. We believe that, by using a combined reference group, we are 
comparing lamotrigine to a population-based use of conventional antiepileptic drugs 
(i.e. use of these drugs for epilepsy and other indications as prescribed by various types 
of physicians). We had to use surrogate markers, however, to illustrate off-label use of 
lamotrigine. The prevalence of a marker in an individual patient will not always mean 
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that off-label use is the case, for some misclassification has certainly occurred.
Furthermore, the GIP database comprises prescription data of the compulsorily 
insured patients in the Netherlands. It might be argued whether the results are also 
representative for the higher socio-economic classes, which are not covered by the 
national health insurance system. However, as there are no reimbursement limitations 
for antiepileptic drugs in both the national health insurance system and the private 
insurance companies, difference between socio-economic classes are not expected. 
Another limitation is that we were not able to evaluate other relevant characteristics 
that enhanced diffusion, such as the physician’s attitude towards new drugs like 
lamotrigine, or the impact of drug marketing by the pharmaceutical company. The 
latter aspect may also be a explanation for the increased use of lamotrigine for women; 
however, we were not able to evaluate this.
Our conclusion is that there are a multitude of factors influencing the diffusion 
of lamotrigine into daily practice. Starting in a selected group of patients with severe 
epilepsy, the drug gradually diffuses to a much more heterogeneous population. 
Understanding the process of diffusion is important in the evaluation of the place in 
therapy of lamotrigine, its effectiveness in real life and its cost consequences.
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ABSTRACT
Objective
Follow-up data on the long-term effectiveness (efficacy and tolerability) of 
lamotrigine are limited. A useful though crude measure for effectiveness in daily 
clinical practice is the treatment retention rate determined from drug dispensing data. 
This study describes the baseline characteristics, the usage patterns and the retention 
rate of this antiepileptic drug in a population-based cohort of lamotrigine users in the 
Netherlands during the first five years after its registration in 1995. Data from this 
cohort are compared with those from the initial randomised clinical trials (RCTs) in 
patients with refractory epilepsy.
Methods 
This retrospective cohort study used dispensing data from community pharmacies. 
Baseline characteristics and usage patterns were evaluated for first time users of 
lamotrigine in this study. Usage patterns were characterised as continued, add-on or 
discontinued use during the patient observation time window. Cox regression analysis 
was used to explore possible relationships between baseline characteristics and specific 
usage patterns defined. The baseline characteristics and discontinuation rates in this 
cohort study were compared with randomised controlled trial data reported in medical 
literature.
Results
A total of 3,598 lamotrigine users were identified. The mean age of the population 
was 39 years and 54% were female. On average, patients used two other antiepileptic 
drugs at the start of lamotrigine therapy and approximately 6% of the patients had 
no history of prior antiepileptic drug use. The discontinuation rate was 25% after one 
year, and approximately 32% at the end of the 5-year study. Addition of another drug or 
discontinuation was seen in more than half of the population three years after the start 
of therapy. Concurrent use of valproic acid was associated with a better retention rate. 
Absence of antiepileptic drug history, use of antidepressants, or use of migraine abortive 
drugs resulted in an increased likelihood of discontinuing lamotrigine. The population 
from randomised controlled trials differed from the study cohort with respect to age, 
concurrent use of antiepileptic drugs and length of follow-up.
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Discussion
Data from randomised controlled trials cannot easily be extrapolated to daily clinical 
practice. In this large, observational study, lamotrigine therapy failed in a considerable 
number of patients, although the mean retention rate was better than previously 
reported by others. Population-based linkage of health care records can be used to 
further clarify the effectiveness of lamotrigine. 
 INTRODUCTION
Lamotrigine was introduced in the Netherlands in 1995, based on data from clinical 
trials regarding its efficacy, tolerability and safety. In add-on trials involving patients 
with intractable epilepsy, lamotrigine reduced seizure frequency by more than 50% in 
approximately 30% of patients (1-3). However, clinical trials do not mirror daily practice, 
as in trials the effects of the drug are examined (a): for a limited period of time; (b): 
under well-controlled conditions and (c): in a homogeneous, though highly selected, 
group of patients (4,5). This may affect the generalisability of findings from clinical 
trials with regard to efficacy, tolerability and safety to daily clinical practice and pleas for 
observational research within the setting of daily clinical practice. 
A useful though crude measure of effectiveness in large observational studies is the 
retention time using drug-dispensing data. Effectiveness is an outcome measure, which 
encompasses both efficacy and tolerability (6). This study focused on the retention time 
on lamotrigine and on patterns of the drug’s use in the Dutch community. By using 
dispensing data, we identified lamotrigine users during the first five years after its 
introduction. The objective of the present study is to describe baseline characteristics, 
and compare these characteristics with those from the initial clinical trials of lamotrigine 
in patients with refractory epilepsy.
METHODS
Data collection and source population
There is a high level of agreement between automated pharmacy data and self-
reported drug use, especially for drugs used chronically (7,8). Analysing computerised 
records of prescriptions actually filled, thus makes it possible to collect information on 
drug use for a large number of patients (9,10).
This retrospective cohort study used prescription data from community pharmacies 
in the Netherlands. A total of 1428 (90%) pharmacies out of 1586 Dutch pharmacies in 
January 2001 received a request for anonymous data of all patients to whom lamotrigine 
was dispensed during the observation period. The selected pharmacies used one of the 
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three major pharmacy computer systems in the Netherlands. These pharmacies serve an 
open population of approximately 13 million persons. 
For each patient who filled at least one lamotrigine prescription during January 
1996 to December 2000, a complete prescription drug dispensing history, covering the 
period 1996 – 2000, was collected by means of computerised data extraction methods. 
Each dispensed drug led to one electronic record containing patient information (unique 
though anonymous identification number, gender, date of birth and residential postal 
code) and information about the prescribed medicine (drug identification number, 
dispensing date, number of units dispensed and the prescribed daily dose). The software 
program Microsoft Access was used for database management, internal quality control 
and validation procedures. The resulting research database consisted of 6,544 patients 
and 660,097 prescriptions.
Study population
For the present study only those patients were included who received lamotrigine for 
the first time. The date of first prescription of lamotrigine was defined as the index date. 
To ascertain first time use, patients were required to have at least 365 days of prescription 
history for any medicine before the index date (180 days for children under 2 years of 
age). Patients who were not regular visitors of the pharmacy, defined by a time gap of 
more than 180 days between two successive prescriptions for whatever medication, 
were excluded from the analysis. Patients with a follow-up time (i.e. observation period 
between index date and the last ever registered prescription) of less than 180 days were 
also excluded. Application of these exclusion criteria resulted in a study population of 
3,598 patients with 468,859 prescription records as shown in table 1.
Inclusion criteria
Initial population
A minimum of 1 year drug history before 
index date*
Less than 180 days between two successive 
prescriptions
A minimum of 180 days of follow up after 
index date
Final study population
Number of patients 
excluded
–
1,786
728
432
– 
Table 1.   Application of inclusion criteria to the initial patient population
Remaining study 
population
6,544
4,758
4,030
3,598
3,598 (55%)
*For children under two years of age an period of 180 days of drug history was required
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DATA ANALYSIS
Baseline characteristics
Baseline characteristics of the study population that were examined included 
gender, age at index date and certain concomitantly used medication. For co-medication 
we focused on the prescription of other antiepileptic drugs, psychotropic drugs 
(antidepressants, antipsychotics, benzodiazepines, lithium salts) and migraine abortive 
drugs. 
Lamotrigine patterns of use and retention rate 
For each prescription, the theoretical duration of use was calculated using 
information on dispensing date, amount supplied and dosage regimen. The observation 
window for each patient was defined as the time between the date of the first 
prescription and the theoretical end date of the last prescription registered. Lamotrigine 
retention time was calculated as the sum of the theoretical duration of consecutive 
lamotrigine prescriptions. Patterns of use (continuation, add-on and discontinuation) 
were defined for cohort members, based on observation window and lamotrigine 
retention time (as shown in figure 1). Continuation of lamotrigine therapy was defined 
for patients with less than 180 days between the theoretical end date of lamotrigine 
and the end of the observation window. Add-on was defined if another antiepileptic 
drug was added to lamotrigine, without discontinuation of lamotrigine therapy. 
Discontinuation of lamotrigine therapy was defined for patients for whom more than 
180 days elapsed between the theoretical end date of the last lamotrigine prescription 
refill and the end of the observation window. The baseline characteristics were explored 
in order to identify a possible association with the specific usage pattern defined using 
C
B
A
Figure 1. Patterns of lamotrigine use
01.01.1996 12.31.2000index date time to event
*
*
Information from all prescriptions (observation window, dashed line) and lamotrigine prescriptions (concrete line) was 
used to measure lamotrigine retention and to defi ne patterns of use. A: continuation of lamotrigine; B: discontinuation 
of lamotrigine (more than 180 days between end date of lamotrigine and end of observation window); and C: add-on 
of another AED (dotted line) after the start of lamotrigine. Time to fi rst event (either discontinuation, add-on or end of 
analysis) was used in statistical analyses.
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Cox proportional hazard modelling. The strength of these associations was expressed by 
hazard ratios with 95% CI. Hazard ratios can be interpreted as relative risks (RR) in this 
analysis. In a subsequent analysis, we stratified patients into those who filled just one 
prescription and those who filled more than one lamotrigine prescription.
Comparison with reported clinical trials
We compared the data from our study with those from randomised controlled 
trials published in the medical literature, that examined the efficacy of lamotrigine 
in patients with refractory epilepsy. Data from unpublished randomised controlled 
trials or from trials that enrolled less than 25 patients in the lamotrigine treatment 
group were summarised from a meta-analysis performed by Marson et al. (3). Baseline 
characteristics and discontinuation rates were compared between trial population and 
population-based cohort.
RESULTS
Baseline characteristics
A total of 1,056 pharmacies (74% response) responded to our request to retrieve 
prescription data of all patients to whom lamotrigine was dispensed. The responding 
pharmacies covered both large and small pharmacies and both low and highly urbanised 
areas. In all, 3,598 new users of lamotrigine were identified during the observation 
period. These patients could be followed for a mean observation window of 4.6 years 
per patient. The corresponding baseline characteristics are shown in table 2. The mean 
age of the population was 39 years, and 54% was female. There were 218 (6.1%) patients 
not using other antiepileptic drugs on the index date. A significant trend towards an 
increased incidence of patients without an antiepileptic drug-history was observed 
from 1996-2000. On average, patients used two other antiepileptic drugs on the index 
date (range 0 – 8); carbamazepine and valproic acid were by far the most frequently 
concomitantly used other antiepileptic drugs. 
Benzodiazepines (excluding clobazam, clonazepam, and diazepam) were the most 
prevalent concomitantly used psychotropic drugs in the year prior to the index date 
(26%), followed by antidepressants (10%), migraine abortive therapy (3%) and lithium 
(1.5%).
Retention rates and patterns of use
The mean time from the initiation of lamotrigine therapy to a change in lamotrigine 
therapy (discontinuation or add-on) or completion of the observation period was 
1.3 years (range 17 days – 4.2 years). One year following the initiation of lamotrigine 
therapy approximately 25% of the study population had discontinued therapy, the 
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discontinuation rate at three years was 32% (figure 2). Addition of another antiepileptic 
drug increased linearly by approximately 10% per year for the first three years after 
initiation of lamotrigine. Clobazam, topiramate and gabapentin were most frequently 
used as add-on antiepileptic drug.
Demographics
Age, years [Mean (SD)]
0 – 17
18 – 34
35 – 49
50 – 64
≥ 65
Female gender
Index year
1997
1998
1999
2000
Number of previous antiepileptic drug trials
(prior and concurrent)
None
1
2
≥ 3
Concomitant use of other antiepileptic drug trials
Carbamazepine
Valproate
Phenytoin
Vigabatrin
Concomitant use of other medication
Antidepressants
Antipsychotics
BenzodiazepinesB
Lithiumsalts
Migraine abortive drugs
Observation window, in years [Mean (SD)]
[38.5 (19.9)]
642 (17.9)
873 (24.2)
1,000 (27.8)
690 (19.2)
393 (10.9)
1,954 (54.3)
605 (16.8)
1,035 (28.8)
1,168 (32.5)
790 (21.9)
218 (6.1)
856 (23.8)
1,263 (35.1)
1,261 (34.0)
1,510 (42)
1,424 (39.6)
566 (15.7)
534 (14.8)
352 (9.8)
243 (6.8)
925 (25.7)
53 (1.5)
118 (3.3)
[4.6 (0.8)]
Table 2.   Baseline characteristics of study population (n = 3,598)
B Others than clobazam, clonazepam, or diazepam. 
Characteristics Number of patients (%)
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In total, there was a change in therapy (either discontinuation or add-on) in 
approximately 52% of the study population after three years of follow-up. 
Usage patterns of lamotrigine treatment stratified according to various baseline 
characteristics are shown in table 3. Males were as likely to continue treatment as 
females. Patients aged 65 years or above discontinued treatment at an earlier phase 
(RR 1.35; 95% CI 1.08 – 1.68). Addition of another antiepileptic drug after the start of 
lamotrigine treatment was less likely for patients that used valproic acid concomitantly 
(RR 0.51; 95% CI 0.29 – 0.90). 
Prior use of migraine abortive drugs lead to a more rapid onset in discontinuation of 
lamotrigine (RR 1.39; 95% CI 1.03 – 1.88). Patients on antidepressants prior to the start 
of lamotrigine were more likely to have a change in lamotrigine therapy (RR 1.60; 95% 
CI 1.35 – 1.88).
Overall, patients with a history of earlier antiepileptic drug treatment were more 
likely to continue lamotrigine treatment compared to patients who had no background 
of antiepileptic drug-treatment prior to using lamotrigine (RR 0.71; 95% CI 0.58 – 0.89). 
Stratification by the number of filled lamotrigine prescriptions (one versus more than 
one prescription) showed that 7% of all patients (n = 257) discontinued lamotrigine 
therapy after filling just one prescription. Patients without a history of antiepileptic 
drugs were more prone for rapid discontinuation, 47 patients (22%) discontinued 
therapy after filling one prescription, compared to 6% (n = 210) in the group with a 
history of antiepileptic drugs.
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0.0
0.2
0.4
0.6
0.8
Figure 2. Cumulative Hazard rates: patterns of discontinuation or add-on
Cumulative hazard rates for occurrence of add-on pattern of use (  ); discontinuation pattern of use (  ); and both 
patterns of use combined (  ).
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Socio-demographics
Age 
0 – 17 year
18 – 34 year
35 – 49 year
50 – 64 year
≥ 65 year
Gender
Male
Female
Index year
1997
1998
1999
2000
Previous number of 
antiepileptic drug trials
None
≥ 1
Concomitant antiepileptic 
drugsC
Carbamazepine
Valproate
Phenytoin
Vigabatrin
Prior use of comedicationC
Antidepressants
Antipsychotics
Benzodiazepines
Lithiumsalts
Migraine abortive drugs
0.92 [0.72 – 1.21]
1.00 [reference]
0.98 [0.81 – 1.17]
1.20 [0.99 – 1.45]
1.35 [1.08 – 1.68]
1.00 [reference]
1.09 [0.96 – 1.24]
1.00 [reference]
1.30 [0.98 – 1.59]
1.27 [0.96 – 1.56] 
0.93 [0.74 – 1.17]
1.00 [reference]
0.61 [0.48 – 0.78]
0.85 [0.71 – 1.10]
1.17 [0.77 – 1.78]
0.77 [0.63 – 1.04]
0.81 [0.61 – 1.08]
1.85 [1.54 – 2.23]
1.12 [0.89 – 1.43]
1.17 [1.01 – 1.34]
0.77 [0.48 – 1.23]
1.39 [1.03 – 1.88]
1.26 [0.95 – 1.68]
1.00 [reference]
0.81 [0.64 – 1.02]
0.77 [0.60 – 1.08]
0.79 [0.56 – 1.13]
1.00 [reference]
0.89 [0.75 – 1.05]
1.00 [reference]
1.49 [0.36 – 6.10]
1.21 [0.59 – 2.45]
1.18 [0.77 – 1.81]
1.00 [reference]
0.75 [0.61 – 0.94]
1.07 [0.75 – 1.51]
0.51 [0.29 – 0.90]
1.08 [0.85 – 1.37]
1.15 [0.82 – 1.61]
1.23 [0.87 – 2.31]
0.79 [0.54 – 2.31]
1.24 [0.81 – 1.42]
0.73 [0.27 – 2.04]
1.43 [0.89 – 2.31]
1.03 [0.86 – 1.25]
1.00 [reference]
0.91 [0.79 – 1.05]
1.01 [0.86 – 1.18]
1.13 [0.94 – 1.36]
1.00 [reference]
1.01 [0.91 – 1.12]
1.00 [reference]
1.21 [0.89 – 1.36]
1.19 [0.91 – 1.39]
1.11 [0.92 – 1.33]
1.00 [reference]
0.71 [0.58 – 0.89]
1.06 [0.81 – 1.38]
0.73 [0.63 – 0.84]
1.02 [0.83 – 1.26]
0.95 [0.76 – 1.18]
1.60 [1.35 – 1.88]
1.03 [0.85 – 1.26]
1.24 [0.94 – 1.40]
0.82 [0.54 – 1.24]
1.39 [1.08 – 1.79]
Table 3.   Determinants of lamotrigine discontinuation or failure
B Relative risk [RR] versus continued use, C Presence versus absence (reference)
Covariant Discontinuation 
(n = 951)
RR [95%CI]B
Add-on 
(n = 534)
RR [95%CI]B
Overall
(n = 1485)
RR [95%CI]B
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Comparison with reported clinical trials
Study characteristics of patients in the add-on randomised controlled trials 
compared with those in the present study are shown in table 4. 1,000 Patients were 
included in the randomised controlled trials and the length of follow-up ranged from 
eight weeks to six months. 
Excluded from the randomised controlled trials were patients under 15 years of age, 
and above 67 years of age. These age categories comprised more than one fourth in our 
cohort of patients. Lamotrigine was used only as an add-on drug in these trials, whereas 
in the present study 6% of patients had no history of antiepileptic drugs. Concurrent 
use of valproate was not allowed in the clinical trials, in the present study 40% of 
patients had concurrent use of valproate. The reported estimates of the discontinuation 
rates at the end of the trial periods ranged from 4 to 19%. In the present study the 
discontinuation rate was 10% at eight weeks, 20% at 6 months and 25% at 12 months 
after initiation of lamotrigine.
Table 4.   Randomised clinical trials of add-on lamotrigine in patients with refractory epilepsy
B Meta-analysis including trials by Matsuo et al, Messenheimer et al, unpublished trials and trials with less 
than 25 patients in the lamotrigine treatment group.
C Concurrent use of valproic acid was an exclusion criterion in clinical trials. N.a. = not analysed.
Characteristics Matsuo 
et al. (1)
Messenheimer 
et al. (2)
Marson 
et al. (3)B
Dutch 
cohort
Study design and Demographics
Design
Patient selection
Number of patients, 
n (LTG:placebo)
Male:Female
Mean age (y) (range)
Duration of follow-up (weeks) 
Concurrent antiepileptic drug 
therapy, n (%)
None
1 antiepileptic drug
2 antiepileptic drugs
3 antiepileptic drugs
CBZ
PHT
VPA
Overall discontinuation rate
RCT, parallel
chronic 
epilepsy
216 
143:73
67:149
33 (18 - 63)
24
0
86 (40)
115 (53)
15 (7)
158 (73)
76 (35)
0C
13%
RCT, crossover
chronic 
epilepsy
88 
46:42
41:47
35 (18 - 64)
14
0
36 (41)
50 (57)
2 (2)
67 (76)
40 (45)
0C 
4%
Meta-analysis
chronic 
epilepsy
1,000 
664: 336
486:514
n.a. (15 - 67)
8 – 24
0
n.a.
n.a.
n.a.
n.a
n.a.
n.a. 
19%
Observational, 
cohort
Population-
based
3,598 
3,598:0
1644:1954
39 (0 - 99)
26 – 222
218 (6)
856 (24)
1,263 (35)
1,261 (34)
1,510 (42)
566 (16)
1,424 (40) 
34%
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DISCUSSION
The baseline characteristics of this Dutch population-based cohort differed from 
those reported from clinical trials, with respect to age, concurrent use of specific 
antiepileptic drugs, and length of follow-up. This may be explained by the use of 
lamotrigine in a broader population of epilepsy patients, including those with less 
severe epilepsy, and newly diagnosed epileptics starting with lamotrigine because of 
intolerable side effects from their previous treatment rather than because of inadequate 
seizure control. As a consequence, data from efficacy studies may not reflect the outcome 
of lamotrigine therapy in daily practice. 
Retention time as an indicator for effectiveness in general practice, reflects a drug’s 
(1) efficacy; (2) tolerability/side effects and (3) ease of use (compliance) (9-11). Addition 
of another antiepileptic drug may reflect insufficient seizure control with lamotrigine. 
The rate of use of an additional antiepileptic drug may therefore reflect lack of efficacy. 
Tolerability or side effects are possibly reflected by the discontinuation rate (without 
previous addition of another antiepileptic drug). Attrition rate appeared to be highest in 
the first year (25%) and slowed in subsequent years. Approximately 7% of patients on 
lamotrigine filled just one prescription. The relatively high discontinuation rate in the 
first year of therapy possibly reflects the rather difficult administration of lamotrigine at 
the start of therapy. The drug should be carefully titrated in order to overcome adverse 
events, particularly rash (12). Approximately 6% of the cohort population had not used 
antiepileptic drugs previously. The discontinuation rate was significantly higher in this 
patient group. In this group of patients 22% stopped with lamotrigine therapy after 
filling just one prescription. Reported predictors of non-compliance are monotherapy, 
and uncomplicated epilepsy (13). Another possible explanation is the availability of an 
increasing number of antiepileptic drugs for patients with newly diagnosed epilepsy, 
and physicians are possibly likely to change treatment sooner. 
There are few published population-based follow-up studies of lamotrigine. Wong 
et al. reported on the long-term retention of add-on lamotrigine in patients with 
refractory epilepsy (n = 1,050) and treated in tertiary referral epilepsy clinics in the 
United Kingdom (UK) (14). They estimated a retention rate for lamotrigine of 48% at 
three years after the start of therapy, compared to approximately 68% in our study. In 
the UK, new antiepileptic drugs (gabapentin, lamotrigine, vigabatrin, and topiramate) 
were available in the UK from the early 1990s onwards. In the Netherlands, registration 
of lamotrigine was in 1995, between that of vigabatrin in 1990, and gabapentin and 
topiramate in 1999. The retention rate on lamotrigine was higher in our study possibly 
because other alternatives were not available for patients with ongoing refractory 
epilepsy. Furthermore, the UK follow up studies focussed on a group of patients with 
difficult-to-manage epilepsy. The reason for lamotrigine initiation in this patient 
group is seizure control. It is possible that our study included a broader population with 
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respect to disease severity and reasons for starting with lamotrigine. The retention rate 
of lamotrigine in patients switching from conventional antiepileptic drugs because of 
intolerable side effects could be better than in those who start lamotrigine for better 
seizure control. 
Another explanation for the observed differences may be an overestimation of the 
retention rate in our study. The date of discontinuation was defined as the date of the 
last recorded lamotrigine prescription plus the duration of that prescription. Moreover, 
the actual time of discontinuation of lamotrigine could not be measured, but was 
assumed if a minimum follow-up period of 180 days exceeded the last lamotrigine 
prescription. This approach may have resulted in an underestimation of the proportion 
of patients stopping lamotrigine therapy. 
Limitations of this study, include absence of clinical information in the pharmacy-
based data. No individual patient information was available on factors such as duration 
of disease, seizure classification and seizure frequency. These factors may also be 
associated with continuity of therapy, e.g. generalised epilepsy is associated with 
higher retention rates of lamotrigine compared to partial epilepsy (14). Also, it remains 
uncertain whether people continuing lamotrigine in the database, experience improved 
seizure control, long-term. Another limitation of using prescription data is that the use 
of lamotrigine is not exclusive to epilepsy treatment, but extends to the treatment of 
bipolar disorder, migraine, or neuralgic pain (15-17). Shackleton et al. estimated the 
prevalence and incidence of epilepsy using the PHARMO database, which contain the 
medication histories of approximately 300,000 individuals (18). They validated the 
use of antiepileptic drugs by checking medical diagnoses of a proportion of identified 
antiepileptic drug users from general practitioners and hospital records. It appeared 
that certain antiepileptic drugs are frequently used for other indications, as only half of 
the patients using carbamazepine monotherapy and 5% of patients using clonazepam 
monotherapy had epilepsy. However, epilepsy was present in 93% of patients using more 
than one antiepileptic drug. As 95% of the new lamotrigine users in our population 
was on polytherapy, it is very likely that the large majority of these individuals had 
epilepsy. Data from a survey of 1,819 patients using lamotrigine, after failure of at least 
one antiepileptic drug, showed that off-label use was less than 6% (own data; not 
published).
The use of antidepressant drugs in patients with epilepsy deserves further attention 
because of the widespread conviction that these drugs facilitate seizures (19,20). 
Moreover, lifetime prevalence of depression in epilepsy is higher than in the non-epilepsy 
population (21). Lamotrigine is an antiglutamatergic agent with activating effects (i.e. 
activation, weight loss) and has been postulated as an effective drug in treating epileptic 
patients with depressive co-morbidity (22). In this study, however, a higher failure rate of 
lamotrigine was observed, indicating that the position of lamotrigine in the treatment 
of this subgroup of patients needs further attention. It is also possible, that lamotrigine 
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was used as an antidepressant or as a drug against neuropathic pain in this group of 
patients. 
This study defines the usage patterns of lamotrigine in a large cohort of patients. 
While treatment retention rate was better than reported previously, there was still a 
substantial proportion of patients who discontinued treatment. The observed use-
patterns are likely to be reflected in populations other than the Dutch. Population-
based linkage of pharmacy data with other clinical data would help in better defining 
the effectiveness of lamotrigine.
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Recruitment of a cohort of lamotrigine 
users through community pharmacists: 
differences between patients who gave 
informed consent and those who did not
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ABSTRACT
Objective
Community pharmacists may function as intermediaries in the recruitment of 
a population-based cohort of patients using specific drugs. In this study baseline 
characteristics and the retention rate of patients that gave informed consent, refused 
and did not answer were compared.
Methods
A total of 1,819 patients using the new antiepileptic drug (AED) lamotrigine were 
asked to provide informed consent for a retrospective chart study via their individual 
pharmacist. Four possible reactions resulted from the consent question: active consent, 
active refusal, passive refusal, and non-informed. Patient characteristics and lamotrigine 
retention rate of the different groups were compared.
Results
Pharmacists did not inform a total of 183 patients (10%). Of the remaining 
patients, a total of 968 (59%) gave consent; 101 (6%) actively refused, and 567 (35%) 
did not respond. Age, burden of illness, psychotropic co-medication, and continuation 
of lamotrigine therapy were related to active consent. Lamotrigine retention rate in 
patients that gave consent was higher than in other patients. 
Discussion
Patient recruitment with community pharmacists as intermediaries for observational 
studies on the effects of (new) drugs is feasible, and allows access to a broad population 
of patients. The recruitment procedure, however, may lead to selection bias.
INTRODUCTION
Electronic records of dispensed prescription drugs obtained from pharmacies are 
a valuable source to evaluate drug effects while used in clinical practice (1,2). Strong 
points of pharmacy data in the Netherlands are: (1) a large catchment area (90% of the 
population); (2) a high patient–pharmacy allegiance; (3) the use of sophisticated and 
standardised pharmacy software. However, a drawback of pharmacy data in general is 
the absence of clinical information on indications for use and on outcomes. Person-
specific data on diagnosis and course of disease can only be obtained from medical 
records after consent by the individual patient, as it is a basic right of the patient to 
be assured that all medical and personal data are confidential. It has been shown that 
the informed consent procedure as generally applied in randomised controlled clinical 
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trials results in a selected group of patients, that may differ with respect to relevant 
prognostic characteristics from the patients who refuse participation (i.e. selection bias) 
(3,4). Whether this phenomena also occurs in observational studies is less well studied. 
The goal of this study is to evaluate whether the consent procedure in an observational 
study into the effectiveness of the new, costly drug lamotrigine induces selection bias.
METHODS
Study setting and design
The present study is part of a larger research project addressing the effectiveness of 
lamotrigine in daily clinical practice. The methods of data collection and the analysis of 
prescription data have been described elsewhere (5). In brief, community pharmacists 
(n = 1428, 90% of all Dutch community pharmacies in 2001) were asked to participate 
in the formation of a cohort of lamotrigine users. They provided complete dispensing 
histories of all patients who had at least one lamotrigine prescription filled between 1
January 1996 and 31 December 2000. The collected data included patient characteristics 
(age, date of birth, postal code) and details (drug name, dispensing date, number of units 
dispensed, dosage regimen, type of prescriber) of all filled prescriptions of lamotrigine as 
well as all other drugs. Over 70% of the pharmacies responded to our request, resulting 
in a research database consisting of 6,544 patients. For a retrospective chart review 
Figure 1. Patterns of lamotrigine use
01.1996 08.2001start date LTG* 12.2000
D
C
B
A
Prescription data were collected in the time frame between 1996 and 2000. The informed consent procedure started in 
August 2001. Information from all prescriptions (observation window, dash-line) and lamotrigine prescriptions (solid line) 
was used to measure lamotrigine retention and to defi ne patterns of use. A: continuation of lamotrigine; B: add-on of 
another antiepileptic drug (dotted line) after the start of lamotrigine; C: discontinuation of lamotrigine (more than 180
days between end date of lamotrigine and end of observation window). Probable loss to follow-up (D) was defi ned if no 
prescription was fi lled after 30 June 2000.
*hypothetical starting date
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study into the effectiveness of lamotrigine, all patients were identified from this cohort 
who met all of the following criteria:
• date of first lamotrigine prescription (index date) after 1 August 1997;
• a minimum age of 18 at the index date;
• availability of pharmacy data for at least one year before the index date;
• prior use of at least one other antiepileptic drug before the index date.
From a total of 3,335 patients who met these inclusion criteria, 1,819 patients were 
randomly selected to participate in the retrospective chart study on the effectiveness 
of lamotrigine. A written informed consent from patients was required to acquire 
access to the medical charts, and we asked for this consent via a recruitment letter. The 
community pharmacists (n = 466) were asked to forward this recruitment letter to the 
patients, who were identifiable for the pharmacist through the patient identification 
code. In case a pharmacist decided not to forward the information to a patient, he was 
asked to provide the reason. Patients were asked to provide their written informed 
consent and the indication for lamotrigine use. Patients who refused to participate were 
asked to state the reason for their refusal on the informed consent sheet and return it. 
In total, this procedure resulted in four possible reactions to the consent question: (1) 
active consent; (2) active refusal, (3) passive refusal (no answer from informed patients) 
and (4) non-informed (pharmacist did not forward the recruitment letter). 
Data collection 
Data on demographic and socio-economic background were available from the 
prescription records. The background characteristics we analysed were age, gender, 
urbanisation level and affluence of the neighbourhood. Neighbourhoods with over 40% 
inhabitants with a yearly income after taxes below 1 12,000 were classified as low-
income using postal code information.
Pharmacoepidemiological characteristics such as previous use of other antiepileptic 
drugs, concomitantly used medication and patterns of lamotrigine use were determined 
from prescription records. Analysis of co-medication included prescriptions of 
psychotropic drugs and migraine abortive drugs in the year before the index date. 
Each patient was classified in one of three mutually exclusive usage patterns of 
lamotrigine: continuation, discontinuation or addition (figure 1). Discontinuation of 
lamotrigine was defined as a period of at least six months between the last refill date 
of lamotrigine and the end of follow-up. Add-on was defined as addition of another 
antiepileptic drug to lamotrigine, without discontinuation of lamotrigine therapy. In 
addition, loss to follow-up was assumed if a patient did not have prescriptions filled 
after 30 June 2000.
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Active consent
(n=968)
Main indications:
Epilepsy (n=907)
Neuropathic pain (n=21)
Bipolar disorder (n=14)
Migraine (n=8)
Other (n=18)
Active refusal
(n=101)
Main indications:
Unknown (n=37)
Privacy (n=27)
Stopped LTG (n=16)
Other (n=21)
Passive refusal
(n=567)
Randomly Selected
(n=1,819)
Not meeting inclusion criteria 
(n=6,544)
Non-informed (n=183)
Main reasons:
Unknown (n=70)
Patient too ill/deceased (n=47)
Patient stopped LTG (n=33)
Other (n=33)
Assesesed for Eligibility
(n=3,335)
Initial study population 
(n=6,544)
Figure 2. Flow diagram of recruitment procedure
In order to analyse whether burden of illness was associated with non-response, a 
Chronic Disease Score (CDS) was calculated based upon prescriptions filled in the last 
year of the observation window for each patient (6).
Data analysis
Patient characteristics were described and compared between the different response 
groups. Chi-square test was used to compare categorical variables. The strength of the 
association between various determinants and giving non-consent was assessed with 
Cox proportional hazard analysis and expressed as hazard ratios (HR) with 95% CI. 
Finally, differences in lamotrigine retention rate between the active consent group and 
the non-consent group were assessed with Kaplan-Meier and Cox regression analysis. 
The retention time was analysed from the index date to the first occurrence of one 
of the following events (figure 1): discontinuation of lamotrigine therapy; add-on of 
another antiepileptic drug; or end of study (censored).
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Sociodemographic
Male gender
Age category:
18 - 44 years
45 - 65 years
≥ 65 years‡
Low socio-economic status†
Urbanisation level:
< 1000 addresses / kmC
1000 - 1499 addresses / kmC
≥ 1500 addresses / kmC‡
Pharmacoepidemiologic
Number of previous AEDs:
1
2
≥3
Chronic Disease Score:
0 – 2
3 – 5
≥ 6‡
Concomitant use of other 
medication:
Antidepressants‡
Antipsychotics‡
Lithiumsalts
Migraine abortive drugs‡
Patterns of use:
Continuation
Add-on†
Discontinuation‡
Loss to follow-up†
Observation window, days 
(mean ± SD)‡
Lamotrigine retention time, 
days (mean ± SD)‡
440 (45.5)
447 (46.2)
374 (38.6)
147 (15.2)
438 (45.2)
373 (38.5)
238 (24.6)
357 (36.9)
251 (25.9)
361 (37.3)
356 (36.8)
565 (58.4)
250 (25.8)
153 (15.8)
74 (7.6)
40 (6.0)
8 (0.8)
21 (2.1)
667 (68.9)
134 (13.8)
167 (17.3)
35 (3.6)
1681 ± 288
579 ± 403
42 (41.6)
47 (46.5)
42 (41.6)
12 (11.9)
40 (39.6)
39 (38.6)
32 (31.7)
30 (29.7)
33 (32.7)
32 (31.7)
36 (35.6)
55 (54.4)
25 (24.8)
21 (20.8)
11 (10.9)
5 (4.9)
1 (0.9)
8 (7.9)
57 (43.6)
12 (11.9)
32 (32.0)
7 (6.9)
1667 ± 336
467 ± 359
258 (45.5)
297 (52.4)
189 (33.3)
81 (14.3)
297 (52.4)
190 (33.5)
119 (21.0)
258 (45.5)
161 (28.4)
215 (37.9)
191 (33.7)
339 (59.8)
138 (24.3)
90 (15.9)
69 (12.2)
34 (6.0)
7 (1.2)
16 (2.8)
361 (63.7)
53 (9.4)
153 (27.0)
50 (8.8)
1643 ± 315
475 ± 392
91 (49.7)
79 (43.2)
55 (30.1)
49 (26.8)
92 (50.3)
65 (35.5)
43 (23.5)
75 (41.0)
56 (30.6)
58 (31.7)
69 (37.7)
84 (45.9)
42 (23.0)
57 (31.1)
30 (16.4)
21 (34.4)
5 (2.73)
1 (0.05)
104 (56.8)
19 (10.4)
60 (32.8)
69 (37.7)
1505 ± 376
344 ± 335
831 (45.7)
870 (47.8)
660 (36.3)
289 (15.9)
867 (47.7)
667 (36.7)
432 (23.7)
720 (39.6)
501 (27.6)
666 (36.6)
652 (35.8)
1043(57.3)
455 (25.0)
321 (17.7)
184 (10.1)
100 (5.5)
21 (1.2)
46 (2.5)
1189 (65.4)
218 (12.0)
412 (22.6)
161 (8.9)
1650 ± 313
516 ± 398
Characteristics Active 
consent
n = 968
Active 
refusal
n = 101
Passive 
refusal
n = 567
Non-
informed
n = 183
Total 
population 
n = 1819
Table 1.   Comparisons of characteristics between different consent groups
Values are number of patients with percentages in parentheses unless otherwise noted. CDS, chronic disease score; SD, 
standard deviation. †p-value < 0.05, using Chi-square test. ‡p-value < 0.01, using Chi-square test.
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RESULTS
Baseline characteristics 
Between August 2001 and August 2002, 1,819 patients were asked to provide 
informed consent through community pharmacists. The breakdown of response 
is shown in figure 2. In 183 cases (10.1%) the pharmacist decided not to forward 
the research letter. Of the remaining 1,635 patients, 1,069 (65%) responded. Of the 
responders, 101 (6%) actively refused participation, the main reasons, if given, being 
“invasion of privacy” or “discontinuation of lamotrigine” (16%). All in all, 968 (59%) 
provided informed consent. Lamotrigine was predominantly used for the treatment of 
epilepsy in the active consent group of patients (94%). 
Table 1 shows the baseline characteristics of the four different response groups and 
the total study population. In comparison to the active consent group, patients who were 
not informed through the pharmacist were older, used antidepressants or antipsychotics 
more often and had higher CDS scores. Loss to follow-up was more prevalent in the 
non-informed group compared to the active consent group. Those who did not respond 
(passive refusal) more often used antidepressants, lived in poor neighbourhoods and 
in more highly urbanised regions than those who did. Cox regression data is shown 
Figure 3. Kaplan-Meier estimates of lamotrigine retention rate
Kaplan-Meier estimates of cumulative lamotrigine retention rate in the active consent group (  ), the active refusal 
group (  ), the passive refusal group (  ) and the non-informed group (  ). 
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Sociodemographic
Gender (male vs. female)
Age category:
18 - 44 years
45 - 65 years
≥ 65 years
Income (≥ 1 12,000 vs. < 1 12,000)
Urbanisation level:
< 1000 addresses / kmC
1000 - 1499 addresses / kmC
≥ 1500 addresses / kmC
Pharmacoepidemiologic
CDS (1-point increments):
0 - 2
3 - 5
≥ 6
Number of previous AEDs (≥ 2 vs. 1)
Co-medication (presence vs. absence)
antidepressants
antipsychotics
lithiumsalts
migraine abortive drugs
Patterns of use (presence vs. absence)
Add-on 
Discontinuation
Loss to follow-up
1.01 (0.89 - 1.17)
reference
0.93 (0.80 - 1.09)
1.49 (1.22 - 1.81)
1.10 (0.96 - 1.25)
reference
1.02 (0.85 - 1.23)
1.23 (1.05 - 1.43)
reference
1.12 (0.92 - 1.36)
1.42 (1.20 - 1.69)
1.34 (1.16 - 1.55)
2.16 (1.77 - 2.64)
1.36 (0.96 - 1.76)
2.14 (1.24 - 3.70)
1.49 (1.00 - 2.23)
1.88 (1.58 - 2.15)
3.98 (3.41 - 4.66)
2.98 (2.50 - 3.61)
1.01 (0.89 - 1.21)
reference
0.92 (0.78 - 1.09)
1.26 (0.99 - 1.60)
1.10 (0.95 - 1.28)
reference
1.03 (0.84 - 1.27)
1.27 (1.01 - 1.51)
reference
1.05 (0.85 - 1.31)
1.24 (1.01 - 1.53)
1.33 (1.12 - 1.57)
2.01 (1.64 - 2.63)
1.21 (0.88 - 1.67)
1.79 (0.89 - 3.59)
1.74 (1.16 - 2.61)
1.96 (1.64 - 2.33)
4.13 (3.46 - 4.94)
2.46 (1.87 - 3.23)
Non-consent groupB
(n = 851) HR (95% CI)
Refusal groupC
(n = 668) HR (95% CI)
Table 2.   Determinants for not giving consent
B Non-consent group consisted of active refusal, passive refusal and non-informed groups.
C Refusal group consisted of active refusal and passive refusal groups.
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in table 2. Higher age (HR 1.49, 95% CI 1.22 – 1.81), highly urbanised regions (HR 1.23, 
95% CI 1.05 – 1.43), CDS scores above 6 (HR 1.42, 95% CI 1.20 – 1.96) and use of two or 
more antiepileptic drugs are significantly related to non-consent. Further the use of 
antidepressants (HR 2.16, 95% CI 1.77 – 2.64), lithium (HR 2.14, 95% CI 1.24 – 3.70), and 
antimigraine drugs (HR 1.49, 95% CI 1.00 – 2.23) were significantly associated with non-
consent. The analysis was repeated after excluding the non-informed group. It revealed 
the same set of significant associations, except that higher age, and use of lithium lost 
significance.
Retention rate analysis
Addition of another antiepileptic drug and discontinuation of lamotrigine were 
significantly related to non-consent (table 1 and 2). The lamotrigine discontinuation 
rate was significantly higher in the active refusal group (HR 1.58, 95% CI 1.15 – 2.15), 
the non-informed group (95% HR 2.06, CI 1.61 – 2.62) and the passive refusal group (HR 
1.43, 95%CI 1.20 – 2.70) than in the group who gave active informed consent (figure 3).
DISCUSSION
In pharmacoepidemiology, it is important to link person-specific drug use data to 
clinical outcome data (7). The present study shows that it is feasible to use a pharmacy-
based recruitment system for this goal, as it facilitates access to a broad population of 
patients and drug-usage patterns without violating the patient’s privacy. Pharmacy-
based recruitment, however, is not without selection bias. First, community pharmacists 
unintentionally applied selection criteria before approaching their patients. They 
approached fewer patients who were elderly or had other (chronic) diseases. These 
results are probably closely related, as elderly patients are more often chronically ill 
than patients in other age categories. Further, in correspondence with previous studies, 
consent was less often obtained among older people, among patients with a higher 
burden of disease, or among people living in highly urbanised neighbourhoods (8,9). 
Consent rates were also lower among patients that used antidepressants, lithium and 
migraine abortive drugs. These drugs can be considered as markers for off-label use of 
lamotrigine. Patients using lamotrigine for other indications are possibly less likely to 
give consent for a study that evaluates the effectiveness of the drug as an antiepileptic 
drug. Failure of lamotrigine was a reason for pharmacists to refrain from approaching 
patients, and also for patients to either actively deny consent or refrain from responding. 
Some well-known reasons for non-response like no personal benefit, no interest in the 
topic, or fear of intrusion of privacy were possibly more prevalent among patients who 
had stopped or failed lamotrigine treatment (10). As a consequence of the response 
bias, the retention rate of lamotrigine was significantly higher in the active consent 
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group compared to the non-consent group. In observational studies retention time is 
a crude measure of effectiveness, an outcome measure that encompasses efficacy and 
tolerability. One could argue that the strength of the association between determinant 
and outcome is not changed by the fact that some subjects are overrepresented in the 
sample (11). However, the goal of the study project is to estimate the effectiveness 
of lamotrigine on a population-based scale, and in this case accurate representation 
remains essential. A higher response rate would have enhanced representation, and 
probably have minimised the occurrence of bias. Response success depends to a 
great extent on the way suitable subjects are approached (11). Perhaps either the 
pharmacy-based approach (instead of recruitment by the treating physician) or the 
retrospective setting of this study resulted in a response rate that was too low to avoid 
bias occurrence. Sturkenboom et al. recruited women who were exposed to the drug 
acitretin for a retrospective cohort study in the Netherlands (12). Recruitment was done 
by dermatologists, pharmacists and dispensing general practitioners. Dermatologists 
recruited only 24% of the suitable patients, whereas the others attained 42% response. 
Also, the majority of women (60%) recruited by dermatologists mentioned that they 
were just as likely to have given consent if their pharmacist had recruited them. The 
response rate in the present study was similar to the one reported by Sturkenboom et 
al: 60% if the non-informed group was excluded.
Our conclusion is that the creation of unbiased personal histories (including both data 
on various exposures and outcomes) is a crucial requirement in pharmacoepidemiology 
(7). Pharmacy-based recruitment has the potential to reach a broad population. 
Selection bias, however, may lead to misrepresentation of outcome data. 
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ABSTRACT
Objective
Evaluation of the effectiveness of lamotrigine in a population-based cohort of 
epilepsy patients. 
Methods
Medical charts of 360 patients treated in 37 centres in the Netherlands were 
reviewed. Effectiveness of lamotrigine therapy was assessed during the first year of use, 
with patients serving as their own controls. Effectiveness was measured by 1) reduction 
in seizure frequency and 2) retention time. 
Results
Effectiveness could only be assessed in 165 patients; assessment in remaining 
patients was not possible due to various reasons, such as insufficient medical chart 
information. Lamotrigine was effective in 40% of patients who had been prescribed 
lamotrigine because of insufficient seizure control (n=112), and 14% of these 112
patients became seizure free. Duration of epilepsy, baseline seizure frequency, valproate 
use, drug load and number of antiepileptic drugs used were related to effectiveness of 
lamotrigine. In this group, 36% continued lamotrigine throughout the first year without 
experiencing a >50% seizure reduction. Lamotrigine was effective in 63% of patients 
who received the drug because other antiepileptic drugs were not tolerated (n = 53). 
Discussion
Lamotrigine is an effective drug in clinical practice. Use of retention time measures 
only may not correctly reflect the efficacy of antiepileptic drugs. 
INTRODUCTION
During the last fifteen years six new antiepileptic drugs (gabapentin, lamotrigine, 
levetiracetam, oxcarbazepine, topiramate and vigabatrin) have become available for 
clinical practice in the Netherlands. This was a welcome development, as no new 
antiepileptic drugs had been introduced during the two preceding decades. In order 
to be licensed, these new drugs had to demonstrate efficacy as add-on drugs in 
patients with refractory epilepsy in placebo-controlled clinical trials. However, in daily 
practice these drugs are used in broader groups of patients and under less-controlled 
and less-monitored conditions. The effectiveness in daily practice may differ from the 
effectiveness found in clinical trials. Therefore the actual merit of these new drugs 
remains to be ascertained in daily practice (1-3).
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One of these new antiepileptic drugs (AEDs), lamotrigine, has been evaluated in 
clinical trials in a variety of patient groups, including patients with newly-diagnosed 
epilepsy (4-8). In addition, the effectiveness of lamotrigine in clinical practice was 
evaluated in a number of observational studies, with retention time as the end point 
(9-13). Retention time is the period during which patients continue using the drug, and 
is considered to be a useful indicator of effectiveness, because it reflects seizure control 
as well as tolerability (14). However, retention time is only a crude indicator, as the actual 
changes in seizure frequency and side effects are not known. In addition, patients in 
these retention-time studies often were participants of previous clinical trials (9). 
The aim of this study was to assess the effectiveness of lamotrigine in a population-
based cohort of epilepsy patients and to assess its tolerability in this population. 
METHODS
Setting and data collection
In a previous study we identified a large number of lamotrigine users through 
pharmacy dispensing records (15). For privacy reasons, these patients were approached 
through their pharmacists for permission to review their medical chart (16). Of the 968
patients who gave consent for chart review, a sample of 368 patients was selected for the 
actual review. This sample was representative for the group of 968 concerning hospital 
type, geographical area, number of antiepileptic drugs used and lamotrigine retention 
rate. The medical records were reviewed by a physician specialised in the field of epilepsy 
(C.D.). Data were collected from 32 general hospitals, 3 academic hospitals and 2 tertiary 
epilepsy centres. The period studied for each patient spanned from the year before the 
start date of lamotrigine (year –1) to the first year after start of lamotrigine (year +1). 
Recorded data covered the following domains:
• demographics: age, gender; 
• epilepsy characteristics: epilepsy type, duration of epilepsy; 
• medication: AEDs used, duration of use, dosage regimen and drug load. Drug load is 
the ratio between the prescribed daily dosage (PDD) and the defined daily dosage 
(DDD, as defined by the World Health Organisation (17)). For example, when a patient 
uses 600 mg of carbamazepine, this represents a drug load of 0.6, as the DDD for 
carbamazepine is 1000 mg. When several drugs are used, the drugs loads per drug are 
summed to arrive at the total drug load for that patient;
• seizure frequency in year –1 and in year +1;
• tolerability: all adverse effects registered in the medical chart for year –1 and year 
+1;
• reason for initiation of lamotrigine therapy.
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A patient was excluded from the study if the information obtained proved that: 
• there was no or an uncertain diagnosis of epilepsy, based on clinical history, seizure 
description and/or EEG registration;
• the patient was younger than 18 at the start date of lamotrigine (index date);
• lamotrigine was the first antiepileptic drug to be prescribed;
• the index date was before 1 August 1997, the reimbursement date of lamotrigine (i.e. 
as of that day, lamotrigine was reimbursed by health insurance companies) ;
• chart data for at least one year before and after the index date were not available;
• seizure frequency had been documented for less than 75% of the evaluated period;
• psychogenic pseudo-epileptic seizures were thought to be present;
• non-compliance was considered to be present.
Outcome
The primary outcome was the effectiveness of lamotrigine in daily clinical practice. 
Data of all eligible patients were analysed, with an intent-to-treat approach. In this 
mirror-image analysis, patients served as their own control group in the lamotrigine 
effectiveness assessment. Criteria for effectiveness during the first year of treatment 
depended on the reason for initiation:
1. If lamotrigine had been prescribed for inadequate seizure control with other 
antiepileptic drugs: lamotrigine therapy was considered effective if a reduction in 
mean seizure frequency of at least 50% in year +1 compared to the mean seizure 
frequency in year –1 was established and lamotrigine use continued for a full 12
months in year +1 without the addition of another antiepileptic drug;
2. If lamotrigine was prescribed because of adverse effects of other antiepileptic drugs: 
lamotrigine therapy was considered effective if there had been no clinically relevant 
increase in mean seizure frequency in year +1 compared to the seizure frequency 
in year –1 (defined as a maximum increase of less than 50%) and lamotrigine use 
continued for 12 months in year +1 without the addition of another antiepileptic 
drug.
Patients were classified as seizure free if treatment with lamotrigine led to the absence of 
any type of seizures for the 12 months following the start of the lamotrigine therapy. 
Data analysis
Continuous variables were compared with the use of the Students’ -t test, categorical 
variables with the Chi-square test. The relationship between patient characteristics and 
lamotrigine effectiveness was assessed with multiple logistic regression analysis, and 
expressed as odds ratios (OR) with 95% CI. 
109
RESULTS
Patients
The medical charts and clinical notes of 360 selected outpatients were reviewed 
in 37 different medical centres (32 general hospitals, 3 university hospitals, 2 tertiary 
epilepsy centres) . This chart review led to the exclusion of more than half of these 
patients: 94 patients were excluded because of insufficient data on seizure frequency, 
42 because charts were unavailable or because the comprised time period was too short, 
27 patients had an unconfirmed diagnosis of epilepsy and 27 were excluded because 
lamotrigine had been initiated before the reimbursement date. 
Furthermore, the chart data of three patients with progressive brain tumours and 
two non-compliant patients were excluded. Thus the final study population consisted of 
165 patients. The study population and the population of excluded patients had similar 
baseline characteristics, no significant differences were found between eligible and 
ineligible patients in the distribution of age, gender, hospital type, duration of illness, 
pre-lamotrigine treatment history or lamotrigine retention time (data not shown).
The baseline demographic and clinical characteristics of the study population per 
hospital type are shown in table 1. In most cases (81%) lamotrigine was started after 
previous use of two or more other antiepileptic drugs. Significant differences were found 
in the distribution of patient characteristics between the three different hospital types 
(table 1).
Initiation of lamotrigine therapy
The baseline demographic and clinical characteristics of the study population per 
indication are shown in table 2. The reasons to start with lamotrigine were insufficient 
seizure control (68%) and antiepileptic drug intolerance (32%). In the first group, adverse 
effects were a concurrent problem in 13% (of the total patient group). There were 
significantly more women than men in the antiepileptic drug intolerance group (table 
2). Also, duration of epilepsy before lamotrigine initiation was significantly shorter and 
mean seizure frequency significantly lower in this group than in the first. Finally, patients 
in the antiepileptic drug intolerance group had used less antiepileptic drugs before start 
of lamotrigine and their drug load was approximately half of that of the seizure control 
group. 
Treatment effectiveness
In the total group of patients, lamotrigine was effective, according to our criteria, 
in 78 out of 165 patients (47%) (table 3). Effectiveness of lamotrigine therapy was 
significantly lower in patients that had insufficient seizure control (40%) compared 
to patients who were prescribed lamotrigine because of adverse effects on other 
antiepileptic drugs (62%). In the former group, 16 patients became seizure free. 
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Values are numbers of patients with percentages in parentheses, or mean values with standard deviations 
(with a ± symbol)
† Statistically signifi cant (p ≤ 0.05) differences compared to patients from general hospitals
‡ Statistically signifi cant (p ≤ 0.05) differences for patients from tertiary centres when compared to patients from other 
hospital types.
Socio-demographic
All Patients
Male
Female
Age 
Epilepsy
Epilepsy type
Partial
Generalised
Unclassified
Duration of epilepsy (years)
Baseline monthly seizure frequency
Pharmacoepidemiologic
Number of previous AEDs trials
One
Two
Three
Four or more
Concurrently used AEDs
Carbamazepine
Phenobarbital
Phenytoin
Sodium valproate
Vigabatrin
Drug load
Reasons for starting LTG
Lack of efficacy
Adverse events
Both
93
37 (39.8)
56 (60.2)
47.7 ± 15.1
85 (91.4)
7 (7.5)
1 (1.1)
14.4 ±13.6
2.1 ± 4.9
29 (31.2)
19 (20.4) 
20 (21.5)
25 (26.9)
33 (35.5)
5 (5.4)
13 (14.0)
41 (44.1)
18 (19.4)
1.1 ± 0.9
43 (46.2)
40 (43.0)
10 (10.8)
25 
13 (52.0)
12 (48.0)
42.5 ± 16.7
21 (84.0)
4 (16.0)
21.4 ±19.3†
4.2   ± 6.4
1 (4.0)†
7 (28.0)†
4 (16.0)†
13 (52.0)†
11 (44.0)
0 (0)
6 (24.0)
8 (32.0)†
11 (44.0)†
1.6 ± 1.0
10 (40.0)
8 (32.0)
7 (28.0)
47
22 (46.8)
25 (53.2)
40.1   ± 12.8†
41 (87.2)
6 (12.8)
22.9 ± 14.6†
4.9  ± 6.5†
2 (4.3)†
11 (23.4)†
9 (19.1)†
25 (53.2)†
30 (63.8)†
5 (10.6)
5 (10.6)
26 (55.3)†
7 (14.9)
1.8 ± 1.1‡
37 (78.7)‡
5 (10.6)‡
5 (10.6)‡
165
72 (43.6)
93 (56.4)
44.9 ± 15.0
147 (89.1)
17 (10.3)
1 (0.6)
17.9 ± 15.3
3.2  ± 5.7
32 (19.4)
37 (22.4)
33 (20.0)
63 (38.2)
74 (44.8)
10 (6.1)
24 (14.5)
75 (45.5)
36 (21.8)
1.4 ± 1.0
90 (54.5)
53 (32.1)
22 (13.3)
General 
hospital
Academic 
hospital
Epilepsy 
centre
All 
hospitals
Table 1.   Demographic and clinical baseline characteristics per hospital type
Characteristics
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In this group, 40 patients continued lamotrigine without experiencing a ≥ 50% seizure 
reduction. In the latter group, the previously non-tolerated drug was sometimes 
continued at a lower dose and sometimes withdrawn concurrently to the introduction 
of lamotrigine. Conversion to lamotrigine monotherapy was significantly lower 
in the seizure-control group: 8% and 37.7% respectively. The spectrum of adverse 
effects mentioned in the medical charts differed in the years before and after start of 
lamotrigine (table 4).
Socio-demographic
All Patients
Male
Female†
Age
Epilepsy
Epilepsy type
Partial
Generalised
Unclassified
Duration of epilepsy (year)†
Baseline monthly seizure frequency†
Pharmacoepidemiologic
Number of previous AEDs†
One
Two
Three
Four or more
Concurrent AEDs
Carbamazepine†
Phenobarbital
Phenytoin
Sodium valproate
Vigabatrin
Drug load†
112
53 (47.3)
59 (52.7)
44.3 ± 14.9
100 (89.3)
12 (10.7)
20.4 ± 15.9
4.4 ± 6.4
19 (17.0)
21 (18.8)
23 (20.5)
49 (43.8)
58 (51.8)
9 (8.1)
17 (15.2)
56 (50.0)
23 (20.5)
1.7 ± 1.1
53 
19 (35.8)
34 (64.2)
45.5 ± 15.3
47 (88.7)
5 (9.4)
1 (1.9)
12.6 ± 12.4
0.5 ± 1.4
13 (24.5)
16 (30.2)
10 (18.9)
14 (26.4)
16 (30.2)
1 (1.9)
7 (13.2)
19 (35.8)
13 (24.5)
0.8 ± 0.8
Table 2.   Demographic and clinical baseline characteristics per indication group
Values are numbers of patients with percentages in parentheses, or mean values with standard deviations 
(with a ± symbol).
† Statistically signifi cant differences (p ≤ 0.05) between the two indication groups.
Characteristics Seizure control AED intolerance
112
Adverse events
concentration loss
weight gain 
mood disorder
diplopia/blurred vision
sleepiness
dizziness
tiredness
tremor
gastrointestinal complaints
hair loss
skin disorders (acne; rash)
headache
Year - 1 (%)
15.2
14.8
9.7
9.7
9.1
9.1
7.9
7.9
6.1
5.5
3.6
3.0
Year + 1 (%)
7.9
2.4
11.5
10.3
4.8
13.3
not mentioned
7.3
9.7
1.2
14.5
9.1
Table 4.   Most frequently reported side effects
Table 3.   Clinical outcome of lamotrigine therapy in the study population
Values are numbers of patients with percentages in parentheses, or mean values with standard deviations 
(with a ± symbol)
n.a: not analysed
† Statistically signifi cant differences (p ≤ 0.05) between the two indication groups.
Seizure control (n = 112) AED intolerance (n = 53)
LTG treatment outcome
Ineffective†
Effective†
Seizure free
Reasons for failure of LTG
Inadequate seizure control†
Adverse events†
Discontinuation in first year
Due to rash
Retention time of LTG (days)
Conversion to LTG monotherapy†
LTG dosage (mg/day)
Range (mg/day)
67 (59.8)
45 (40.2)
16 (14.3)
50 (83.6)
17 (16.4)
27 (24.1)
10 (8.9)
313 ± 106
9 (8.0)
206 ± 128
12.5 - 600
20 (37.8)
33 (62.2)
n.a.
7 (35.0)
13 (65.0)
11 (20.7)
2 (3.8)
312 ± 113
20 (37.7)
194 ± 128
12.5 - 500
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Table 5.   Factors associated with success of lamotrigine therapy
AEDs: antiepileptic drugs.
Seizure control group
OR (95% CI)
AED intolerance group
OR (95% CI)
Socio-demographic
Gender
Male
Female
Age category
18 - 44 years
45 - 65 years
≥ 65 years
Epilepsy
Epilepsy type
Partial
Generalised
Unclassified
Duration of epilepsy
Baseline seizure frequency
Pharmacoepidemiologic
Number of previous AEDs trials
One
Two
Three
Four or more
Concurrent antiepileptic drugs
Carbamazepine
Phenobarbital
Phenytoin
Sodium valproate
Vigabatrin
Drug load
0 – 1
1 – 2
≥ 2
1.00 (reference)
1.41 (0.66 – 3.02)
1.00 (reference)
2.44 (0.98 – 5.58)
1.69 (0.51 – 5.61)
1.00 (reference)
0.72 (0.20 – 2.55)
n.a.
0.96 (0.94 – 0.99)
0.91 (0.84 – 0.97)
1.00 (reference)
0.18 (0.05 – 0.70)
0.33 (0.09 – 0.89)
0.13 (0.04 – 0.43)
0.82 (0.39 – 1.76)
0.41 (0.11 – 1.47)
0.20 (0.05 – 0.81)
1.24 (1.09 – 1.54)
0.59 (0.22 – 1.57)
1.00 (reference)
0.45 (0.23 - 0.92)
0.29 (0.10 - 0.83)
1.00 (reference)
2.67 (0.83 – 8.54)
1.00 (reference)
1.10 (0.32 – 3.78)
1.89 (0.38 – 9.39)
1.00 (reference)
0.38 (0.06 – 2.49)
n.a.
0.98 (0.94 – 1.02)
0.21 (0.12 – 5.37)
1.00 (reference)
0.39 (0.08 – 1.96)
0.30 (0.05 – 1.80)
0.54 (0.10 – 2.93)
0.70 (0.21 – 2.30)
n.a.
n.a.
0.53 (0.17 - 1.68)
0.96 (0.27 - 3.48)
1.00 (reference)
0.35 (0.08 – 1.43)
n.a.
Characteristics
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Logistic regression analysis
Logistic regression analysis showed that several characteristics were significantly 
associated with effectiveness in the seizure control group (table 5). Both length of 
duration of epilepsy (OR 0.96, 95% CI: 0.94 - 0.99) and baseline seizure frequency (OR 
0.91, 95% CI: 0.84 - 0.97) were inversely related to lamotrigine effectiveness. Baseline 
drug load was also related to successful lamotrigine response; compared to drug loads 
between 0 and 1, higher drug loads were related to failure of therapy (drugloadb-c: 
OR 0.45, 95% CI: 0.23 - 0.92; drugload≥2: OR 0.29, 95% CI: 0.10 - 0.83). The number of 
antiepileptic drugs used before the start of lamotrigine was significantly correlated 
to the successful outcome of lamotrigine therapy; the success rate (i.e percentage of 
patients with ≥ 50% seizure reduction) in patients that used one antiepileptic drug 
previously being at least threefold higher than in patients who used two or more 
antiepileptic drugs previously. Effectiveness of lamotrigine therapy was more likely in 
patients who had used sodium valproate concurrently (OR 1.24, 95% CI: 1.09-1.54). 
Effectiveness of lamotrigine was less likely in patients using phenytoin (OR 0.20, 95% 
CI: 0.05 – 0.81). There was no association in this group between treatment outcome and 
gender, age, epilepsy type, or use of carbamazepine, phenobabital or vigabatrin. 
The impact of the number of previously used antiepileptic drugs on the effectiveness 
of lamotrigine in this group is illustrated in figure 1. Effectiveness of lamotrigine after 
failure of one antiepileptic drug was 74%, including 21% seizure-free patients. The 
effectiveness of lamotrigine after four previously used antiepileptic drugs was 26%, and 
a total of 2% became seizure free. There were no differences in effectiveness between 
patients with localization-related epilepsy and patients with generalised epilepsy. 
In the antiepileptic drug intolerance group no individual characteristics were found 
to be significantly related to the treatment outcome. 
Figure 1. Efficacy of lamotrigine related to the number of AEDs previously used
seizure free
50% seizure reduction
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DISCUSSION
This study aimed at assessing the effectiveness of lamotrigine in clinical practice. 
The results add to the present knowledge concerning the efficacy and tolerability of 
lamotrigine. 
(1) Seizure control (efficacy): A higher success rate of lamotrigine therapy was found 
in this study than in previous add-on trials. In the first year of treatment, lamotrigine 
therapy was effective in 40% of the patients with refractory epilepsy. In the initial 
regulatory trials, with a maximum follow-up of 24 weeks, the percentage of patients 
experiencing a ≥ 50% reduction was lower (4;18). This difference in efficacy may be 
due to a broader study population in our sample, i.e. more patients who had tried only 
one or two antiepileptic drugs prior to lamotrigine. Seizure reduction of 50% or more is 
broadly accepted as the recognisable threshold of effect in add-on trials, and there is 
evidence that reducing a patient’s seizure frequency is the most important contributor 
to a change in quality of life (19). However, the relevance of reducing seizures by 50% 
may not be obvious to individual patients. Seizure freedom is a much more relevant 
and easier to interpret efficacy parameter. In the seizure-control group of this study, 
seizure freedom was attained in 14% after addition of lamotrigine. In patients that had 
previously used four or more other antiepileptic drugs, addition of lamotrigine only 
rendered 2% seizure free, which is comparable to the 5% seizure-free rates reported in 
regulatory trials. However, 15 to 20% of patients who had previously used one, two or 
three other antiepileptic drugs, became seizure free in this group (figure 1). These data 
on the efficacy of lamotrigine compare favourably with the observational data reported 
by Kwan and Brodie (20). These authors reported seizure freedom with any drug or 
combination of drugs in only 4% when patients did not become seizure free on their 
first or second antiepileptic drug. 
Our study confirms the general finding that an early response to drug therapy or a low 
seizure frequency confirms a favourable prognosis (21). The combination of lamotrigine 
and valproate seems to exhibit a favourable pharmacodynamic interaction in patients 
with refractory epilepsy, an observation that has been made previously (22;23).
(2): antiepileptic drug intolerance (tolerability): lamotrigine therapy was effective 
in 60% of the patients who started taking the drug because of adverse events with 
other antiepileptic drugs. In previous observational studies on the effectiveness of 
lamotrigine, only patients with inadequate seizure control were evaluated (9;24-26). In 
clinical practice, physicians also prescribe lamotrigine because the drug is known to have 
a more favourable side-effect profile than conventional antiepileptic drugs (6;27;28). 
Due to lamotrigine’s mild side-effect profile, the drug is an effective alternative for 
cases of antiepileptic drug intolerance. In the present study, adverse effects necessitated 
withdrawal of lamotrigine therapy in 22% of the patients, with rash as the most 
common cause for discontinuation (7%). This is actually higher than in the clinical 
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trials; pooled trial data showed a discontinuation rate of lamotrigine therapy of 10%, 
rash being reported the most frequently (3.8%) as the reason for discontinuation (29). 
Seven of the 53 patients prescribed lamotrigine because of adverse effects on previous 
drug or combination of drugs, experienced a significant worsening of seizure control. 
However, 33 of the patients in this group responded well to lamotrigine, which implies 
that lamotrigine was able to maintain seizure control in these patients.  
The methods of patient recruitment and reviewing charts in different medical centres 
employed for this study are quite laborious, certainly compared with the aforementioned 
retention-time studies. They do, however, have important advantages. First, our methods 
produce more information than retrospective studies that focus only on retention time, 
as the actual seizure-frequency reduction per patient and the percentage of seizure-free 
patients are determined. We found that 36% stayed on lamotrigine for longer than 12
months, despite their not experiencing a >50% seizure reduction. In the observational 
studies focusing only on retention time, more patients discontinued lamotrigine than 
in our study, but the study period in these studies was longer. Second, the employed 
methods result in studying a cross-section of patients visiting different hospital types. 
The retention-time studies mostly concerned patients from tertiary referral epilepsy 
clinics, which represent less than one third of the epilepsy population as a whole (3). 
As table 2 shows, patients attending tertiary clinics have a high number of previous 
antiepileptic drug trials, are on high drug loads and have higher seizure frequencies. 
These are factors that have a negative impact on the success of antiepileptic drug 
treatment. 
The results of the present study must also be considered within the context of 
several limitations. First, this study only included patients who had given consent to 
their community pharmacist. This may have led to biased enrolment towards patients 
in which lamotrigine was effective (16). Second, this was a retrospective cohort study. 
The resultant data acquisition was non-blinded and drug selection was non-random. 
Third, we used a mirror-image design (patients serving as their own control group) 
instead of an independent control group. Physicians start lamotrigine at the peak of 
disease activity: either an unacceptable seizure frequency or intolerable side effects. The 
course of epilepsy is variable, and improvements could have occurred without any special 
intervention (i.e. regression to the mean). One may nevertheless claim that monitoring 12
months before and after the start of lamotrigine is sufficiently long to rule out regression 
to the mean as sole reason for lamotrigine effectiveness. Fourth, the data for this study 
were collected with the use of medical chart notes. These notes are primarly kept to aid 
in the treatment of individual patients, and not for outcome research. Therefore seizure 
counts are not always recorded into the notes, and in these cases retrospective baselines 
could not be obtained, and these patients had to be excluded. Nevertheless, eligible and 
ineligible patients seemed comparable with respect to baseline characteristics. 
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Despite these limitations, this study allowed us to assess the effectiveness of 
lamotrigine in a population-based setting. The data for the present study came from 
diverse regions of the country and from diverse medical centres. As such, the results are 
likely to be representative. Therefore, the study should be considered as complementary 
to the initial randomised add-on trials and subsequent post-marketing studies 
addressing the efficacy of lamotrigine in selected patients. It can be concluded from the 
present study that lamotrigine is an effective treatment option and a useful alternative 
for patients with varying needs, including those with inadequate seizure control and 
intolerable side effects. 
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ABSTRACT
Objective
This observational study addresses the cost effectiveness of add-on therapy with 
lamotrigine in a population-based cohort of patients. 
Methods
Two years’ observational data of 165 patients were used. The effectiveness of 
lamotrigine therapy during the first year was assessed, with patients as their own 
control group. Therapy effectiveness was measured by 1) reduction in seizure frequency 
and 2) retention time. A mirror design was used to compare differences in costs 
and effectiveness in the years before and after the start of lamotrigine therapy. The 
incremental cost-effectiveness ratio expressed the direct medical cost per patient 
treated effectively with lamotrigine.
Results
The cost of medication was 1 492 (95% CI 1 399 - 1 583) higher after the start of 
lamotrigine therapy. The extra cost of lamotrigine therapy (1 622) was partly offset by 
a reduction of the cost of co-medication (-1 130, 95% CI – 1 210 : – 1 50). Overall, the 
total medical cost was 1 453 higher in the first year of lamotrigine therapy than in the 
year before the start of lamotrigine. Lamotrigine was effective in 47% of all the patients, 
making the resultant incremental cost per successfully treated patient 1 954 per year.
Discussion
Add-on therapy of lamotrigine for patients with uncontrolled epilepsy offers 
improved health outcomes. Lamotrigine therapy is associated with increased cost 
(1 453) and an annual incremental cost per successfully treated patient of 1 954. Both 
the quality-adjusted life-years data published in medical literature and the data 
resulting from this study provide evidence that lamotrigine could be adopted as an 
efficient therapy for patients with refractory epilepsy.
INTRODUCTION
Conventional antiepileptic drugs (AEDs) have traditionally been the cornerstone 
of clinical epilepsy management. Approximately 30% of the epilepsy patients respond 
poorly to these agents, either because of a lack of efficacy or because of intolerable side 
effects. New antiepileptic drugs have broadened the treatment options for patients 
with uncontrolled epilepsy, but they have higher acquisition costs than the conventional 
antiepileptic drugs. Because of the tension between budget constraints and the growing 
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treatment possibilities, health-economic evaluations are increasingly important in the 
field of epilepsy. These health-economic evaluations are particularly important for the 
treatment options of patients with refractory epilepsy, as they suffer more than other 
patients from the economic and social effects of their illness (1). Jacoby et al. found 
that the costs of illness for patients with refractory epilepsy were up to eight times the 
costs for those with controlled epilepsy (2). In addition, Van Hout et al. found that higher 
seizure frequencies are associated with increases in the cost of illness as well as with the 
reduced quality of life (3). Estimates of direct medical costs of patients with refractory 
epilepsy found in medical literature vary from 1 850 to 1 4,250 per year (3-7).
In order to establish a high external validity of a study, observational studies can be 
used to asses the effectiveness and cost-effectiveness (or efficiency), as a supplement 
to the establishment of the efficacy of healthcare technology in a highly controlled 
situation for selected patients (8). This study addresses the health economic aspects of 
add-on therapy with lamotrigine (LTG) in a population-based cohort of patients. The 
aim of this retrospective, observational cost-effectiveness analysis is: 1) to compare 
healthcare utilisation and cost in the year before the start of lamotrigine treatment with 
the year after; and 2) to relate the difference in cost to the difference in effectiveness.
METHODS
Setting
The present study took the form of a retrospective cohort study using a mirror-
image design. The cost-effectiveness analysis was performed along with a detailed 
observational study on the effectiveness of lamotrigine. The results of the effectiveness 
study are published elsewhere (8). In brief, the study population consisted of 165 adult 
patients (≥ 18 years) who received add-on lamotrigine therapy because of uncontrolled 
epilepsy on conventional antiepileptic drugs or vigabatrin. All patients met at least one 
of the following inclusion criteria:
1. Treatment resistance, defined as a suboptimal response to a therapeutic 
dosage of at least one antiepileptic drug;
2. Drug intolerance, defined as intolerable side effects leading to the 
discontinuation of antiepileptic medication.
Data were collected from 31 general hospitals, 4 academic hospitals and 2 tertiary 
epilepsy centres. Data of patients who switched to lamotrigine were collected 
retrospectively from their medical records; data on patient characteristics, treatment 
outcome and healthcare utilisation were recorded. In a mirror-image design, data were 
extracted for one year before (year –1) and one year after (year +1) the day of switching; 
the sum of both mirror periods is defined as the study period. 
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Resource utilisation
Chart review of all epilepsy related resource utilisation was performed, with a pre-
tested standard list of resource items. Resource use during the study period was directly 
recorded in a specially designed database. The epilepsy-related resource utilisation 
included hospital services, diagnostic procedures and antiepileptic medication, as 
specified in table 1. Type and dosage of the medication used, as well as date and reason 
for therapy changes, were recorded. Resources related to patient and family domain (e.g. 
transportation, paid care) or to other domains (e.g. time loss from work/usual activity) 
could not be distilled from the medical charts. 
Cost valuation
Epilepsy-related direct medical cost was estimated from a healthcare perspective. 
In the analysis, the cost was calculated by multiplying the epilepsy related resource 
use of each patient with unit cost. The assignment of unit cost to the various elements 
of epilepsy care is based on guideline prices for economic evaluation in Dutch health 
care (9;10). For these unit costs, no distinction was made between the actual hospital 
settings (general or academic hospital, tertiary epilepsy centre). When no guideline price 
for an item was available, tariffs were used as shadow prices. In our study this applied to 
drug cost, laboratory tests and imaging procedures (table 1). All prices were expressed 
in euros (1 ; exchange rate in March 2005: 1 1 = USD 1.3) and updated to January 2004
according to the rate of inflation by the Consumer Price Index (Statistics Netherlands, 
http://www.cbs.nl). Non-parametric bootstrap analysis was used to analyse differences 
in cost between year –1 and year +1. 
Effectiveness
Lamotrigine treatment was considered to be effective if the drug was not 
discontinued during the first year of treatment and the following criteria were met:
1. For the Treatment resistance group: lamotrigine therapy was considered effective if 
a reduction in mean seizure frequency was established of at least 50% in year +1
compared with the mean seizure frequency in year –1, and no other antiepileptic drug 
had been added.
2. For the Drug intolerance group: lamotrigine therapy was considered effective if the 
therapy was tolerated and there was no clinical relevant increase in mean seizure 
frequency in year +1 compared with the seizure frequency in year –1 (defined as a 
maximum increase of less than 50%).
This outcome encompasses the efficacy endpoint used in randomised clinical trials of 
antiepileptic drugs (seizure reduction of at least 50%) and the effectiveness endpoint 
used in observational studies (retention time). The Students’ t-test was used to analyse 
differences in effectiveness.
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Cost-effectiveness analysis
The pre-specified incremental cost-effectiveness ratio (ICER) was the annual direct 
medical cost per patient effectively treated with lamotrigine. The ICER is calculated as: 
[(mean annual cost per patient) year + 1 – (mean annual cost per patient) year - 1 ]
(% effectively treated patients) year + 1
All health outcomes and resource utilisation were recorded for the two-year period 
and analysed by intention-to-treat. Normal distribution assumptions are not valid 
when dealing with healthcare costs, which have a right skewed distribution (11). Non-
parametric bootstrap analysis was used to estimate the uncertainty of the ICER by 
defining the 2.5th and 97.5th percentiles of 1,000 bootstrapped replications (12). The 
uncertainty surrounding the ICER is presented graphically by plotting the bootstrap 
Hospital services
Outpatient
Outpatient consult
Telephonic consult
Inpatient
Hospital visit
Intensive care visit
Diagnostic procedures
Imaging procedures
CT scan
EEG
EEG, 24 hour
MRI scan
Laboratory procedures
Clinical chemistry
Drug monitoring
MedicationB
Carbamazepine, 1,000 mg
Phenytoin, 300 mg
Vigabatrin, 2,000 mg
Valproate, 1,500 mg
Lamotrigine, 300 mg
per visit
per call
per admission day
per admission day
 per procedure
 per procedure
 per procedure
 per procedure
 per procedure
 per procedure
 per month
 per month
 per month
 per month
 per month
62.1
31.1
316.1
1294
160.3
87.7
740.7
211.9
5.5 – 15.2
12.8 – 21.5
10.20
2.3
80.2
17.2
110.6
guideline price 
guideline price 
guideline price 
guideline price
CVZ tariff
CVZ tariff
CVZ tariff 
CVZ tariff
CVZ tariff
CVZ tariff
CVZ tariff
CVZ tariff
CVZ tariff
CVZ tariff
CVZ tariff
Table 1.   Unit cost in 2004
B Monthly total cost for daily defi ned dose based on most frequently used oral-dosage form (only the most frequently 
used antiepileptic drugs in this study are listed). CVZ: Dutch Health Care Insurance Board.
Cost item Cost measure Unit cost (3 ) Source of unit cost
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ICERs on a cost-effectiveness plane (13). Because the value of the highest acceptable 
incremental cost-effectiveness ratio is unknown, the likelihood that lamotrigine is cost-
effective at different values of this threshold is plotted as an acceptability curve. 
Characteristics
All Patients
Male
Female†
Age (year)*
Hospital type†
General hospital
Academic hospital
Tertiary epilepsy centre
Epilepsy characteristics
Epilepsy type
Partial
Generalised
Unclassified
Duration of epilepsy (year)*†
Baseline monthly seizure frequency*†
Number of previous AEDs†
One
Two
Three
Four or more
Concurrent AEDs
Carbamazepine†
Phenytoin
Sodium valproate
Vigabatrin
Health Outcome†
LTG therapy effective
LTG therapy not effective
Seizure control
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53 (47.3)
59 (52.7)
44.3 (14.9)
53 (57.0)
17 (68.0)
42 (89.4)
100 (89.3)
12 (10.7)
20.4 (15.9)
4.4 (6.4)
19 (17.0)
21 (18.8)
23 (20.5)
49 (43.8)
58 (51.8)
17 (15.2)
56 (50.0)
23 (20.5)
45 (40.2)
67 (59.8)
AED intolerance
53 
19 (35.8)
34 (64.2)
45.5 (15.3)
40 (43.0)
8 (32.0)
5 (10.6)
47 (88.7)
5 (9.4)
1 (1.9)
12.6 (12.4)
0.5 (1.4)
13 (24.5)
16 (30.2)
10 (18.9)
14 (26.4)
16 (30.2)
7 (13.2)
19 (35.8)
13 (24.5)
33 (62.3)
20 (37.7)
Total
165
72 (43.6)
93 (56.4)
44.9 (15.0)
93 (56.4)
25 (15.1)
47 (28.5)
147 (89.1)
17 (10.3)
1 (0.6)
17.9 (15.3)
3.2 (5.7)
32 (19.4)
37 (22.4)
33 (20.0)
63 (38.2)
74 (44.8)
24 (14.5)
75 (45.5)
36 (21.8)
78 (47.3)
87 (52.7)
Table 2.   Demographic and clinical baseline characteristics per indication group
Values are number of patients with percentages in parentheses, except ‘*’: Mean (SD).
† Statistically signifi cant differences (p ≤ 0.05) between the two indication groups.
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RESULTS
Demographics
The study population of 165 patients included 93 women. The mean age at the start 
of lamotrigine therapy was 45 years (table 2). The mean duration of epilepsy before the 
start of lamotrigine was 18 years. In most cases (81%) lamotrigine was started after 
previous use of two or more other antiepileptic drugs. Treatment resistance was the 
main reason (68%) to start with lamotrigine, while in the other 32% antiepileptic drug 
intolerance was given as reason.
Effectiveness
Lamotrigine was effective, according to our criteria, in 78 of 165 patients (47%) 
(table 2). Effectiveness of lamotrigine therapy was significantly lower in the treatment 
Hospital services
Outpatient
Outpatient consult
Telephonic consult
Inpatient
Hospital stay
Intensive care stay
Subtotal
Diagnostic procedures
Imaging procedures
CT scan
EEG
MRI scan
laboratory procedures
Clinical chemistry
Drug monitoring
Subtotal
Medication
AED co-medication
Lamotrigine
Subtotal
Total
247.6
233.5
14.2
481.6
358.8
122.8
729.3
97.6
20.3
53.2
24.1
42.5
25.1
17.4
140.1
396.9
0
396.9
1,266.3
256.5
235.8
20.7
449.7
449.7
0
706.2
80.3
8.1
65.6
6.7
44.0
25.8
18.2
124.3
266.8
621.7
888.5
1,719.0
 8.9
 2.4
 6.50
- 31.9
90.9
- 122.9
- 23.1
- 17.3
- 12.2
12.3
- 17.4
1.5
0.7
0.8
- 15.8
- 130.1
621.7
491.6
452.8
- 12.5 : 30.2
- 17.1 : 21.9
0.4 : 12.6
- 445.0 : 381.2
- 284.7 : 466.6
- 297.9 :  52.2
- 438.7 : 392.6
- 71.7 : 37.0
- 20.0 : - 4.4
- 39.4 : 64.0
- 26.6 : - 8.3
- 7.1 : 10.2
- 5.2 : 6.6
 -3.3 : 5.0
- 71.0 : 39.4
- 210.2 : - 49.9
573.0 : 670.3
399.9 : 583.3
20.9 : 884.6
Year before LTG Year with LTG Difference 95% CI
Table 3.   The mean healthcare cost per patient and year in 2004
128
Figure 1. Impact of treatment outcome on cost
medication
diagnostics
hospital services
Figure 2. Bootstrap replicates of incremental cost-effectiveness ratio
1,000 Bootstrap replicates of ICER showing the joint distribution of costs and health outcomes in the cost-effectiveness 
plane. On the x-axis the difference in effectiveness between year+1 and year-1, on the y-axis the difference in average 
annual costs. 
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resistance group than in the antiepileptic drug intolerance group: 40.2% and 62.3% 
respectively (p < 0.05). 
Cost
Total cost was 1 1,266 in year –1 and 1 1,719 in year +1, a difference of 1 453 (95% 
CI 1 21 - 1 885; table 3). The cost of hospital services or diagnostic procedures was only 
slightly different between year +1 and year –1: - 1 23 and - 1 16 respectively. The costs 
of medication was higher in year +1 than in year –1, the difference being 1 492 (95% CI 
1 399 - 1 583).The extra cost of lamotrigine therapy (1 622) was partly offset by a 
reduction of the cost of co-medication in year +1 (- 1 130, 95% CI - 1 210 - -1 50). The 
costs in year +1 for patients treated effectively with lamotrigine were not different than 
in year –1 (cost difference 1 84; 95% CI - 1 215 - 1 383; figure 1). Despite the relatively 
small number of patients, a cost difference compared to year –1 was seen in patients 
with a lack of effectiveness from lamotrigine (cost difference 1 803, 95% CI 1 278 - 1
1,329). This was related to the relatively high cost of hospital services (mean cost 1
1,017) and medication (1 926) for these patients in year +1, as shown in figure 1. 
Cost-effectiveness analysis
By definition, the effectiveness in the year –1 period was zero. The ICER per patient 
between year +1 and year –1 was therefore (1 1.719 - 1 1.266.3)/ (0.47-0) = 1 954. 
Figure 3. Cost-effectiveness acceptability curve for treatment with lamotrigine
Acceptability curves for the treatment resistance cohort (  ), drug intolerance cohort (  ) and total cohort (  ). 
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Consequently, an extra 1 453 per patient was needed to increase the effectiveness of 
epilepsy treatment by 47%, amounting to an investment of 1 954 per successfully treated 
patient. In figure 2, the distribution of bootstrap replicates is displayed graphically in a 
cost-effectiveness plane. Overall, 6% of the bootstrap replicates were found in the 
South-East quadrant, which indicates that lamotrigine therapy is dominant (more 
effective and lower costs) and 94% of replicates were found in the North-East quadrant, 
indicating that lamotrigine therapy is more effective, but at a higher cost. The ICER for 
the treatment resistance cohort was 1 849, and 1 1,094 for the drug intolerance cohort. 
The acceptability curves are shown in figure 3.
DISCUSSION
In this study the cost of lamotrigine therapy is related to the effectiveness of this 
intervention using data from a population-based cohort of patients from various 
treatment centres in the Netherlands. In the first year of lamotrigine treatment an 
overall effectiveness rate of 47% was found. lamotrigine treatment was associated with 
an average higher annual epilepsy-related cost of 1 435. The largest cost difference was 
found in the cost of drug, as the extra cost for lamotrigine (1 622) was only partly offset 
by a reduction in cost for other antiepileptic drugs (– 1 130; 21% reduction). It has been 
argued that despite the high acquisition cost, lamotrigine may constitute an important 
money saver because of its fewer side effects and increased tolerability (14;15). We could 
not confirm overall savings for the entire cohort. For patients who had been treated 
effectively with lamotrigine there was no cost difference between year +1 and year –1, 
as savings in hospital services (1 350) offset most of the rise in drug cost (1 452). For 
patients with whom lamotrigine was not effective, cost savings were absent in year +1
and a cost increase compared with year –1 was noticed.
The direct medical cost found in this study fell within the previously mentioned 
range of 1 850 to 1 4,250 per year for patients with uncontrolled epilepsy (3-7). This 
study shows that the ICER associated with the add-on use of lamotrigine was 1 954
per year. The economic question, based on the cost-effectiveness analysis, is whether 
1 954 annually for an extra patient treated effectively is good value for money. Previous 
studies regarding the cost-effectiveness of add-on lamotrigine do not provide relevant 
information, as they varied in terms of cost measures addressed, time periods covered, 
treatment pathways and outcome measures (16-20). These studies were based on 
decision-analysis models. Their validity was questioned, as their input depends on 
the extrapolation of trial data and estimations of expert panels (20). To address the 
economic question raised above, a cost-utility analysis rather than a cost-effectiveness 
analysis is required. Cost-utility analysis and cost-effectiveness analysis are identical on 
the cost side, but differ on the outcome side. In cost-utility analysis, the incremental cost 
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of a programme is compared to the incremental health improvement attributable to the 
programme, in which health improvement is measured in quality-adjusted life years 
(QALYs) gained (21). The advantage of a cost-utility analysis is that its results are more 
universal than a specific cost-effectiveness analysis. The results can be compared with 
other studies regarding different health care topics. Moreover, quantitative thresholds 
for cost per QALY gained have been proposed upon review of economic evaluations 
(21;22). If cost per QALY are under the threshold of 1 20,000, it is accepted that strong 
evidence exists for adoption of the new therapy.
The available data from the medical records did not allow the quality of life to be 
measured. Nevertheless, the impact of a potential utility increase on the cost per QALY 
can be modelled, as in figure 4. This figure shows that a potential utility increase of 
0.06 for those patients who were treated effectively with lamotrigine would result in an 
additional cost per QALY gained of 1 15,897. According to the aforementioned threshold, 
the cost-utility analysis from the healthcare perspective shows strong evidence for the 
adoption of lamotrigine, provided that lamotrigine therapy would actually increase 
baseline utility by at least 0.06. Relying on data from medical literature and our own 
experience, we believe that an increase of 0.06 utility is an appropriate estimation. 
Messori et al. used a time-trade-off method to value health states of patients with 
epilepsy (23). According to these data, a patient treated effectively (i.e. 50% reduction 
in seizure frequency) gained an increase in utility of at least 0.13. Forbes et al. used the 
EuroQol-5D Health State instrument, and found that for a 50% reduction in seizure 
Figure 4. Relation between cost per QALY and utility value associated with lamotrigine
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frequency a mean gain in health could reasonably be valued at 0.17 utility extra (24). 
We sought to reproduce these data and used the EuroQol-5D Health State instrument 
to measure the quality of life in three subgroups of patients with epilepsy (data not 
published): patients with complete seizure freedom (n=12), patients with a partial 
response (decrease in seizure frequency by at least 50%; n=8) and patients with no 
response to antiepileptic drug therapy (n=7). Seizure-free patients had a mean utility of 
0.76 ± 0.11, for partial responders it was 0.70 ± 0.15 and for non-responders 0.55 ± 0.13. 
According to these assumptions, add-on lamotrigine therapy is an efficient therapy for 
patients with refractory epilepsy. No data are available on a gain in health for patients 
who suffer from antiepileptic drug side effects.
Crucial to the acceptance of the outcome of this study is that observational 
design, with its fortes and drawbacks, be acknowledged as a valid scientific tool. A 
strong point of the design is that actual utilisation data are collected and analysed, 
whereas a disadvantage of an economic evaluation piggybacked to a clinical trial 
is the occurrence of protocol-driven costs (25). Furthermore, observational design 
enabled us to continue the collection of data from patients who had not been treated 
effectively with lamotrigine for the full study period. The economic evaluation followed 
the intention-to-treat principle. Data missing because of patient withdrawal from a 
clinical trial before reaching the scheduled end date cause a well-known problem in 
data analysis (26). This study presents population-based data. In a former study, we 
demonstrated that the baseline characteristics of this Dutch population-based cohort 
differ from those reported in clinical trials, with respect to age, concurrent use of specific 
antiepileptic drugs, and length of follow-up (27). This might be explained by the use of 
lamotrigine in a broader population of epilepsy patients than in add-on lamotrigine 
regulatory trials. In our study, we included patients with less severe epilepsy, and newly 
diagnosed patients starting with lamotrigine because of intolerable side effects from 
their previous treatment, rather than inadequate seizure control. As a consequence, data 
from the present study reflects the outcome of lamotrigine therapy in daily practice 
more reliably than clinical trials do. 
With regard to weaknesses, the non-blinded and non-controlled design allowed for 
selection bias and confounding variables that could have occurred in the evaluation of 
the effectiveness of lamotrigine (28). The fact that this is an uncontrolled study would 
bias the results in the case of spontaneous improvement of the epilepsy situation of 
the patients occurring (i.e. regression to the mean). Although the course of epilepsy is 
variable and improvements could have occurred without any special intervention, we 
believe that, given the characteristics of our cohort and the length of the study period, 
the considerable degree of effectiveness seen in year +1 cannot entirely be attributed to 
regression to the mean.
We used a mirror-image design (patients serving as their own control) instead of 
a control group, a study method previously used to evaluate the cost-effectiveness of 
133
clozapine, a new antipsychotic drug (29). Physicians start lamotrigine at the peak of 
disease activity, either an unacceptable seizure frequency or intolerable side effects. This 
may result in a higher utilisation of hospital services or diagnostic procedures in year –1. 
However, if only the utilisation of medication was considered (and utilisation of hospital 
services or diagnostic procedures ignored) an ICER of 1 1,042 was obtained, compared 
to an ICER of 1 954 if all cost sources were included. This indicates that there was not 
much difference regarding the utilisation of hospital services or diagnostic procedures 
between year +1 and year -1.
For the cost analysis, a healthcare perspective was chosen by us in which all 
direct costs are recorded. In general, a societal perspective is preferred, nevertheless, 
there is recognition that the use of other perspectives is acceptable (21). Cost items 
that are missing in our study include non-medical costs, such as loss of productivity, 
transportation and paid or unpaid care for patients (7). There is no reason to believe that 
these costs are likely to be higher for year +1 than for year –1. On the contrary, there is 
convincing evidence that increasing the effectiveness of epilepsy treatment is the most 
important contributor to a change in quality of life and a reduction in cost (3;30).
CONCLUSION
Therapeutic options should be available for epilepsy patients with varying needs, 
including those with persistently high seizure frequencies and those with unacceptable 
side effects. Several drugs should be listed in case add-on therapy is mandated or 
the quality of life is adversely affected by the initial selections. These new drugs, like 
lamotrigine, should not be incorporated without an assessment of their value compared 
to current standards or acceptable options. In the first year, add-on lamotrigine therapy 
was effective in 47% of the patients who had uncontrolled epilepsy, the additional cost 
per successfully treated patient in our study was 1 954 annually per patient. Results from 
the CUA model indicate that lamotrigine could be adopted as an efficient therapy for 
patients with refractory epilepsy.
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ABSTRACT
Objective
The retention time of drug use reflects a therapy’s effectiveness. Electronic 
prescription records as available from pharmacies, for example, are often used to 
determine the retention time. The validity of this approach has rarely been assessed.
Aim of this study is establishing the validity of electronic pharmacy data for the 
assessment of the retention time of lamotrigine, a new antiepileptic drug.
Methods
Events that determine the retention time of lamotrigine are 1) the discontinuation 
and 2) the addition of another antiepileptic drug. The retention time is the time period 
between the start of therapy and the occurrence of one of these end points. For 216
patients, we compared the retention time in the pharmacy records with the retention 
time according to the treating neurologist’s records. In addition, the optimal time 
window for assessment of the end point discontinuation was determined by means of 
a receiver operator characteristics (ROC) curve.
Results
The positive predictive value of the discontinuation criterion was 96.7%. For the 
addition criterion, we found a positive predictive value of 62.5%. The lamotrigine 
retention time assessed from pharmacy records correlated well (r = 0.91) with the 
retention time derived from medical records. The ROC curve showed an optimal interval 
of 80 days for the discontinuation criterion.
Discussion
Pharmacy records can be used validly to establish the retention time of drug therapy 
and are a valuable tool in pharmacoepidemiology. 
INTRODUCTION
A long retention time with drug therapy is generally desirable for persons with 
chronic diseases. Retention time is closely related to persistence. Retention time is the 
duration of continuous treatment with a given drug; persistence reflects the percentage 
of patients still using the drug after a certain period of time since start of treatment. 
In 1995, Andrade et al. showed that discontinuation rates of lipid-lowering drugs in 
clinical practice were much higher than those seen in randomised controlled trials 
(1). Their landmark publication is important for two reasons. First, the results of their 
study should be regarded as a word of caution with respect to the generalisability of 
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randomised controlled trials for daily clinical practice. The well-controlled circumstances 
under which randomised controlled trials are conducted make the strategies available 
to patients to adhere to therapy and to manage drug side effects usually more 
extensive than those available in routine clinical practice (1). Second, Andrade et al. have 
demonstrated that databases with information on drug prescriptions as available from 
pharmacies or health insurance providers can be used with relative ease to estimate the 
continuity of medication use as well as changes in therapy for large, population-based 
cohorts in a standardised way and without the problem of recall bias (2). Since 1995, 
persistence in daily practice with medication of various therapeutic classes intended 
for long-term use has increasingly been assessed with such databases (3-7). These 
studies have consistently showed that the real-life retention time in drug therapy is 
considerably lower than could have been assumed from randomised controlled trial 
data, with persistence rates of various drugs of less than 50% after several years of 
follow-up. Information on drug-retention time from automated databases can be 
of value for physicians, healthcare providers and decision-makers, provided that this 
information is valid. The condition that the retention time of drug therapy is accurately 
reflected by automated databases has, however, hardly been addressed in literature.
This study evaluates the validity of pharmacy records in estimating the retention 
time of lamotrigine, a new antiepileptic drug that has been available in the Netherlands 
from 1997 onwards. For that purpose, we have compared information on lamotrigine 
use obtained from pharmacy databases with information from medical records of the 
treating neurologist.
METHODS
This study is part of a project to asses the effectiveness of lamotrigine in daily 
practice. The present study details the validity of pharmacy data with regard to the 
determination of the retention time of lamotrigine use and the events associated 
therewith, namely:
• discontinuation of lamotrigine therapy;
• addition of another antiepileptic drug to lamotrigine therapy. 
In most studies on persistence, the event that determines the retention time is the 
discontinuation of the drug of interest, that is either the discontinuation of any drug 
intended for the disease concerned or switching to a different drug. However, in the case 
of antiepileptic drugs, sudden withdrawal can result in severe worsening of seizures. 
Therefore, another antiepileptic drug is often first added on and the existing therapy is 
subsequently tapered off (8). Furthermore, as monotherapy often fails in patients with 
refractory epilepsy, antiepileptic drugs are added in order to enhance the treatment 
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outcome for these pxatients using polytherapy. In this case, the addition of another 
antiepileptic drug reflects inadequate seizure control. For this reason we included 
addition as an event that determines retention time.
Study population
Anonymous prescription data was available from 1,056 community pharmacies 
(approximately 65% of all pharmacies in the Netherlands). From those pharmacies 
the drug-dispensing histories for the period of January 1996 to December 2000 were 
collected from all incidental lamotrigine users. An incidental user was defined as a 
patient who received the first lamotrigine prescription after a one-year run-in period 
from 1 January 1996. This resulted in a database with all prescription data of 3,598
incidental users, as previously described in detail (7). The database provided information 
on the following domains: the patient (age, date of birth, postal code), the drug (trade-
name, ATC-classification, Defined Daily Doses (9)) and the prescription (dispensing date, 
number of units dispensed, prescribed daily dose). A random selection of lamotrigine-
using patients (n = 1,819) was asked, through their community pharmacist, to give their 
written approval for use of their medical record of the treating neurologist for this study. 
The details of this recruitment procedure have been described elsewhere (10). In brief, the 
criterion for inclusion of subjects in this study was that medical records and pharmacy 
records both comprise at least the first year before and after the start of lamotrigine 
use. The medical records of 360 subjects were reviewed. However, during the reviewing 
process, data from 144 subjects was excluded for various reasons (lack of information 
(n=85), unconfirmed diagnosis of epilepsy (n=27), and other reasons (n=32)), leaving 216
patients included in the present study.
Pharmacy data
For each prescription the theoretical duration of drug use according to the pharmacy 
records was calculated, using information about the dispensing date, the number 
of units dispensed and the prescribed daily dose. In the Netherlands medicines are 
dispensed for a maximum of 90 days, with the exception of oral contraceptives. An 
observation window for each patient was defined as the time between the date of the 
first prescription of any drug and theoretical end date of the last prescription for any 
drug during the study period. The three study criteria were defined as follows (figure 1):
1. Discontinuation of lamotrigine therapy: more than 180 days between the theoretical 
end date of the last lamotrigine prescription and the end of the observation 
window;
2. Addition of another antiepileptic drug: after the initiation of the lamotrigine therapy, 
with at least one other prescription of lamotrigine after the start of the other 
antiepileptic drug;
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3. Retention time: the sum of the theoretical durations of the consecutive lamotrigine 
prescriptions until one of the aforementioned end points. 
Medical records of the treating neurologist
The retrieved information from the medical records on drug use concerned drug 
name, prescribed daily dose and the dates of initiation and termination of antiepileptic 
drugs. Medical records were verified for the start date of lamotrigine and for the 
occurrence of the discontinuation and addition end points. The retention time was 
calculated as the time between the initiation of lamotrigine and the occurrence of 
one of the two events. In addition, the reasons for discontinuation and addition were 
extracted from the medical record. 
Data analysis
Data from the pharmacy records and the medical records of 216 subjects was 
incorporated in a study database in SPSS 11.5. Several aspects of drug exposure according 
to the pharmacy records were analysed in order to assess the validity of these records.
Validity of using pharmacy records with respect to retention time 
Sensitivity, specificity, positive predictive value (PPV) and negative predictive value 
(NPV) were calculated for the two end points discontinuation and addition. The relation 
between the retention time of lamotrigine estimated from the pharmacy records and 
the retention time determined from the medical records was evaluated using Pearson’s 
correlations measure.
C
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Figure 1. End points of lamotrigine therapy
01.01.1996 12.31.2000inception date end point
*
*
Information from all prescriptions (observation window, dash line) and lamotrigine prescriptions (solid line) was used to 
defi ne patterns of use. 
A: continuation of lamotrigine; 
B: discontinuation of lamotrigine (more than 180 days between the theoretical end date of the last prescription of 
lamotrigine and the end of the observation window); 
C: addition (dotted line): of another antiepileptic drug after the start of lamotrigine. 
Retention time of lamotrigine use is defi ned as the time between the inception date and the occurrence of one of the 
two end points or end of the observation window, whichever came fi rst. 
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Optimisation of discontinuation criterion 
Discontinuation of lamotrigine on the basis of pharmacy records was defined at 
the outset as an interval of at least 180 days between the theoretical end date of the 
last lamotrigine prescription and the end of the observation window. This time window 
was optimised by means of a ROC curve, using various cut-off points for the duration 
between the theoretical end date of the last lamotrigine prescription and the end of the 
observation window as the ‘diagnostic test’. 
Reported reasons for changing lamotrigine therapy
The reasons underlying both end points (discontinuation and addition) were 
investigated. Possible reasons were insufficient effect and/or the occurrence of adverse 
effects. Our assumptions were that discontinuation was primarily related to adverse 
effects of lamotrigine and that addition was primarily related to insufficient effect. 
RESULTS
The data from pharmacy records and hospital medical records of 216 first-time 
users of lamotrigine was included in this study. The median age was 43.5 years (range 
18 – 84), with a male-female ratio of 39%-61%. Duration of follow-up ranged from 1 to 
4 years (mean 1.8 y). The median duration of a lamotrigine prescription was 58.3 days. 
Discontinuation +
Discontinuation -
Total numbers
Addition +
Addition -
Total numbers
Both endpoints
Endpoint present
Endpoints absent
Total numbers
Discontinuation +
29
8
37
Addition +
15
3
18
Endpoint present
41
12
53
Discontinuation -
1
178
179
Addition -
9
189
198
Endpoints absent
9
154
163
Total
30
186
216
24
192
216
50
166
216
Table 1.   Validity parameters
Pharmacy records Medical records N
Sensitivity : 78.4%
Specificity : 99.4%
PPV : 96.7%
NPV : 95.7%
Sensitivity : 83.3%
Specificity : 95.5%
PPV : 62.5%
NPV : 98.5%
Sensitivity : 77.3%
Specificity : 94.5%
PPV : 82.0%
NPV : 92.8%
Validity
PPV: positive predictive value; NPV: negative predictive value.
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Table 1 presents the validity parameters data for the two end points (discontinuation 
and addition). For 29 of the 37 patients who discontinued lamotrigine therapy according 
to the medical record, this event (determined by the 180-day interval) could also be 
assessed on the basis of pharmacy records (sensitivity 78.4%). Specificity, positive 
predictive value (PPV) and negative predictive value (NPV) were 99.4%, 96.7% 95.7% 
respectively. The sensitivity of the addition criterion was 83.3%. Specificity, positive 
predictive value (PPV) and negative predictive value (NPV) were 99.5%, 62.5% and 98.5% 
respectively. The correlation between the retention time determined from pharmacy 
records and from medical records was good (Pearson r = 0.91; figure 2). 
The ROC curve used to determine the optimal interval for the discontinuation 
criterion is presented in Figure 3. The interval defined at the outset of 180 days between 
the date of the last prescription of lamotrigine and the end of the observation window 
resulted in a sensitivity of 78% and a specificity of 99%. The optimal interval proved to 
be 80 days. This resulted in a sensitivity of 92%, a specificity of 97%, PPV 94.4% and NPV 
98.3%. 
The occurrence of adverse effects was the predominant reason (51%) for 
discontinuation of lamotrigine (table 2). In 50% of the patients for whom another 
antiepileptic drug was added, the reason was insufficient efficacy of lamotrigine. 
Therapy discontinuation occurred sooner than antiepileptic drug addition, mean time 
to event being 180 and 399 days respectively (p < 0.05). 
Figure 2. Retention time: correlation between electronic prescription data and medical records
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DISCUSSION
This study demonstrates that pharmacy data is valid as a tool for population-based 
persistence studies. For both end points together, 80% was confirmed after reviewing 
the medical records of the treating neurologists. Andrade et al. used the same criterion 
and found similar results in their validation study: a PPV of 80% (11). For the addition 
criterion, which is specific for antiepileptic drugs and not used in other studies (see 
“Methods”), the PPV was substantially lower. If the maximum interval between two 
subsequent prescriptions of a specific drug was less than 180 days in the pharmacy 
database, we registered this as ongoing use. This interval may be too crude, and as a 
result underestimation of discontinuation of antiepileptic drugs could have occurred. 
Possibly, an antiepileptic drug could be discontinued and a restarted again within the 
timespan of 180 days, which may be an explanation for the relative low PPV we found 
for the addition criterion.
The chosen interval of 180 days used to determine discontinuation of lamotrigine 
therapy was based on an underestimation of the discontinuation frequency. Application 
of the optimal interval of 80 days (i.e. 40% more than the average prescription duration) 
resulted in a better estimation of the true frequency of discontinuation. 
As expected, discontinuation of therapy was predominantly seen in patients 
who suffered from adverse effects of lamotrigine. Discontinuation of therapy was 
Figure 3. ROC curve for the time between the end of lamotrigine and the end of 
                   the observation window as a criterion for discontinuation of lamotrigine
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effectuated earlier than addition of a second antiepileptic drug. Lamotrigine has to be 
titrated carefully to minimise the risk of severe, idiosyncratic adverse effects. An effect 
of lamotrigine treatment is not to be expected in the first months of treatment. This 
probably explains the differences in the time patterns of both end points a finding in 
line with a study on antipsychotic drugs (12).
An aspect that we were not able to evaluate was whether the validity of pharmacy 
data is influenced by patients not complying with drug taking. Recently, Tobi et al. have 
showed that in community pharmacies 99.5% of the prescriptions issued by physicians 
are claimed within one month (13). Refill compliance, although not similar to actual 
daily adherence to a drug, can be seen as a valid proxy for compliance.
We have demonstrated the validity of pharmacy data in studying drug retention 
time. Benefits of pharmacy data include that it is population-based and represents 
large populations typical of daily clinical practice (6). The data has already been collected 
and computerised for administrative purposes; therefore, retention-time analyses can 
be performed relatively quickly and inexpensively. Nevertheless, retention-time studies 
using only pharmacy data have several limitations. Important, demographic or disease-
related, baseline characteristics are lacking. These factors may be associated with drug 
retention time and also drug preference. Moreover, pharmacy data lacks information on 
reasons for changing the therapy (e.g. lack of effectiveness, side effects). This information 
is essential for the full appraisal of the retention-time concept. As pharmacy records and 
medical records can be seen as complementary with respect to the aspects mentioned 
above, an approach that uses the benefits of both data sources is to be preferred in 
the post-marketing assessment of drug therapy. Ideally, record linkage of different 
automated databases would provide information from the different domains needed to 
evaluate the retention time of drug therapy rapidly, efficiently and validly.
Table 2.   Reported reason for changing lamotrigine treatment
Reason for change in lamotrigine therapy, n
insufficient efficacy
occurrence of adverse events
unknown 
Time to change in lamotrigine therapy (days) 
mean ± SD†
range
early change (≤ 6 weeks after start LTG), n
Discontinuation 
(n = 37)
10 (27%)
19 (51%)
8 (22 %)
180 ± 148
8 - 473
6 (20%)
Addition
(n = 18)
9 (50%)
2 (11%)
7 (39%)
399 ± 294
6 - 1,071
1 (4.2%)
† p < 0.05
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CONCLUSION
The retention time of prescription drugs is an indication of the success of the 
therapeutic goal. Studies in a population-based setting are an important way of 
monitoring this success. The conclusion of this study is that pharmacy records are a 
valid way of measuring the discontinuation, addition and retention time of drugs, and 
are therefore a valuable tool in pharmacoepidemiology.
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ABSTRACT
Objective
To be able to stem the rising cost of the treatment of epilepsy the Dutch Health 
Care Insurance Board (CVZ) used a new instrument for the first time in the Netherlands: 
prescription guidelines. The antiepileptic drug lamotrigine, a newcomer on the market 
in 1995, would only be refunded if prescribed according to a prescription guideline. This 
article describes the results of a survey held among Dutch neurologists to evaluate the 
implementation and assessment of this guideline.
Methods
A survey was designed by the Nijmegen Epilepsy Research Group and sent to all 490
members of the Dutch Society for Neurology.
Results
A total of 232 neurologists (51%) responded. Of the 232 respondents, 51 (22%) were 
familiar with the guideline. Of these 51 neurologists, 80% subscribe either completely or 
largely to the guideline. A majority of neurologists (77%) favoured guidelines developed 
by the the medical profession. None of the respondents preferred a guideline that was 
unconditionally binding. 135 Neurologists agreed upon taken cost into consideration in 
the development of protocols, 67 neurologists disagreed.
Discussion
From the results of this survey the conclusion may be drawn that the guideline is 
insufficiently well-known and that adherence is also insufficient. Both this survey and 
literature show that support for a guideline for the treatment of epilepsy does exist. 
Furthermore, a majority of the responding neurologists feel that such a guideline may 
take cost into account, but that the effectiveness of the treatment must always be their 
primary concern. For the acceptance of a guideline it is important that it be drawn up by 
members of the profession.
INTRODUCTION
In the past few decades the Dutch government has been trying to rein in the fast-
rising cost of public health care. With an average annual rise of ten percent the cost of 
medication is the fastest rising cost component in the Dutch health care system (1). 
In order to arrest these rising costs, the government has developed the Drug Refund 
System and is encouraging the use of formularies.
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One particular new development is that for medicine to be refunded it must be 
prescribed according to a prescription guideline. Through the use of prescription 
guidelines, authorities try to impose restrictions on the claim made for the drug (2). 
These restrictions usually relate to follow a treatment guideline, in order to limit the 
range of prescribers or to limit the range of indications. In the Netherlands this measure 
was first introduced in 1997 for the antiepileptic drug lamotrigine. When this drug was 
registered in the Netherlands in 1995, it was initially not included in the Drug Refund 
System. The then Public Health Care Council (which in 1999 became the CVZ, Dutch 
Health Care Insurance Board) gave two reasons for this: first, there was insufficient 
evidence of the added value of lamotrigine over existing antiepileptic medication; and 
second, lamotrigine cost approximately five times as much as the existing antiepileptic 
agents. The stalemate on the refunding of lamotrigine was resolved in August 1997, 
when the Public Health Care Council introduced the Lamotrigine Prescription Guideline. 
The essence of the guideline is that lamotrigine is reimbursed only for the indication 
of refractory epilepsy. In the guideline, refractory epilepsy was described as insufficient 
seizure control after treatment with at least three conventional drugs. The Health Care 
Insurance Board developed the Lamotrigine Prescription Guideline in co-operation 
with one independent neurologist and presented it to the Netherlands Association for 
Neurology. The guideline was then sent to all the Dutch neurologists. The same guideline 
was applied for the refunding of the antiepileptic drugs that were subsequently 
introduced, i.e. topiramate, gabapentin and levetiracetam. 
It is unclear to what extent the guideline has been accepted and applied in 
medical practice. This is important to know because it may show to what extent such 
prescription guidelines may be used in future. This article describes the results of a 
survey held among Dutch neurologists to evaluate the implementation and assessment 
of this guideline. The Lamotrigine Prescription Guideline was designed to contain costs 
by restricting lamotrigine to the (smaller) group of patients with refractory epilepsy. The 
central question in the survey is: how large is the support for cost containment in such 
a matter among members of the profession. Finally, possible implications of the results 
will be discussed.
METHODS
The four-part survey was designed by the Nijmegen Epilepsy Research Group and 
the department of Medical Technology Assessment of the UMC Nijmegen. The first 
part asked for general information about the responding neurologist (e.g. practice type, 
number of epilepsy patients seen weekly others). The second part questioned whether 
the respondent was aware of the guideline and whether the neurologist adapted the 
guideline. The third part inquired about the respondents general attitude towards 
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protocols for the treatment of epilepsy. Finally, the fourth part offered the opportunity 
for comments.
The survey was sent to all 490 members of the Dutch Society for Neurology (on the 
basis of the January 2002 address list). Six weeks after the first mailing a reminder was 
sent to non-responding neurologists. 
Data Analysis
In order to assess any possible bias because of non-response, respondents and non-
respondents were compared on gender, and practice type. Any significance between 
respondents and non-respondents was analysed by means of the Chi-square test.
RESULTS
A total of 232 neurologists (51%) responded. There were no significant differences 
between the demographical data and the nature of the practices (academic hospital, 
general hospital and epilepsy centre) between respondents and non-respondents. 
Do you generally follow 
protocols that are intended 
for your profession?
Protocols are needed for 
the treatment of epilepsy
Who should develop these 
protocols?
Do you believe protocols 
should be general enough 
to be used without the 
registered indication?
Is cost something 
you consider in your 
treatment of individual 
epilepsy patients?
In developing protocols 
effectiveness should be 
considered as well as cost
Which way do you prefer 
to use protocols?
Who should evaluate the 
guideline?
Yes 95%
I agree 93%
Profession 77%
Yes 35%
Never 34%
I agree 58%
As an advice 86%
No 4%
No opinion 5%
CVZ 0.4%
Yes, if used under 
the responsibility 
of a doctor 54%
Occasionally 52%
No opinion 13%
I will deviate only for 
a good reason 14%
Not 
applicable 2%
I disagree 2%
By joint 
effort 23%
No 11%
Always 14%
I disagree 29%
As binding 0%
Profession 
83%
CVZ  
0.4%
Profession 
& CVZ 3%
Independent 
group 12% 
No evaluation 
necessary 2%
Table 1.   The questions and answers from the survey on protocols
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The average age of the male respondents was 49, that of the female respondents 46. 
A neurologist working in an epilepsy centre sees an average of 49 epilepsy patients a 
week, whereas neurologists in academic and general hospitals only see nine.
Awareness, acceptance and application of the Lamotrigine Prescription Guideline
Of the 232 respondents, 51 (22%) were familiar with the guideline. Of these 51
neurologists, 80% subscribe either completely or largely to the guideline. The main 
reasons given by those that know the guideline but do not adapt it are (1) “not properly 
tailored to the individual patient”, (2) “too stringent” and (3) “intrinsically wrong” .
Neurologists opinions on the content, development and evaluation of guidelines
The respondents’ answers are shown in table 1. The respondents were almost 
unanimous about the need for guidelines for the treatment of epilepsy: 93% are in 
favour of a guideline, leaving 5% with no opinion and 2% against. Moreover, 95% of 
the respondents indicated that they actually would adhere to the guideline in their 
practice. In answer to the question who they thought should develop these guidelines, 
77% answered the medical profession and 23% the medical profession together 
with the CVZ. Only one respondent (0.4%) preferred to see the CVZ as sole developer. 
Regarding the evaluation of guidelines, 83% chose the medical profession and 12% an 
independent study group. In answer to the question how strictly the guideline should 
be followed, 86% said they felt it should be of an advisory nature and 14% felt it should 
be mandatory, albeit with the possibility of deviating for good reasons. None of the 
respondents preferred a guideline that was unconditionally binding.
Opinions are divided about the role cost play in the treatment of epilepsy patients. 
Of the respondents 34% claim never to consider the cost of treatment, 53% claim to do 
so sometimes and 14% to do so always. The question whether cost should be taken into 
consideration in the development of protocols was answered affirmatively by 58% of the 
entire group of respondents and negatively by 29%, leaving 13% with no opinion.
50 Respondents made use of the opportunity to add comments and remarks in this 
section of the survey. Thirty-one of these neurologists remarked that cost plays a part, 
but only if the effect of the treatment is not compromised, whereas nine stated that 
cost is never a consideration. One-fifth of the comments was of a different and broad-
ranging nature. 
Remarks and comments
Finally, the respondents were given the opportunity to add their own comments 
about the prescription guideline and the role of cost within the treatment of epilepsy 
patients. The 54 remarks could be divided into several categories, which are listed in 
table 2.
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DISCUSSION
It may be concluded from the results of this survey that the guideline was known 
by less than a quarter of Dutch neurologists. Several reviews on the effectiveness of 
clinical guidelines in general show that a guideline’s success depends on three factors: 
(1) awareness of it, (2) having been involved with its development and (3) acceptance of 
it (3-7).
Regarding awareness of the guideline, it is clear that the target group is insufficiently 
aware of its existence and contents. Generally speaking, passive distribution is not an 
effective way to introduce a guideline, regardless of its importance or its explicitness 
(3,4). The lamotrigine prescription guideline was distributed only once and no enquiry 
was later made into how well it was known. A more active role of the CVZ and the health 
care insurers in publicising the guideline might have helped to make it better known. 
The second aspect of making a guideline succeed is the extent to which a target 
group feels involved with such a directive. The effectiveness of a guideline is very 
positively influenced if the experts among the target group are involved with developing 
it (5-7). The respondents also have a marked preference for a guideline that is developed 
by the profession itself.
Acceptance is the third point. Results show that 92% of the respondents feel the 
need for guidelines when treating epilepsy and that 94% of them actually do follow 
guidelines in their daily practice. However, the respondents to this survey indicated that 
their main need is for a guideline that aims primarily for effectiveness. The fact that 
only one of the respondents prefers a guideline to be developed by the Health Care 
Insurance Board alone might be accounted for by the difference in viewpoint between 
Effectiveness and 
side-effects first
New drugs
Netherlands Society 
of Neurologists
Protocol is 
unknown
Content
Positive
14
14
12
11
11
5
“In a protocol it should be: effectiveness first and cost second.”
“The guidelines became outdated when the new drugs topira-
mate, gabapentin and levetiracetam appeared on the market.”
“(…) let the NVN draw up and evaluate protocols.”
“As I am not familiar with the protocol and am generally serious 
about my mail, it might be concluded that there is something 
wrong with the way the protocol was distributed.”
“Phenytoin is not the best choice for primary epilepsy.”
“I thought it was an excellent protocol, only its use has now 
become limited.”
Category Number of 
reactions
Typical comment
Table 2.   A selection of comments and remarks
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the Health Care Insurance Board (whose main concern was cost containment) and 
medical specialists (whose concern is patient care only).
It does seem possible to develop a guideline for epilepsy that combines content and 
cost. After all, the results of this survey among Dutch neurologists show that 52% of the 
respondents sometimes take cost into account when treating an individual patient and 
that 13% always do. The sharply rising cost of medication and medical interventions 
in general appears to have led to a heightened awareness of the importance of cost 
containment (8). A survey among 800 neurologists in the United States showed that 
75% of the respondents are prepared to take cost into account (9). A different US survey, 
in which 1,000 doctors were sent a questionnaire on cost and cost effectiveness, showed 
that 84% of the respondents agreed with a guideline that took cost into account (10). 
The response percentages of these two surveys were 44% and 52% respectively.
As for many conditions, little information exists for epilepsy about important 
economic issues such as the cost of treatment programs, the possibility of achieving 
similar clinical outcomes at lower cost or the cost-effectiveness of new treatments 
(11). This information is needed to use health care resources more efficiently., and this 
information should be incorporated in adequate guidelines. Adherence to a prescription 
guideline based on cost containment only will be poor. Guidelines addressing the issues 
of effectiveness and cost and allowing room to tailor the treatment of epilepsy patients 
to the individual patients needs are needed.
CONCLUSION
This survey has made it clear how great the support is among neurologists for 
guidelines in general and for those regarding epilepsy in particular. Both this survey 
and the literature show that there is support for the idea of taking cost into account 
when guidelines are developed, but that the effectiveness of the various drugs should 
remian the main consideration. It is important for the adherence to guidelines that the 
viewpoint of the profession is taken into account when these guidelines are drawn up 
and that members of the profession themselves are involved in the process. When the 
1997 prescription guideline was drawn up, there was insufficient use of existing know-
how in the field of guideline implementation.
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Non-compliance on the part 
of the professional community 
with a national guideline: 
an argumentative policy analysis
158
ABSTRACT
Objective
In 1997, the National Health Insurance Board of the Netherlands (College voor 
Zorgverzekeraars, CVZ) introduced a guideline for the use of a new anti-epileptic drug, 
lamotrigine. The goal was to limit the use of this relatively expensive drug to patients 
with difficult-to-treat epilepsy. A survey had shown that only a minority of neurologists 
were familiar with the guideline, and even fewer applied it in practice. The aim of this 
study is to identify the contents of the interpretative frames of policy makers and 
members of the target population.
Methods
The method of reconstructing interpretative frames was used to elicit problem 
definitions, possible solutions, background theories and preferences. Data were collected 
by anonymous semi-structured interviews with a representative of the policy-making 
institute and with seven members of the target group.
Results
The results indicate that the problem definitions of policy makers and practising 
neurologists differed widely, and that the policy measure conflicted with certain 
professional beliefs. In such cases, the theory of argumentative policy predicts that policy 
is unlikely to succeed, unless policy makers take action to ensure a greater congruence in 
interpretative frames between themselves and their target population.
Discussion
This study shows that interviews with a limited number of neurologists allowed the 
reconstruction of that part of their interpretative frames that are relevant to the issue 
and the usage of novel anti-epileptic drugs.
INTRODUCTION
       
The intractable problems associated with the implementation of public policy 
are well known (1-3). On the basis of an analysis of the nature and causes of these 
problems, policy makers have argued that policy should be conceived as an instance of 
co-production between policy makers and the target population (4,5). A key feature of 
this argumentative policy theory is the acknowledgement that different stakeholders 
may define policy problems quite differently, which may lead to different and sometimes 
opposing appreciations of proposed solutions. Differences in problem definition may, 
in turn, be related to differences in theoretical backgrounds and preferred ways of 
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social organisation. Such ensembles are usually referred to as ‘appreciative system’ or 
‘interpretative frame’ (6,7). In this concept of policy, it is crucial to identify the target 
population (Whose co-operation is necessary to make this policy successful?) and to 
identify their interpretative frames (How do they define the problem and how does this 
relate to other elements of their appreciative system?). Argumentative policy theory 
predicts that when there is evidence of insufficient congruence in problem definition 
between policy makers and target population, implementation is likely to fail. In order to 
succeed, policy should also be directed towards achieving better congruence in problem 
definition. In other words, it should also be aimed at inducing a process of social 
learning. This may require adjustment on the part of policy makers, target population, or 
both, and may entail reconsideration of policy options, evaluation criteria, or underlying 
assumptions and preferences (8).
In this study, we present the results of an argumentative policy analysis of a 
specific health-care policy, enacted by the National Health Insurance Board in the 
Netherlands. This board is an advisory body to the Ministry of Health on coverage issues. 
In 1997 it issued a guideline for the use of a novel anti-epileptic drug, lamotrigine. The 
Lamotrigine Prescription Guideline was distributed among all registered neurologists 
in the Netherlands. This initiative was taken because the costs of the new drug were 
substantially higher than that of conventional drugs, while there was no clear evidence 
that lamotrigine had a stronger anti-epileptic effect. The gist of the guideline was that 
the novel drug should be prescribed only to patients who show insufficient response or 
unacceptable side effects to (combinations of) conventional drugs. The guideline was 
issued to prevent lamotrigine from substituting conventional anti-epileptic drugs on 
a wide scale, with cost control as a major motive. From a survey among neurologists, 
we found that the policy measure had been largely ineffective: only a minority (22 %) 
of the respondents knew the guideline, and an even smaller proportion approved of its 
content and put it into practice (9). The aim of this study was to identify the contents 
of the interpretative frames of policy makers and members of the target population. On 
the basis of this material, we discuss whether more congruence in interpretative frames 
should have been sought, and how this might have been done.
METHODS
The method of reconstructing interpretative frames was used to elicit problem 
definitions, possible solutions, background theories and preferences (10). Data were 
collected by anonymous semi-structured interviews with a representative of the 
policy-making institute and with members of the target population (seven prescribing 
neurologists engaged in the treatment of patients with epilepsy). One neurologist was 
employed in a teaching hospital, one was employed in both a teaching and a general 
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hospital, three neurologists were employed in general hospitals, and two neurologists 
were employed in tertiary centres, specialised in treatment for patients with epilepsy. 
Two neurologists were also involved in the development of a broader guideline on the 
clinical management of patients with epilepsy, to be issued by the Dutch Society of 
Neurology. 
In the interviews, questioning focussed on perceived problems and reasons for 
actions or decisions concerning care for patients with epilepsy. All interviews were 
taped, summarised, and coded, with a distinction being made between four layers 
of interpretative frames: appreciation of solutions, definition of problems, theoretical 
backgrounds, and normative preferences. Respondent validation was conducted by 
sending a summary and interpretation of each interview to the respondent for correction. 
All respondents received an overview of results from all other interviews. Finally, a 
summary was given of the key problem definitions, possible solutions, background 
theories, and preferences according to (1) the policy maker, (2) neurologists working in 
a general hospital, (3) neurologists working in a tertiary centre, (4) neurologists working 
in a teaching hospital, and (5) neurologists participating in the guideline of the society. 
Triangulation was conducted by checking findings from interviews with literature and 
documents. 
RESULTS
The reconstructed interpretative frames of the respondents are presented in table 1. 
Policy maker
To the policy maker, the guideline was a means with which to prevent neurologists 
from prescribing lamotrigine to patients for whom a similar seizure control could be 
achieved at lesser cost with conventional anti-epileptic drugs. The problem stems 
from a fixed health-care budget on the one hand, and the continuous development of 
novel health technologies on the other, for which funding is sought. Also, the problem 
had been anticipated because, more generally, physicians are thought to be inclined to 
prescribe novel drugs to an extent that may not be supported by scientific evidence, 
so encouraged by manufacturers. A crucial aspect of the policy maker’s theoretical 
background was the notion that the majority of patients with epilepsy can be adequately 
treated with conventional drugs. An important aspect of the policy maker’s appreciative 
system was that an efficient use of public resources justifies restrictions on professional 
autonomy.
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Neurologists
None of the respondents were aware that the prescription of lamotrigine should be 
in accordance with the CVZ guideline in order to obtain reimbursement from health-
insurance companies. Neurologists reported that their key problem was finding, for the 
individual patient, the optimal (combination of) anti-epileptic drugs, and finding this 
optimal drug regimen as quickly as possible without inflicting unnecessary harm. To 
them, there are two aspects that determine optimality: seizure control and side effects. 
The optimum may vary among patients, as patients respond differently to drugs, and 
because they experience seizure control and the various side effects differently. Moreover, 
the optimum may not be stable over time: side effects may become apparent only after 
a prolonged period of time, acceptance of side effects or seizures may change, or drug 
effectiveness may decrease or may be affected by concurrent events, such as pregnancy. 
These aspects are the major challenge for the clinician, and anything that helps to 
achieve the optimal treatment strategy will be welcomed. A guideline restricting the 
use of a novel anti-epileptic drug on the basis of its costs is not one of them. Costs were 
not an issue, or, to be more accurate, costs were defined differently. To neurologists, costs 
are incurred as long as no seizure control is achieved, without acceptable side effects. 
In this context, costs are defined more broadly, in terms of unpredictability, interference 
with daily life, and costs of self-inflicted harm (resulting from seizures) to the patient 
and his family. Although not quantified, they are considered to outweigh the costs of 
drug treatment.
Apart from this commonality, there were certain differences between neurologists 
working in general hospitals and those working in teaching hospitals or specialised 
centres.
Neurologists working in general hospitals
Interestingly, the novelty of the anti-epileptic drug lamotrigine was mentioned as 
a major problem by neurologists working in general hospitals. Inevitably, because of its 
novelty, relatively little is known, especially about the safety profile of the drug. Although 
trials have been published, the medical profession has had little opportunity to obtain 
experiential knowledge. This was considered particularly relevant, since earlier drugs 
that had been introduced on the basis of trial results had turned out to be inferior to the 
then available drugs in terms of safety and effectiveness. One respondent remarked:
“Some drugs promised to be very good; however, they turned out to have many side 
effects, which holds true for vigabatrin, or were not as effective as promised, for example 
gabapentine” (respondent N2, interview)
Respondents also considered lamotrigine relatively difficult in its daily use, since its 
dosage needs to be gradually increased in order to prevent rash. In general, neurologists 
thought that lamotrigine is not more effective than conventional drugs. They also 
emphasised that in general hospitals, patients are treated who have uncomplicated 
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epilepsy. Neurologists, in general, found no need to treat these patients with novel drugs, 
nor a justification to do so, in view of the limited knowledge about these drugs. Patients 
with more complicated epilepsy are referred to tertiary centres, specialised in care for 
epilepsy. As such, respondents considered it inappropriate to examine drug effects in this 
group of patients, and not part of their professional responsibility. 
Neurologists working in tertiary or teaching hospitals
In patients with more complex types of epilepsy, finding the best treatment is a 
process of trial and error: “Predominantly, you follow the textbooks, but sometimes 
you try drugs or combinations of them as presented at conferences. Sometimes it is an 
improvement, sometimes not.” (respondent N5, interview)
Respondents considered the toxicity profile of lamotrigine an advantage, as well as 
its lesser potential for interaction with other drugs. Furthermore, they had observed a 
positive psychotropic effect of lamotrigine, which was sometimes an additional reason 
for prescribing it. An objection of these neurologists to the guideline of the National 
Health Insurance Board was that it was too static. “New anti-epileptic drugs are missing, 
the guideline is not updated […] Opportunities for evaluation of the treatment protocol 
should be incorporated.” (respondent N4, interview)
Neurologist involved in guideline development
An additional problem that was mentioned by the neurologist who was involved 
in the development of the guideline by the Dutch Society of Neurology was that 
evidence from trials does not always translate easily into clinical practice. The purpose 
of trials is to support the registration of a new drug on the basis of its efficacy and 
safety. Because of differences in study populations and patients seen in daily practice, 
the generalisability of trial findings may be limited. According to this respondent, the 
National Health Insurance Board should support the conducting of naturalistic trials, to 
assist the professional community in finding the value of new drugs in daily practice. 
With respect to costs, the respondent pointed out the arbitrariness of health-care 
policy. Why should the use of lamotrigine be restricted on efficiency grounds, while 
many treatments are covered that have never been assessed for their efficiency? Clearly, 
to this respondent, consistency in health-care policy was an important element in his 
appreciative system.
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DISCUSSION
This study shows that interviews with a limited number of neurologists allowed for 
the reconstruction of part of their interpretative frames that are relevant to the issue of 
the usage of novel anti-epileptic drugs. This resulted in information that is important to 
the policy maker in a number of ways:
First, the target population turned out to be heterogeneous. Neurologists working in 
general hospitals differed from neurologists working in teaching hospitals or specialised 
centres in a way that should be taken into account when devising policy measures.
Second, little ground appeared to exist to assume that neurologists would start 
prescribing the new anti-epileptic drug on a wide scale.
Third, neurologists experience other problems in their treatment of patients with 
epilepsy. The National Health Insurance Board might assist in resolving these problems, 
thereby realising its own policy objectives: optimisation of quality and efficiency of 
health care.
The gist of the guideline issued by the National Health Insurance Board was: try to 
achieve seizure control without incurring serious side effects, using (combinations of) 
conventional anti-epileptic drugs. The reason for this recommendation was cost control. 
Interestingly, the recommended strategy is common practice among neurologists 
working in general hospitals. The rationale, however, is different: they consider the novel 
drug not particularly easy to use, and, more importantly, they have learned in the past 
that novel drugs, although approved by national agencies, need not always be better 
than existing ones. Their professional ethic prohibits neurologists from experimenting 
with new drugs when the annual number of patients seen in their practice is too small. 
This may be especially true of patients with epilepsy, with whom achieving seizure 
control without incurring side effects is notoriously difficult. For neurologists working in 
teaching hospitals or specialised centres, however, the guideline was largely irrelevant. 
They treat patients with refractory epilepsy only; attempts to achieve seizure control 
with conventional drugs had already been made and were unsuccessful.
The type of problems neurologists experience in their management of patients with 
epilepsy is related to the unpredictability of responses of individual patients to various 
treatments. The challenge, then, is to find the optimal treatment for each individual 
patient as quickly as possible. Data from published trials are relevant to this purpose, 
but only to a limited extent: study populations may, and often do, differ from patients 
seen in daily practice, and treatment protocols may be a-typical (11). It would be helpful, 
therefore, to conduct more naturalistic studies (12) and to conduct N of 1 trials (13). Also, 
the setting-up of central registries, where unexpected events can be reported when 
treating patients with anti-epileptic drugs, would help to identify possible side-effects 
at an earliest possible stage, since trials have not always been found to constitute a 
reliable source for this type of information (14). 
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The National Health Insurance Board might consider ways of assisting or encouraging 
the professional community to introduce such measures, e.g. by co-funding naturalistic 
trials (which are unlikely to be funded by manufacturers) or by covering the costs of 
setting up N of 1 trial facilities or central registries.
The study has, of course, certain limitations. There may be other areas where 
physicians are more likely to adopt novel drugs. Policy makers should, therefore, examine 
this aspect for each case individually. Also, it cannot be excluded that in other general 
hospitals neurologists will not refer patients who fail to respond to conventional drugs to 
specialised centres. However, on the basis of our results, it would be justified to stipulate 
that novel drugs be used exclusively in specialised centres. When policy institutes help 
funding naturalistic trials and setting up research facilities, it would not be unreasonable 
to demand that they are involved in deciding whether novel drugs should continue to be 
used in specialised centres or may be released for general usage. Such a role would be 
more appropriate than developing and distributing a guideline, which – according to the 
respondents in this study – should be left to the professional community.
This case study supports the idea that it is important to establish at an early stage of 
policy development how the target populations of policy measures experience problems 
and which solutions appear sensible to them. The investment that this requires in terms 
of funds and human resources is almost certainly modest compared to the costs of 
(repeated) health policy failures.
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ABSTRACT
Objective
To establish the cost-effectiveness of antiepileptic drug treatment strategies of 
newly diagnosed patients with epilepsy. 
Methods
A decision analysis was carried out comparing effectiveness and treatment cost 
of six treatment strategies comprising carbamazepine, lamotrigine and valproate as 
first-line and second-line drugs. Three outcome groups were defined: complete success, 
partial success and failure. Data on seizure control and failure due to adverse effects 
were derived from the literature. Data on resource use, costs and quality of life were 
collected for each outcome group by means of a patient survey.
Results
Cost and quality of life data were obtained from 71 patients. Cost increased 
and quality of life decreased from complete success to failure outcome groups. The 
probability of obtaining complete success varied from 64% (VPA-CBZ strategy) to 74% 
(LTG-VPA strategy). The strategy LTG-VPA was more effective than the least expensive 
strategy CBZ-VPA, but at higher costs per additional effectively treated patient. 
Probabilistic sensitivity analysis confirmed the conclusions based on calculations not 
taking uncertainty into account. Subsequent analysis showed that changing inclusion 
criteria used in the selection of the studies from the literature had a major effect on 
cost-effectiveness ratios of the various strategies. Lamotrigine first-line strategies did 
not show to be cost-effective. However, lamotrigine second-line strategies can be cost-
effective depending on the willingness to pay for patient improvement.
Discussion
Only few studies satisfied our inclusion criteria for employment in our decision 
model. Our model add to the use of conventional antiepileptic drugs for patients wit 
newly diagnosed epilepsy. This study illustrates that with the data presently available, 
decision analysis for antiepileptic drug treatment choice depends on the trials included. 
Prospective real-life studies are needed in which first and second-line treatment 
strategies are compared with respect to both effectiveness and costs. 
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INTRODUCTION
Carbamazepine (CBZ), phenobarbital, phenytoin and valproate (VPA) have been the 
leading antiepileptic drugs for more than 30 years. Several new antiepileptic drugs have 
however been introduced during the last decade. 
In order to be licensed, these new antiepileptic drugs had to demonstrate efficacy 
as adjunctive therapy in so-called intractable patients; i.e. in patients with inadequate 
seizure control despite optimal therapy. Once a new compound is licensed and has 
demonstrated its effectiveness in daily practice, it will often be compared to existing 
compounds in monotherapy trials for patients with newly diagnosed epilepsy. 
Lamotrigine (LTG), one of the new antiepileptic drugs, has been involved in several of 
these comparative monotherapy trials (1-4). A main advantage of lamotrigine over 
conventional antiepileptic drugs seems to be its favourable tolerability profile, leading 
to fewer treatment failures, fewer cognitive side effects and a better disease-related 
quality of life in patients with newly diagnosed epilepsy (4-6). 
These results may contribute to a more widespread use of lamotrigine. However, 
the acquisition cost of lamotrigine is several times higher than that of conventional 
antiepileptic drugs. In this era of constrained health care resources, health authorities 
are beginning to demand economical justification for new antiepileptic drugs. The 
purpose of this study is to establish the cost-effectiveness of lamotrigine in patients 
with newly diagnosed epilepsy. In this study the cost-effectiveness of lamotrigine is 
compared with carbamazepine and valproate through a decision analytic approach. 
Drug-specific effectiveness data were derived from randomised clinical trials and 
observational studies published in the international literature. Patient data on cost 
consumption and health-related quality of life were collected for patients in one out of 
three different outcome groups via a patient questionnaire. 
Six treatment strategies are compared in this study, i.e., carbamazepine first-line 
monotherapy followed by either valproate or lamotrigine in case carbamazepine fails 
due to either lack of seizure control or adverse effects, valproate first-line followed by 
either carbamazepine or lamotrigine in case valproate fails due to either lack of seizure 
control or adverse effects and lamotrigine first-line monotherapy followed by either 
carbamazepine or valproate in case lamotrigine fails due to either lack of seizure control 
or adverse effects.
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METHODS
Study Design
This paper details a cost-effectiveness analysis evaluating first and second-line 
treatment strategies in patients with newly diagnosed epilepsy. The analysis uses 
a decision tree as a modelling instrument. In accordance with Dutch guidelines on 
pharmacoeconomic research a societal perspective was adopted for the economic 
evaluations (7). The time span comprises the first year of treatment.
Decision Tree Model 
A decision tree analysis (software program DATA; TreeAge Software, Williamstown, 
MA) was used as a model to depict potential clinical pathways and outcomes within 
the first year of treatment. Figure 1 shows the structure of the model. Three first-line 
drugs are studied, carbamazepine, valproate and lamotrigine. Six treatment strategies 
are evaluated comprising all possible variations of first and second-line treatment with 
these three agents. In the model the effectiveness of the first drug is evaluated after six 
months. When a patient is seizure free and does not experience unacceptable adverse 
effects, the patient continues with the first-line drug for the remaining six months. If 
there are unacceptable side effects on the first drug, the patient is switched directly 
to a second drug in monotherapy. In case of inadequate seizure control the second-
line treatment is first added to the first-line drug. In this case the first-line drug is 
withdrawn after two months and second-line monotherapy is used for the last four 
months of the study. Thus, the assumption is made that at the end of the first year all 
patients are in one of three outcome groups, i.e. complete success, partial success or 
failure. Complete success implies the patient being seizure free. Partial success is defined 
as a reduction in seizure frequency of more than 50% compared with baseline. Failure 
is defined as inadequate seizure control (i.e. less than 50% seizure reduction) or the 
occurrence of unacceptable adverse effects.
Decision Model Input
Path probabilities, reflecting the effectiveness of the different treatment strategies, 
were based upon literature data. A limited number of studies with comparable study 
designs were selected from the available full-published comparative monotherapy 
studies. The inclusion criteria used for this selection procedure were: 
• study participants had to be over 12 years of age with newly diagnosed epilepsy;
• seizures had to be partial and / or generalised tonic-clonic seizures;
• starting dosages and titration schedules had to be in accordance with present 
guidelines;
• evaluation period of at least 24 weeks;
• no dose adjustments allowed during evaluation period.
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From the selected studies, first-line probabilities on seizure freedom, failure due to 
side effects and failure due to insufficient seizure reduction were calculated. All analyses 
were performed on a per protocol basis. Individual probabilities were based on weighted 
probabilities from the different studies based on their study size.
Second-line studies were selected from available full-published studies evaluated in 
two earlier review papers (8;9). The inclusion criteria were:
• titration and taper schedules in accordance with present guidelines;
• combination period of 8 –12 weeks;
• monotherapy phase of 8 –12 weeks.
Collection of data on cost and quality of life
From a societal viewpoint three sectors can be identified in which epilepsy-related 
costs may occur: health care sector, patient and family sector and others (10). To 
estimate cost of epilepsy care in the first sector, data were obtained from the medical 
records of patients. Data on costs in the two latter sectors were collected using patient 
questionnaires. In this questionnaire information was collected retrospectively over a 
period of 3 months and prospectively the same data were collected for 6 months following 
the inclusion date. Three months is a recommended recall period for retrospective data 
collection, based on validity study of Severens et al (11). Adult epilepsy patients visiting 
the outpatient department of Neurology of the University Medical Centre Nijmegen and 
the University Hospital Maastricht could participate. The treating physicians classified 
each patient into one of the three outcome groups based on seizure frequency. Patients 
were classified as complete success (seizure free), partial success (more than 50% 
reduction in seizure frequency) or failure (less then 50% seizure reduction). 
The daily maintenance doses defined in the decision model are based on the 
average doses achieved in the trials considered, i.e. 600 mg for carbamazepine, 150 mg 
for lamotrigine and 1,000 mg for valproate. For lamotrigine used in combination with 
carbamazepine the daily dose was set at 300 mg.
Cost Valuation
The assignment of unit cost to the various elements of epilepsy care is based on 
an instruction document for economic evaluation in Dutch health care by Oostenbrink 
et al (12). This document provides guideline prices relevant for the Netherlands for 
various items, such as outpatient clinic visits, hospitalisation et cetera. When there is 
no guideline price for an item, these items were valued by using official tariff lists for 
allowable reimbursement rates. 
Table 1 mentions these cost units and their prices. All figures were updated to January 
2002 according to the rate of inflation. Inflation was measured by the Consumer Price 
Index published by Statistics Netherlands (http://www.cbs.nl). All costs were expressed 
in Euro (1).
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Health care sector
GP services
Physician services
Hospital services
Neurologic ward
Diagnostics
Laboratory
Imaging (EEG, CT, MRI)
Drug therapy
CBZ 600 mg
LTG 150 mg
VPA 1000 mg
Patient & family sector
Unpaid care
Other sectors
Absence of work
cost per visit
cost per visit
cost per admission day
cost per procedure
cost per procedure
cost per month
cost per hour
cost per day
16.7
46.1
304.3
4.4
95.6
9.7
69.6
15.9
8.9
106.5
guideline price 
guideline price 
guideline price 
tariff a
tariff b
tariff
guideline price
guideline price c
Table 1.   Unit cost per item
a Weighted composition of tariffs from different laboratory investigations
b Weighted composition of tariffs from different imaging tests
c Weigthed composition of different ages
Cost item Cost measure Unit cost (3 ) Source
Cost-effectiveness Analysis
The analysis of the decision-tree model results in probabilities of a theoretical patient 
to end up in one of three outcome groups, i.e. complete success, partial success or failure, 
the so-called path probabilities. Based on these path probabilities the expected cost 
of each of the six strategies was determined. General principles of cost-effectiveness 
analysis were applied to these results (10). First, it was determined whether certain 
strategies were dominated by other strategies. A dominated strategy is more costly, but 
less effective than another strategy. For nondominated strategies, the cost-effectiveness 
analysis combines the expected costs with the probability of complete success, i.e. the 
incremental cost-effectiveness ratio (ICER). Beginning with the least costly strategy, 
non-dominated alternatives were compared to calculate incremental ratios.
The ICER is calculated as 
[(mean annual cost per patient)strategy 2 – (mean annual cost per patient)strategy 1] 
[(complete success)strategy 2 – (complete success)strategy 1]. 
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Sensitivity Analysis
Second order uncertainty of the cost-effectiveness estimates of the six strategies 
was investigated by Monte Carlo simulation techniques. Distributions were defined for 
the probabilities and costs used in the model (complete success, incomplete seizure 
reduction, unacceptable side-effects). As probabilities are supposed to have a value 
between 0 and 1, Beta-distributions were fitted for all these parameters. For costs 
gamma distributions (zero to infinity) were defined. Of course, the effectiveness measure 
complete success was dichotomous and assumed to be deterministic and therefore 
not part of the probabilistic sensitivity analysis. All 6 strategies were evaluated in the 
simulation that was performed with 1,000 iterations. As a result of the iterations, for 
every cost and effectiveness pair of a strategy, net benefits were calculated for a range 
of levels of ceiling cost-effectiveness ratios. For each iteration a strategy is considered 
optimal in case of the highest net benefit and the proportion of the iterations being 
optimal is determined for each strategy. Subsequently, cost-effectiveness acceptability 
curves were drawn for each of the six strategies, showing the cost-effectiveness 
acceptability frontier in relation to different levels of the ceiling cost-effectiveness ratio 
(13).
RESULTS
Decision tree analysis
A literature search yielded fourteen first-line monotherapy trials. Only three of 
these 14 studies met our inclusion criteria (2,14,15). The probabilities for the various 
outcome groups derived from these studies are presented in table 2. The other studies 
were excluded for various reasons. Two studies also concerned patients that did not have 
newly diagnosed epilepsy (6,16). One study only considered patients older than 65 years 
of age (3). Titration schedules used in two studies were no longer in agreement with 
present guidelines (1,4). The evaluation period was too short in one study (17). In five 
studies the number of patients becoming seizure free at the end of the evaluation phase 
was not mentioned (18-22). 
Two second-line studies met our inclusion criteria (23,24). No data were found on 
probabilities for second-line valproate or carbamazepine after failure of lamotrigine. An 
assumption was made that these latter probabilities were the same as for second-line 
lamotrigine after failure of valproate or carbamazepine. No drug specific data were 
found on the probability of a second drug leading to complete success after failure of 
a first drug due to side effects. A general probability for this scenario was derived from 
the observational study by Kwan et al (25). The probabilities for second line treatments 
are shown in table 3.
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Cost item Complete success Partial success Failure
Table 5.   Average breakdown of costs per patient group in 2 per month (and ranges)
Health care sector
GP services
Physician services
Hospital services
Diagnostics 
(laboratory & imaging)
Patient & family sector
Unpaid care
Others
Absence of work
subtotalB
0 (0-0)
8.5 (0.1 -35.3)
0 (0 - 0)
24.5 (0.2 - 161.8)
2.8 (0 – 64.5)
-
35.8
0.5 (0 - 10.7)
8.3 (0 - 46.2)
17.6 (0 - 625.5)
33.8 (0 - 302.2)
67.4 (0 – 3642.7)
-
127.6
4.9 (0 - 46.2)
13.1 (0.1 - 73.6)
54.6 (0-727.6)
41.0 (0.2 - 330.0)
16.8 (0-413.6)
-
130.4
Number of patients
Age (mean years ± SD)
Gender (% male)
QOLIE-31
question 1-30
(mean score ± SD)
Complete success
30
48.5 ± 18.6
70
74.0 ± 13.9
Partial success
27
42.5 ± 17.6
48
60.6 ± 16.6
Failure
14
54.3 ± 20.3
50
48.6 ± 12.7
Table 4.   Patient characteristics 
Table 6.   Cost effectiveness analysis
Strategy
(model A)
CBZ – VPA
VPA – CBZ
CBZ – LTGC
VPA – LTG
LTG – VPAD
LTG – CBZ
Expected
1-year cost
per patient (3 )
975
1,111
1,230
1,255
1,861
2,036
Expected 
complete 
success
0.684
0.635
0.726
0.722
0.742
0.706
Incremental
cost effectiveness
ratioB
Reference
(Dominated)
6,079
(Dominated)
40,422
(Dominated)
B The ICER is calculated relative to the next less costly nondominated strategy.
C Calculation ICER CBZ-LTG : (1230-975)/(0.726-0.684)
D Calculation ICER LTG-VPA : (1861-1230)/(0.742-0.726)
B The cost of drug therapy is strategy specifi c and therefore not shown in Table 5.
SD = standard deviation
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Figure 2. Cost-effectiveness plane showing for each of the strategies the results of 1,000
                   iterations of the Monte Carlo simulation
CBZ - VPA
VPA - CBZ
VPA - LTG
CBZ - LTG
LTG - VPA
LTG - CBZ
Figure 3. Cost-effectiveness acceptability curves for the decision regarding the most efficient 
                   strategy for antiepileptic drug treatment in newly diagnosed epilepsy patients
CBZ - VPA
LTG - CBZ
VPA - LTG
LTG - VPA
CBZ - LTG
VPA - CBZ
178
Collection of data on cost
Self-reported data on cost and quality of life were collected from a total of 71
patients: 30 patients were in the complete success outcome group, 27 patients in the 
partial success outcome group and 14 patients in the failure outcome group. The patient 
characteristics are described in table 4. Patients in the complete success outcome group 
had the highest mean total score on the QOLIE-31 (74.0). Patients in the partial success 
and the failure outcome group had lower mean scores, 60.6 and 48.6 respectively. 
Average monthly costs per patient, with the exception of drug costs, are presented in 
table 5. Overall, an inverse relation between cost consumption per item and outcome 
groups was demonstrated. Patients in the complete success group appeared to incur 
the lowest costs (1 35.8/month) in contrast to patients in the failure outcome group (1
130.4/month). The items ‘hospital services’ and ‘unpaid care’ contributed most to the 
costs. Lost productivity due to absence of work was negligible. 
Cost-effectiveness Analysis
The results of the cost-effectiveness analysis are presented in table 6 and ranked in 
ascending order of expected costs. The probability of obtaining complete success varied 
from 64 (VPA-CBZ strategy) to 74% (LTG-VPA). The treatment strategy with the lowest 
cost, the reference treatment, was CBZ-VPA with expected annual costs per patient 
for the first year of treatment of 1 975 (probability complete success is 68.4%). The 
treatment strategy LTG-CBZ took up the highest costs, 1 2,036 annually. The LTG-CBZ 
strategy and also the strategies VPA-LTG and VPA-CBZ were dominated strategies (more 
expensive and less effective). Two treatment alternatives, CBZ-LTG and LTG-VPA, were 
nondominated strategies. The incremental cost-effectiveness ratio of CBZ-LTG relative 
to the CBZ-VPA strategy is 1 6,079 per additional complete success patient. That of LTG-
VPA relative to CBZ-LTG is 1 40,422 per additional complete success patient. 
Sensitivity Analysis
The results of the probabilistic sensitivity analysis are graphically shown in figure 
2. In this figure cost-effectiveness is shown for all six strategies. Figure 3 shows the 
cost-effectiveness acceptability curves of the different strategies. The CBZ-VPA strategy 
turns out to have the best probability to make a cost-effective decision. In case society 
is willingness-to-pay more than 1 5,000 per effectively treated patient, strategies 
including a switch to lamotrigine as a second-line drug become more favourable. The 
first-line strategies with lamotrigine as a first-line drug are clearly shown not to be 
cost-effective, despite a high cost-effectiveness threshold of 1 25,000 per effectively 
treated patient. It can be concluded that probabilistic sensitivity analysis confirms the 
conclusions based on calculations not taking uncertainty into account.
In a subsequent analysis the impact of the selected studies (used for determining 
first-line path probabilities) on the outcomes of the cost-effectiveness model was 
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evaluated. Three additional models were designed that incorporated studies that did 
not meet the inclusion criteria used for our initial model (which will be called model A 
from here on). These models are shown in table 7.
In model B a study by Brodie et al. was added (1). This study was not included into 
model A because titration schedules for both carbamazepine and lamotrigine were 
not conform present guidelines (26). Incorporation of this study leaves the reference 
strategy CBZ–VPA unchanged, the strategies CBZ-LTG and LTG-VPA become dominated 
strategies (where as in model A they were non-dominated strategies). 
Model C consists of the studies included in model A plus a study by Richens et al. (18). 
This study was left out of model A for two reasons. The starting dosage of VPA was rather 
low compared to present guidelines, and this resulted in a prolonged period before the 
eventual effect of this drug could be expected. Furthermore, the number of patients 
becoming seizure free was not clearly mentioned in this study and had to be estimated 
from a Kaplan-Meier graph. Incorporation of this study leaves the reference strategy 
unchanged, the ICER of the LTG-VPA strategy becomes 1 8,021 (whereas in model A the 
ICER was 1 40,422).
In model D all studies from aforesaid models are included and consequently all first-
line path probabilities changed compared to model A. Model D resembled model A, the 
strategy with the least costs was CBZ-VPA and strategies CBZ–LTG and LTG-VPA were 
more effective compared to this reference strategy. 
DISCUSSION
Ideally, an economic evaluation consists of a real-life study in which both clinical 
and cost data are assessed (10,27). Such a study is not available for antiepileptic drugs 
and therefore we used existing published literature for estimates of effectiveness and a 
patient questionnaire for estimates on cost items. As there is no randomised trial directly 
comparing carbamazepine, valproate and lamotrigine, a decision model was used for 
an indirect comparison of a number of original, controlled trials. To strengthen these 
comparisons stringent inclusion criteria to the eligible trials were applied. This resulted 
in a limited number of included trials. For the probabilities of second-line treatment 
we had to rely on several assumptions, since only two studies satisfied our predefined 
inclusion criteria. In our opinion, it is justified to assume that the effectiveness of 
carbamazepine and valproate as second-line treatments following lamotrigine is equal 
to that of lamotrigine used as a second-line treatment following carbamazepine or 
valproate. One would expect that the total number of patients responding to A, possibly 
followed by B, is the same as the total number of patients responding to B, possibly 
followed by A. This is supported by two crossover studies in the literature (28,29),
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All models in our study show that CBZ-VPA is the reference treatment and that 
there are more effective treatments, but at considerable costs per extra patient treated 
effectively. Assessing levels of certainty is important in cost-effectiveness analysis 
because of the assumptions made about the relation between the intervention and 
the outcome (30). This is, however, rather complicated because the outcome in a cost-
effectiveness analysis is a ratio of two different outcomes (costs and effects), rather than 
an estimate of a single outcome (say, adequate seizure reduction). Sensitivity analysis, 
preferably probabilistic, is an accepted method to evaluate if the result is robust to 
changes in the different parameters involved. This study shows that it is also important 
to use transparent inclusion criteria for data used to build the decision tree model. The 
set of literature data used as input data was of influence on the outcome, especially on 
the ICER, as the differences between models A-D show. It became clear that the results 
of cost-effectiveness analyses of first-line antiepileptic drugs monotherapy depend on 
the included clinical trials.
In this study we used a cost questionnaire to obtain data on cost consumption and 
quality of life. The validity of a cost questionnaire such as ours was assessed previously 
(31). This comprehensive questionnaire allows collecting patient-based costs of epilepsy, 
as is widely recommended for cost-effectiveness studies (32). Another approach to 
estimate cost items is the use of an expert panel (Delphi panel), as has been employed in 
previous economic studies in epilepsy (33,34). Such a panel estimates the costs incurred 
by patients. We believe that patient-based cost collecting is at least as adequate, and 
gives additional valid data. The cost are assumed to be equal within each of the three 
outcome categories, except for drug costs. It seems reasonable that the frequency of 
visits to the outpatient department and of investigations are dependent on the response 
to treatment, rather than on the drug with which this outcome is realised. 
It also is likely that the utility within an outcome category is related to that category, 
rather than to the drug used. 
We found that cost of treatment of patients with newly diagnosed epilepsy was 
lowest for the conventional strategy CBZ–VPA. The LTG–VPA strategy, with first-line use 
of lamotrigine, was more effective but against considerably higher cost per individual 
seizure free patient. The cost-effectiveness of lamotrigine monotherapy was compared 
to carbamazepine monotherapy in one cost minimisation study and to carbamazepine, 
phenytoin and valproate monotherapy in a second cost minimisation study (33,34). The 
first study was based on only one comparative monotherapy trial, while the second study 
was based on 8 different monotherapy studies. In cost minimisation studies the efficacy 
of the respective treatments is assumed to be equal; the only outcome is treatment cost 
per initial strategy and the costs considered are drug costs, costs of resources employed 
in the management of adverse events, and costs associated with therapeutic switching. 
Both cost minimisation studies showed that lamotrigine is considerably more expensive 
for newly diagnosed patients in health service costs incurred. There are several differences 
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between our study and these two cost minimisation studies: (a): efficacy is not assumed 
to be equal in our study; (b): we determined costs per additionally effectively treated 
patient in comparison to the reference treatment; (c): we used stringent inclusion 
criteria to yield a sample of comparable studies; (d): our sensitivity analysis evaluated 
the effects of including further studies instead of evaluating best-case and worst-case 
scenario’s of included studies; and (e): we used a patient questionnaire instead of a 
Delphi panel. Despite differences in methodology between the approaches, the findings 
are overall rather similar. 
In our study we obtained health-related quality of life outcomes from epilepsy 
patients using the QOLIE-31 questionnaire. Besides this, we were not able to establish 
a health state utility for our patient population. For a small subgroup Visual Analogue 
Scale values were measured and these were clearly related to the effect of treatment: 
for complete success 75.8 (S.D. 16.2), for partial success 70.0 (S.D. 16.3) and 54.8 (S.D. 9.6) 
for failure. VAS values can be used for calculating utility values and thus perform cost per 
Quality adjusted life year-calculations. However, in this study the number of patients, 
respectively 12, 5, and 4 were too small to have valid cost/QALY results. Due to the small 
sample size of the present study we could not collect treatment strategy-specific data 
but had to confine the data to three outcome groups. This may have been detrimental 
to lamotrigine, as lamotrigine offered patients with newly diagnosed epilepsy a better 
health-related quality of life in clinical trials compared to carbamazepine and valproate 
(5,35). The small sample size of our study population and the limited data on health-
related quality of life available in literature made that we used a conservative approach 
with seizure frequency as only outcome measure. 
Our study results adds to use of conventional antiepileptic drugs as first-line 
treatment. Our findings agree with the technology appraisal guidance ‘newer drugs 
for epilepsy in adults’ from the National Institute for Clinical Excellence (NICE) from 
the United Kingdom (36). In the NICE guidance the newer antiepileptic drugs like 
lamotrigine are recommended for the management of epilepsy in people who have not 
benefited from treatment with the conventional antiepileptic drugs, or for whom the 
older drugs are unsuitable because of contraindications, interactions, or the person is a 
woman of childbearing potential.
Our study also illustrates that with the data presently available, decision analysis 
for drug treatment choice is very dependent on the trials included. Neurologists are 
counting on cost-effectiveness data in order to make rational choices (37). Therefore 
there is a need for prospective real-life studies comparing strategies of first and second-
line treatment and incorporating both cost and outcomes.
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INTRODUCTION
In this final chapter the individual studies regarding the value assessment of 
lamotrigine in daily practice will be put into the broader perspective of the value 
assessment of new drugs after their approval in general. For a discussion of the 
shortcomings and merits of the individual studies on the value of lamotrigine the reader 
is referred to the discussion section of the individual studies. 
At the moment of drug approval there is still a high degree of uncertainty about 
the value of a drug for daily clinical practice (1). This uncertainty applies to all value 
domains: safety, effectiveness and cost-effectiveness in daily practice (2). This is mainly 
due to the well known and accepted limitations of drug evaluation before approval. 
For the purpose of this discussion, the most important limitations include relatively 
short follow-up and small sample sizes, concern that compliance with the medications 
in the trial will exceed that in actual practice, different characteristics of patients and 
clinicians in the trial compared with actual practice (which may influence the efficacy 
and safety of the drug), poor reporting of side effects and “drug creep” (the tendency for 
drugs to be used for indications not studied in the trials) (3-5). The limited applicability 
of premarketing study results to daily practice reveals a “knowledge gap” that is relevant 
to health-care professionals as well as policy makers. The essence of postmarketing 
drug evaluation is to bridge this gap by increasing the amount of knowledge needed to 
make rational therapy decisions on an individual patient level as well as for populations. 
What the most sensible and efficient method is to bridge this gap is still unclear (1;6). 
At least three different study types can be used to evaluate new drugs and to rationalise 
drug policy (table 1): (1) randomised trials to determine efficacy and safety (which are 
required for approval) and (1a) real-world randomised, or pragmatic, trials to determine 
effectiveness and safety in regular practice; (2) decision analysis models; (3) prospective 
observational studies with targeted data collection and (3a) retrospective observational 
studies that use data collected routinely as part of the treatment process. 
In our approach to assess the value of a new drug, we used observational study 
methodologies in chapters 2 (prescription databases) and 3 (targeted data collection). 
A decision analysis model is presented in chapter 4. In our approach we addressed the 
value domains effectiveness and cost-effectiveness but not the value domain safety. 
THE POSITIONING OF NEW DRUGS USING EXISTING DATA (CHAPTER 2)
The position of a new drug within the therapeutic arsenal reflects its value in daily 
practice. Information on the incidence of drug use over time provides insight into 
the uptake of a new drug from the moment of market introduction and reflects the 
perceived effectiveness by prescribers and patients. Information on the retention time 
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(i.e. persistence) of a drug reflects its general effectiveness in daily practice over time. 
In chapter 2 the computerised registration of dispensed prescription drugs formed 
the cornerstone for population-based research on the positioning of lamotrigine. 
Prescription databases represent one of the most accurate means of measuring drug 
exposure as they do not suffer from recall bias and are virtually complete (6-9). The 
large prescription databases used in this thesis provide a relatively easy, inexpensive 
and rapid way of collecting information on drug use for a large number of patients. 
Furthermore, the link between the drugs prescribed and the prescribing physician offers 
the opportunity to examine patterns of drug use as well as prescribing patterns, as is 
done in chapter 2 sub 3. 
In chapter 2, three important aspects in the positioning of a new drug are addressed: 
(1) diffusion, (2) persistence and (3) selective prescribing.
Diffusion of a new drug in daily practice
The position of a new drug is subject to change after approval for use, because 
the drug suddenly becomes available for a much broader population of patients with 
regard to factors like demographics, disease severity and indication of use. This diffusion 
process has consequences for the market share of a new drug, therefore we studied 
the cost impact of a new drug in chapter 2 sub 2. The diffusion process of lamotrigine 
has been studied in chapter 2 sub 3. Most of the variance in the rate of diffusion of an 
innovation, from 49 to 87 per cent, can, according to the diffusion theory of Rogers, be 
explained by five attributes (10): 
1. Relative advantage: the degree to which an innovation is perceived as being better 
than the idea it supersedes;
2. Compatibility: the degree to which an innovation is perceived as being consistent with 
existing values, past experiences and needs of potential adapters;
3. Complexity: the degree to which an innovation is perceived as difficult to understand 
and use;
4. Trialability: the degree to which an innovation may be experimented with on a limited 
basis; 
5. Observability: the degree to which the results of an innovation are visible to others.
In addition to these attributes of an innovation, other variables, such as the extent of 
the pharmaceutical company’s promotion efforts, affect an innovation’s rate of diffusion 
(10-12). 
Opinion leaders are able to classify new drugs as innovative, semi-innovative or 
me-too drugs. The diffusion rates of innovative and me-too drugs in daily practice 
differ; nevertheless, drugs that are not considered to be innovative may still reach high 
diffusion rates (11;12). 
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The resultant of all the aforementioned factors that influence diffusion can be 
evaluated with databases of prescription records. These databases, however, lack 
important information to elucidate this process fully. For instance, prescription 
databases cannot adequately evaluate the impact of commercial influence, an essential 
component that is found to lower the barriers of adoption of semi-innovative drugs 
(13).
Persistence use of a new drug
Measuring patient persistency with drug therapy provides valuable information 
concerning the overall effectiveness of a drug in daily practice (14). Analysing automated 
records of prescriptions actually filled, as is done in chapter 2 sub 4, makes it possible to 
use a standardised measure from pharmacy data to define continuity of medication use 
and gaps in therapy. Although a prescription filled is not identical to a drug consumed, 
patterns of ongoing prescription filling represent an accurate way of estimating actual 
medication use in large populations (15). In chapter 3 sub.4 we showed that the 
structured form in which pharmacy data are registered allows for the valid measurement 
of persistence of drug use.
Disappointing persistence rates with long-term medication of various classes are 
found in daily practice (16-18). Low drug persistence can contribute substantially to 
the variability observed in the therapeutic outcome of drugs, i.e. the number needed 
for treatment may increase substantially and thus can markedly lessen the cost-
effectiveness of these drugs in daily practice. This should be considered as a word of 
caution that results obtained in daily clinical practice may differ substantially from 
those of randomised clinical trials. On the other hand, it is important to bear in mind 
the limitations of pharmacy databases. These databases lack potentially important 
information about the reason for prescribing, the physician’s rationale regarding 
changes in treatment decisions and baseline characteristics of the patient related to 
the outcome of therapy. Furthermore, it is important to realise that ongoing drug use, 
measured accurately using prescription data, is not necessarily equivalent to effective 
drug treatment, as is illustrated in chapter 3 sub.2.
Selective prescribing 
An important consideration in the assessment of a drug’s position in daily practice 
is that new drugs may be prescribed predominantly to patients with severe disease due 
to various factors, like normal human behaviour of physicians, treatment guidelines or 
marketing strategies (19). Selective prescribing is a general phenomenon that has been 
described for various classes of drugs; it should be considered a special form of allocation 
bias, as interventions are given to patients with large prognostic differences (20-22). 
Selective prescribing may have important consequences for the validity of observational 
studies if this aspect remains unrecognised in their analysis (20). 
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Ways to account for imbalances in baseline characteristics pertaining to the outcome 
are stratification of the patients in subgroups for these characteristics and adjusting for 
the differences in the analysis by multivariable techniques such as multiple logistic 
regression. Relatively newer techniques such as modelling propensity scores have shown 
to be valuable alternatives (23). For the outcome studies in this thesis (chapter 3.sub 2
& 3sub.3) the selection of control patients was avoided by using patients as their own 
control, which was done by comparing different periods of each patient’s medical history 
(20). 
Value assessment of new drugs with existing data 
The potential of prescription databases in the value assessment of new drugs is 
related to the fact that these data can be obtained on a population-base level, are 
relatively inexpensive and almost real-time available (table 1). At present, however, 
the potential of these data for use in health-economics and health-services research is 
hampered because detailed information from several domains (e.g. disease-, prescriber- 
and patient-related domains) is missing. The strengths of pharmacy data are enhanced 
if their weaknesses are overcome. The key to this is population-based record linkage of 
pharmacy data with other routine health data that is stored electronically, e.g. clinical 
data, diagnostic data or administrative data (24;25). At present, there is a lot of work to 
be done to overcome validity issues related to difficulties in identifying and extracting 
data, and the lack of uniformity in coding systems, definitions and data structure (25;26). 
Observational studies that use linked databases can play a key role in drug evaluation 
after regulatory approval. Some of the research questions (regarding the value of new 
drugs) posed by health technology assessment through randomised controlled trials can 
indeed be answered using this approach (25).
VALUE ASSESSMENT OF NEW DRUGS USING TARGETED DATA COLLECTION 
(CHAPTER 3)
We have proposed an observational model with targeted data collection for outcome 
research regarding the effectiveness of a new drug in daily practice. The proposed model 
is presented in figure 1, the different generic steps of this model are discussed below. 
Randomised versus non-randomised 
The key step in outcome research is to choose an appropriate design that produces 
interpretable findings. Our choice to use observational design is based on its lower 
costs and greater timeliness and because, due to the better generalisability of the 
results, a broader range of patients could be reached. In the present study design, 
multiple observations are made within a single group before and after the intervention 
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is implemented. In this mirror analysis, the ‘control’ observations are those made 
before the intervention is implemented (27). Due to the lack of randomisation, the 
observational study offers less opportunity to control for biases and confounding factors 
(28). The principal difference between experimental designs (randomised studies) and 
observational designs (non-randomised studies) can be characterised as a difference in 
their susceptibility to selection bias. It could also be argued that with the chosen study 
design one cannot differentiate a true drug effect from spontaneous variation (1). 
Recruitment of a diverse study population
Dutch privacy regulations include the law on persons registries and the law on 
individual health care agreement (29;30). The first law is a general law applicable to all 
areas of society and is about how to deal with confidentiality and privacy issues. The 
second law regulates the relationship between the patient and the health-care provider 
and how clinical data are kept within the context of individual health care provision. 
Both legal frameworks need to be considered if one wants to use patient data for 
research purposes. 
The goal of the recruitment step is to gather, within the boundaries of the legal 
framework, a diverse study population which reflects the range and distribution of 
patient characteristics, physician characteristics and treatment settings as observed 
in daily practice. The recruitment of patients from a community-based cohort 
accommodates this need for diversity, as prescriptions from the various treatment 
settings are processed at the pharmacy. Using pharmacy data enabled us to apply filter 
criteria for age, concomitant medication and length of follow-up in the recruitment 
procedure. Because information is available on eligible subjects who do not participate, 
it is possible to compare characteristics of participants to non-participants. In addition, 
we were able to select patients who had already discontinued lamotrigine treatment, 
because pharmacy data do not suffer from recall bias. However, this advantage was 
somewhat counteracted because those patients were less likely to give consent (chapter 
3.sub1). If patients were recruited prospectively through community pharmacies this 
might not have been an issue. Another advantage of the recruitment procedure 
proposed in this thesis, is that recruitment of patients for the study is independent of 
the initiation of the therapy. These two decisions are not always so distinct in studies 
conducted after approval where the physician initiates the drug and recruits the patient 
for evaluation (31). Sometimes such postmarketing studies lack scientific justification 
and are simply meant to increase sales, i.e. postmarketing seeding studies (32). 
We conclude that recruitment of patients for outcome research through community 
pharmacies complies with existing privacy legislation and that it is pragmatic and 
efficient.
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Measuring health outcomes
It is preferable that a broad set of relevant health outcomes is measured in the final 
step of outcome research. The selection of the outcomes to be measured is based on 
the most important anticipated effects of the intervention, taking into account those 
outcomes that are of the greatest relevance to the prescribers and the health-policy 
decision makers. This means that ideally the outcomes should include functional end 
points (like quality of life, satisfaction, compliance and costs) as well as the traditional 
end points (like effect on disease, adverse effects, morbidity and mortality) (33). In 
this case, the retrospective chart review proved to be the Achilles’ heel of the study. 
A considerable number of cases had to be excluded from the analysis, because the 
chart did not contain sufficient information to assess the effect of the lamotrigine 
intervention on the traditional end point of seizure reduction, let alone that information 
on functional end points was available. 
Observational design in value assessment
A dilemma remains the interpretation of the cost-effectiveness ratio obtained 
from observational studies, as a comparator group using a reference drug is either 
lacking or prone to bias. The vulnerability of retrospective, observational studies is that 
they depend on information that primarily serves a different goal (the registration of 
treatment aspects of an individual patient). Although it may seem odd that outcome 
information like seizure frequency is not consequently registered, this is frequently 
the case. In Chapter 4, sub 3 we showed that data on functional end points can be 
obtained with the use of a (cost) diary. Information on these end points can be obtained 
retrospectively with the items from this diary, but validity decreases if the recall period 
is more than two to three months (34). Therefore information on both traditional and 
functional end points is best obtained if these data are collected prospectively. The 
observational data could be used to validate and to enrich the findings of observational 
studies using administrative databases. 
CLINICAL AND HEALTH-POLICY DECISION MAKING (CHAPTER 4)
Rising drug costs and constraints in health-care budget have inspired the growing 
interest in clinical and health-policy decision making. Traditional cost-containment 
measures, like reference price systems, co-payment and reduction of the number of 
reimbursed drugs through the use of positive and negative lists, proved to be only 
partially successful (35). Recently three parallel trends were started in the Netherlands 
to establish incentives for efficient health-care delivery: 
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1. More decentralisation of drug policy responsibilities; e.g. the Dutch government 
considers giving the local health insurers the responsibility for the purchasing process 
for drugs; 
2. Usage of prescription restrictions; 
3. Usage of health economic analysis by reimbursement authorities (35;36).
Use of prescription guidelines (chapters 4.sub 1 & 2)
While reimbursement decisions traditionally applied to the officially registered 
indication, authorities like the Dutch Health Insurance Board (CVZ) have recently been 
imposing restrictions on the claim made for the drug (35). This illustrates the fact that 
total costs are important in the reimbursement decision, along with cost-effectiveness. 
Total costs are determined by the price of the drug, the total number of patients with 
the disease for whom the drug has been demonstrated to be efficacious and the number 
of patients without that disease for whom the drug is prescribed. The last, ‘off-label’, use 
is of considerable concern and can be caused by the use of the drug for other diseases 
or for patients with the same disease that could have benefited from older drugs. 
Prescription guidelines were developed to influence the use of new drugs, aiming at 
ensuring that patients who will benefit the most from these drugs will receive them, 
while at the same time limiting overall expenditure. There is little information available, 
however, to support the efficacy of prescription guidelines (37). 
The first prescription guideline issued by the Dutch Health Insurance Board was not 
sufficiently implemented in daily practice as can be concluded from chapters 4. sub 1
and 2. Translating guidelines into daily practice is known to be difficult, and even the use 
in practice of high-quality guidelines is not ensured (38;39). Argumentative policy theory 
predicts that when there is evidence of insufficient congruence in problem definition 
between policy makers and health-care professionals (i.e. the target audience), 
implementation is likely to fail. A physician’s clinical decision making is shaped by 
considerations of medication effectiveness, risk assessment, patient characteristics, 
drug reimbursement and cost (40). Dissemination and implementation in daily practice 
of a policy maker’s guideline focussing on cost containment solely will not be successful. 
Whereas guidelines are more likely to be adopted when the clinical context is reflected, 
professionals are involved and the guidance is based on stable and convincing evidence 
(41). 
Health economic analysis (chapter 4 sub.3)
Demonstration of efficacy, safety and quality of manufacture are currently recognised 
as the three hurdles that must be overcome in drug approval and the reimbursement 
process. To help evaluate and contain costs, several jurisdictions have imposed a 
fourth hurdle, one that requires the demonstration of a drug’s cost-effectiveness 
prior to establishing reimbursement (42). In the Netherlands a formal requirement 
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for consideration of economic evidence as part of the reimbursement decision was 
introduced in 2005. It is expected that the reimbursement of a majority of submitted 
drugs will be based on decision-analysis models (43;44). There are several ways in 
which modelling may be used in economic evaluations. These include generalising the 
results (from a clinical trial to clinical practice, or from one geographical location to 
another), extrapolating from the available data (e.g. beyond the follow-up period of the 
clinical trial, or to final endpoints based on intermediate endpoints), and synthesising 
comparisons between treatments in the absence of head-to-head comparisons (43). 
Despite the increasing use of modelling in economic evaluations, several concerns 
have been raised. These are related to the inappropriate use of clinical data and 
the difficulties of extrapolating the data. In chapter 4 sub .3 more general concerns 
about the transparency or validity of models were raised. This chapter shows that the 
researcher can frame the model to favour one intervention over another. It is therefore 
important that (1) All choices and assumptions that form the input for the model are 
transparently justified in the description of the model; (2) The robustness of the results 
is tested by undertaking a thorough sensitivity analysis and (3) The findings of model-
based economic evaluations are revisited, or updated, as more data become available. 
Otherwise, decision analysis models will continue to be considered a ‘black box’ by many 
people (43).
FUTURE PERSPECTIVES
The gap between the premarketing phase (clinical trials) and daily medical practice 
has been widely recognised. Clinical research should consistently produce an adequate 
supply of information to meet the needs of clinical and health-policy decision making, 
in other words: to close this gap. A strategy that can be applied is the introduction of 
an interactive, two-stage approach of marketing approval (45;46). In the two-stage 
appraisal discussed here the initial appraisal is done at the time of market approval, 
with the second appraisal done at a later date when more is known about the value of 
the new drug.
Stage 1: Initial approval
An initial appraisal of a new drug is done at the time of market approval. The new 
drug is reimbursed by default for a pre-determined number of years. This period enables 
an evaluation of the safety, effectiveness and pharmacoeconomic aspects of the new 
drug to be made. The initial appraisal is based on the quality of manufacture, efficacy 
and safety data from the regulatory approval trials and a preliminary cost-effectiveness 
analysis using decision models. In the initial approval stage a prescription guideline 
should be made in a joint effort by policy makers (e.g. Health Care Insurance Board) and 
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health-care professionals (e.g. associations of physicians) to come up with a (mandatory) 
clinical guideline, which incorporates clinical guidance, health technology and economic 
aspects of the new drug. The prescription guideline tries to translate the experimental 
experience with the drug and balances it with uncertainty, evidence and experience with 
therapeutic alternatives and costs. On the basis of the prescription guideline the new 
drug becomes available to those who need it, within restricted indications of use. 
Stage 2: Second approval
After the initial approval stage data on the outcome of the drug has to be 
accumulated prospectively, with the use of both routine data collection and targeted 
data in order to for the second appraisal to be done. The outcome data are provided 
by patients and providers and contain information on both traditional end points 
(disease parameters, adverse drug reactions) and functional endpoints (quality of life, 
cost). At present, postmarketing studies aim at only one value domain, namely safety. 
It is, however, difficult to make sense of the concept of safety without the vantage 
point of special patient populations and therapeutic goals (2). Assessments targeting 
both effectiveness and safety are more informative than those evaluating safety alone. 
The preferred way to collect these data is by means of an electronic data file, because 
this provides a rational, standardised method of data collection. An advantage of this 
approach is that it is more informative than the present postmarketing surveillance of 
new drugs, which aims at safety data only (2). 
During the second stage, the collected data can be analysed with the use of different 
observational study designs or pragmatic trials. These studies generate evidence on use, 
effectiveness and safety outcomes and cost, which form the basis for a second approval 
decision. This decision is best made by a post-marketing body (‘centre of excellence’) that 
is independent from the agencies responsible for initial approval and reimbursement. 
This separation of powers is essential to ensure objectivity and to avoid conflict of 
interest. The second approval is completed when:
• properly structured effectiveness and economic endpoints have been completed; 
• sufficient number of patients have been exposed to detect rare (e.g. 1 in 10,000) 
adverse drug reactions; and 
• the recommended dose has been clearly established (46). 
This two-stage approach should create an operational infrastructure in which the 
value of a drug is assessed and constantly re-assessed (figure 2). The latter aspect, 
continuous reassessment, is vital to obtain the import goals of this staged approach:
1. Get the evidence to prescribers. The challenge, for regulators and health-policy 
makers, is to see that the necessary information is developed and disseminated 
appropriately. As to the greater part of medical interventions, it is broadly acknowledged 
that physicians do not change their behaviour only on the basis of information 
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published in journals (5). Additional methods are needed, such as summaries of tailor-
made information, simple practice guidelines and audit and feedback. These methods 
should be used to encourage cost-effective prescribing. The aim is to promote the use 
of certain drugs for cost-effective indications, as well as discourage the cost-ineffective 
use of drugs.
2. Evaluate and constantly re-evaluate the evidence. Decisions about the 
reimbursement of drugs should be made on an ongoing basis. All parties concerned 
must be fully aware that an initial decision to fund a drug will be regularly re-evaluated 
and may be reversed. The latter may be the case for a drug with an inappropriately high 
utilisation in a group of patients in whom its cost-effectiveness has not been established, 
or the emergence of new information about unexpected side effects (5). 
This new strategy will require more investments in research and outcome 
assessment, and there will be considerable discussion about who should pay for what 
(47). However, in the end the benefits generated by the more appropriate use of drugs 
will be considerable, as information about drug effects is an extremely valuable resource 
for sound therapeutic choices and future product development (2). 
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SUMMARY
In this thesis several pharmacoepidemiologic approaches to the value assessment of 
lamotrigine, a new antiepileptic drug, in daily clinical practice are described. Epilepsy is 
a neurological disorder characterised by recurrent, unprovoked seizures. The incidence of 
epilepsy in developed countries has been estimated to be around 50 cases per 100,000
people per year. The severity of the condition and the prognosis vary according to the type 
of epilepsy. Drug therapy is the mainstay of epilepsy treatment, and the aim is to abolish 
seizures completely, while keeping the side effects of treatment to a minimum.
The field of antiepileptic drug therapy has been an unusual one, being/having been 
dominated for decennia by older drugs. These older antiepileptic drugs have several 
limitations, among them the adverse effects on the central nervous system and other side 
effects, the potential to interact with numerous drugs and the effects of these drugs on 
the unborn child. 
With the introduction of lamotrigine, in 1995, a new treatment option was offered to 
patients with epilepsy. A reimbursement decision for lamotrigine was taken almost two 
years after market approval. The late reimbursement decision was a consequence of the 
high acquisition cost of lamotrigine and the relative lack of information about up-to-date 
clinical (added) value at the moment of approval. This deadlock was ended when the Dutch 
Health Care Insurance Board imposed restrictions on the claim made for the drug. These 
restrictions were included in a prescribing guideline that was subsequently published. The 
Lamotrigine Prescription Guideline was the first prescription guideline in the Netherlands 
aiming at cost containment. The case of lamotrigine, among others, illustrates that 
registration and reimbursement procedures have become clearly distinct processes.
In this thesis, the value of lamotrigine in daily clinical practice, as well as the 
implementation of the Lamotrigine Prescription Guideline have been assessed.
In Chapter 1, the scope and objective of this thesis are described. It outlines the 
thinking about drug evaluation by presenting the four phases of drug evaluation: efficacy, 
accessibility, effectiveness and cost-effectiveness. Even after marketing approval of a new 
drug, much is still unknown about the drug, its safety and its effects at the start of use in 
daily practice. Within this scope, the objective of this thesis was to gain insight in the value 
of lamotrigine in daily clinical practice using observational study designs.
Chapter 2 comprises four studies describing the positioning of new antiepileptic drugs 
in general, and lamotrigine in particular. Chapter 2, sub 1 reviews the available, published 
pharmacological information on the new antiepileptic drugs. The current insights on 
mechanisms of action, efficacy, effectiveness, adverse effects, pharmacokinetics are 
discussed, and selection criteria for the appropriate use of the new antiepileptic drugs are 
presented.
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Chapter 2, sub 2 describes the impact new antiepileptic drugs had on the volume 
and the cost of antiepileptic drugs in the Netherlands during 1995 - 2001. For this study, 
data were obtained from the Dutch Drug Information Project (GIP). The GIP is a unit 
of the Dutch Health Care Insurance Board. GIP databases contain data of extramurally 
prescribed drugs, the statistics refer to 5.6 million persons compulsorily insured in 2000, 
which is about 55% of all compulsorily insured Dutch. 
The total volume of antiepileptic drugs in 1995 was 5.4 DDD per 1,000 insured persons 
per day in 1995, and increased by 130% to 7.0 DDD per 1,000 insured persons per day in 
2001. The larger part of this increase, 60%, was accounted for by the new antiepileptic 
drugs. Gabapentin, lamotrigine and oxcarbazepine were the most frequently prescribed 
new antiepileptic drugs. The volume share of new antiepileptic drugs increased from 5% 
in 1995 to 18% in 2001. The cost of antiepileptic drugs amounted to 1 21.5 million in 
1995 and rose to 1 47 million in 2001; 80% of this increase was due to the introduction 
of new antiepileptic drugs.
Chapter 2, sub 3 evaluates, in a retrospective follow-up using GIP data, the diffusion 
process of lamotrigine into daily clinical practice. Understanding the process of diffusion 
is important in the evaluation of the place in therapy of lamotrigine, its effectiveness in 
real life and its cost consequences. The study population consisted of a total of 29,718
patients who were prescribed carbamazepine, phenytoin, valproate or lamotrigine for 
the first time during 1996 - 2000. On average, the market share of lamotrigine was less 
than 10% of new users. It was found that lamotrigine patients had more frequently 
used one or more antiepileptic drug prior to the index date when compared to users 
of one of the conventional antiepileptic drugs (OR 35.5; 95%CI 31.6 – 39.9). In addition, 
prescribers of lamotrigine were more often neurologists (OR 2.8; 95%CI 2.6 – 3.0) and 
the prevalence of psychotropic medication was significantly lower (OR 0.35; 95%CI 0.31
– 0.39) with users of lamotrigine than in users of conventional antiepileptic drugs. As 
time progressed since its introduction in 1995, more patients with characteristics not 
included in clinical trials started using lamotrigine. The number of patients outside of 
the age category 18 – 65 increased from 14% in 1997 to 32% in 2000. The number of 
patients using lamotrigine without prior use of any antiepileptic drug increased from 
3% in 1997 to 16% in 2000. Also, the number of patients with off-label use markers in 
their history increased significantly.
Chapter 2, sub 4 describes a cohort study that used dispensing data from community 
pharmacies. A total of 1,428 out of 1,586 Dutch pharmacies (90%) received a request 
in January 2001 to provide anonymous data of all patients to whom lamotrigine was 
dispensed. The selected pharmacies used one of the three major pharmacy computer 
systems in the Netherlands. These pharmacies serve an open population of approximately 
13 million persons. A total of 1,056 pharmacies (74% response) responded to our request 
to retrieve the prescription data of all patients to whom lamotrigine had been dispensed. 
The responding pharmacies covered both large and small pharmacies and both rural and 
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highly urbanised areas. In all, 3,598 new users of lamotrigine were identified during the 
observation period. These patients could be followed for a mean observation window 
of 4.6 years per patient. Baseline characteristics and usage patterns were evaluated 
for all 3,598 first-time users of lamotrigine. On average, patients were using two other 
antiepileptic drugs at the start of lamotrigine therapy and approximately 6% of the 
patients had no history of prior antiepileptic drug use. The discontinuation rate was 25% 
after one year, and approximately 32% at the end of the 5-year study. Addition of another 
drug or discontinuation, a global measure of effectiveness, was seen in more than half 
of the population three years after the start of therapy. The population of randomised 
controlled trials differed from the study cohort with respect to age, concurrent use of 
antiepileptic drugs and length of follow-up. This study showed that lamotrigine therapy 
failed in a considerable number of patients. Furthermore, it showed that data from 
randomised controlled trials cannot easily be extrapolated to daily clinical practice.
In Chapter 3, four studies are presented concerning the outcomes of lamotrigine in 
daily clinical practice. These studies were based on a population-based cohort of patients 
with refractory epilepsy who were recruited via community pharmacists. Chapter 3, 
sub 1 describes the results of the recruitment procedure. A total of 466 community 
pharmacists were asked to help with the recruitment of adult patients (n = 1,819) who 
used lamotrigine. Pharmacists did not inform 183 patients (10%). Of the remaining 
1,636 patients, 968 (59%) gave consent; 101 (6%) actively refused, and 567 (35%) did 
not respond. We found that higher age (HR 1.49, 95% CI 1.22 – 1.81), highly urbanised 
regions (HR 1.23, 95% CI 1.05 – 1.43), chronic disease scores above six (HR 1.42, 95% CI 
1.20 – 1.96) and use of two or more antiepileptic drugs are significantly related to non-
consent. Also, addition of another antiepileptic drug and discontinuation of lamotrigine 
were significantly related to non-consent. Our conclusion is that pharmacy-based 
recruitment has the potential to reach a broad population, but that selection bias may 
lead to the misrepresentation of outcome data. 
Chapter 3, sub 2 assesses the effectiveness of lamotrigine in a population-based 
cohort of refractory epilepsy patients and its tolerability in this population. Of the 968
patients who gave their consent for chart review, a sample of 368 patients was selected 
for the actual review. Effectiveness of lamotrigine therapy was assessed during the first 
year of use, with patients serving as their own controls. Effectiveness was measured 
by 1) reduction in seizure frequency and 2) retention time. Effectiveness could only 
be assessed in 165 patients; assessment in the remaining patients was not possible 
due to various reasons, such as insufficient medical chart information. Lamotrigine 
was effective in 40% of the patients who had been prescribed lamotrigine because of 
insufficient seizure control (n=112), with 14% of these 112 patients becoming seizure 
free. Lamotrigine was effective in 63% of the patients who received the drug because 
other antiepileptic drugs were not tolerated (n=53). Logistic regression analysis showed 
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that several characteristics were significantly associated with effectiveness in the seizure 
control group. Both longer duration of epilepsy (OR 0.96, 95% CI: 0.94 - 0.99) and higher 
seizure frequency (OR 0.91, 95% CI: 0.84 - 0.97) were inversely related to lamotrigine 
effectiveness. The number of antiepileptic drugs used before the start of lamotrigine 
was significantly correlated to the successful outcome of lamotrigine therapy; the 
success rate in patients who used one antiepileptic drug previously being at least 
threefold higher than in patients who used two or more antiepileptic drugs previously. 
It can be concluded from the present study that lamotrigine is an effective treatment 
option for patients with varying needs, including those with inadequate seizure control 
and intolerable side effects.
Chapter 3, sub 3 describes a cost-effectiveness analysis based on the data from 
the cohort of patients presented in Chapter 3, sub 2. All health outcomes and resource 
utilisation were recorded for the two-year period, and epilepsy-related direct medical cost 
was estimated from a health-care perspective. In the analysis, the cost was calculated by 
multiplying the epilepsy-related resource use of each patient with unit cost. Overall, the 
total medical cost was 1 453 higher in the first year of lamotrigine therapy than in the 
preceding year. Lamotrigine was effective in 47% of all the patients, making the resultant 
incremental cost per successfully treated patient 1 954 per year.
In Chapter 3, sub 4, data from pharmacy records (Chapter 2, sub 4) and from medical 
charts (Chapter 3, sub 2) were combined. In this study the validity of electronic pharmacy 
data was assessed for the criteria discontinuation of lamotrigine, addition of another 
antiepileptic drug and retention time. For 29 of the 37 (sensitivity 78.4%) patients who 
discontinued lamotrigine therapy according to the medical record, this event could also 
be assessed on the basis of pharmacy records. The sensitivity of the addition criterion 
was 83.3%; in 15 of the 18 patients who had another antiepileptic drug added after start 
of lamotrigine therapy (noted in the chart record), this event could also be assessed on 
the basis of pharmacy records. The correlation between the retention time determined 
from pharmacy records and from medical records was high (Pearson r = 0.91). The 
conclusion of this study is that pharmacy records are a valid way of measuring the 
discontinuation, addition and retention time of drugs, and are therefore a valuable tool 
in pharmacoepidemiology.
Chapter 4 goes into clinical and health-policy decision making in three subchapters. 
Chapter 4, sub 1 describes the results of a survey held among 490 Dutch neurologists to 
evaluate the implementation and assessment of the Lamotrigine Prescription Guideline. 
Of the 232 respondents, only 51 (22%) were familiar with the guideline. Of these 51
neurologists, 80% comply either completely or largely with the guideline. Over 90% of 
all respondents are in favour of a guideline, preferably developed and evaluated by the 
medical profession. A majority (58%) of the respondents was positive about taking cost 
containment measures into consideration in the development of guidelines.
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In Chapter 4, sub 2 we present the results of an argumentative policy analysis 
regarding the Lamotrigine Prescription Guideline. A key feature of this argumentative 
policy theory is the acknowledgement that different stakeholders may define policy 
problems quite differently, which may lead to varying and sometimes opposing 
appreciation of proposed solutions. The results indicate that the problem definitions of 
policy makers and practising neurologists differed widely, and that the policy measure 
conflicted with certain professional beliefs. In such cases, the theory of argumentative 
policy predicts that policy is unlikely to succeed unless policy makers take action to 
ensure a greater congruence in interpretative frames between themselves and their 
target population. 
In Chapter 4, sub 3 a decision analysis was carried out comparing effectiveness and 
cost of six treatment strategies comprising carbamazepine, lamotrigine and valproate as 
first-line and second-line drugs. Three outcome groups were defined: complete success, 
partial success and failure. Data on seizure control and failure due to adverse effects were 
derived from literature, cost and quality of life data were obtained from 71 patients. The 
probability of obtaining complete success varied from 64% (valproate-carbamazepine 
strategy) to 74% (lamotrigine-valproate strategy). The strategy lamotrigine-valproate 
was more effective than the least expensive strategy carbamazepine-valproate, but cost 
more for each additional effectively treated patient. Subsequent analysis showed that 
changing the inclusion criteria used in the selection of the studies from the literature 
had an important effect on cost-effectiveness ratios of the various strategies. The 
conclusion from the decision analysis is that lamotrigine first-line strategies did not 
prove to be cost-effective. However, lamotrigine second-line strategies can be cost-
effective depending on the willingness to pay for patient improvement.
The general discussion (Chapter 5) aims at putting the individual studies regarding 
the value assessment of lamotrigine into a broader perspective. There is still a high 
degree of uncertainty about the value of a drug for daily clinical practice at the moment 
of drug approval, this is due mainly to the well known and accepted limitations of drug 
evaluation before approval, such as the relatively small, selected study populations and 
the limited study duration. Observational studies, either with target data collection 
or administrative databases, may provide additional information about the safety, 
effectiveness and cost-effectiveness of a new drug in daily practice. A staged approach 
for this way of value assessment is presented in the final paragraph of this chapter.
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SAMENVATTING
In dit proefschrift staat de waardebepaling van het nieuwe anti-epilepticum 
lamotrigine in de klinische praktijk centraal. Epilepsie is één van de frequentst 
voorkomende neurologische ziektebeelden, de incidentie in westerse landen wordt 
geschat op circa 50 patiënten per 100.0000 inwoners. Het is een aandoening die ontstaat 
door spontane, plotselinge en kortdurende overmatige ontladingen van hersencellen, die 
functiestoornissen veroorzaken afhankelijk van het hersengedeelte waar deze cellen zich 
bevinden. De behandeling van epilepsie berust voornamelijk op het onderdrukken van 
de aanvallen door medicamenteuze interventie met anti-epileptica. De meest gebruikte 
anti-epileptica zijn al meer dan 30 jaar beschikbaar, deze geneesmiddelen onderdrukken 
de aanvalsfrequentie bij de meeste patiënten goed. Toch is bij 30-40% van de patiënten 
het behandelingsresultaat onvoldoende; de patiënt wordt niet aanvalsvrij of heeft 
onacceptabele bijwerkingen. Daarnaast worden de oudere anti-epileptica gekenmerkt 
door een groot interactiepotentieel en door een verhoogde kans op vruchtbeschadiging. 
De komst van lamotrigine, in 1995, heeft het aantal behandelstrategieën voor patiënten 
met epilepsie vergroot. Het geneesmiddel kwam echter niet direct voor vergoeding 
door zorgverzekeraars in aanmerking. Redenen hiervoor waren de hogere kostprijs van 
lamotrigine en onvoldoende duidelijkheid omtrent de meerwaarde van lamotrigine 
ten opzichte van de oudere anti-epileptica. In 1997 doorbreekt het College voor 
zorgverzekeringen (CVZ) de vergoedingsimpasse. Het College voor zorgverzekeringen 
stelt het protocol ‘Gebruik Lamotrigine’ op, met als doelstelling het gebruik te beperken 
tot die situaties waarin lamotrigine een therapeutische meerwaarde bezit. Essentie 
van het protocol is dat lamotrigine pas overwogen dient te worden wanneer de 
mogelijkheden van behandeling met bestaande middelen optimaal benut zijn. Niet 
eerder zijn in Nederland via een protocol nadere voorwaarden gesteld aan de aanspraak 
op een geneesmiddel. 
Hoofdstuk 1 is een algemene inleiding waarin nader wordt ingegaan op 
het ziektebeeld epilepsie en de behandeling hiervan. Ook worden de vier fasen 
voor de waardebepaling van een geneesmiddel geïntroduceerd: werkzaamheid, 
toegankelijkheid, effectiviteit en doelmatigheid. Gegevens omtrent de werkzaamheid 
van een geneesmiddel worden verzameld in gerandomiseerde klinische onderzoeken in 
strikt geselecteerde patiëntpopulaties. Direct na registratie van een nieuw geneesmiddel 
is er dan veelal nog weinig bekend van de effectiviteit en veiligheid in de dagelijkse 
praktijk, een situatie waarin het geneesmiddel ook aan andere patiëntpopulaties 
wordt voorgeschreven. Observationeel, farmacoepidemiologisch onderzoek is geschikt 
om de waarde van een geneesmiddel in de dagelijkse praktijk nader te bestuderen. 
Dit proefschrift bundelt een aantal observationele onderzoeken naar de waarde van 
lamotrigine in de dagelijkse praktijk. 
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Hoofdstuk 2 beschrijft de plaatsbepaling van de nieuwe anti-epileptica en in 
het bijzonder die van lamotrigine. Hoofdstuk 2.1 is een literatuuronderzoek over de 
nieuwe anti-epileptica. Hun werkingsmechanismen, werkzaamheid, effectiviteit, 
bijwerkingenprofiel en farmacokinetiek worden beschreven en diverse keuzecriteria 
worden aangereikt.
In hoofdstuk 2.2 staan de volume- en kostenontwikkeling van anti-epileptica in 
Nederland centraal. Om het gebruik van anti-epileptica te onderzoeken zijn gegevens 
ontleend aan het Geneesmiddel Informatie Project (GIP) van alle in de periode 1995
– 2001 afgeleverde anti-epileptica. Het aantal Defined Daily Doses (DDD) per 1000
verzekerden per dag stijgt met 130% van 5,3 DDD per 1000 verzekerden per dag in 
1995 naar 7,0 in 2001. De nieuwe anti-epileptica dragen voor 60% bij aan deze stijging. 
Hun aandeel stijgt van 0,27 DDD per 1000 verzekerden per dag (5%) in 1995 naar 
1,2 DDD per 1000 verzekerden per dag (17,5%) in 2001. Gabapentine, lamotrigine en 
oxcarbazepine zijn de meest voorgeschreven nieuwe anti-epileptica. 
In 1995 bedragen de totale kosten van farmaceutische zorg voor anti-epileptica 
1 21,5 miljoen. De bijdrage van de conventionele anti-epileptica is in dat jaar 1 17,8
miljoen (83%). In 2001 zijn de totale kosten meer dan verdubbeld en wordt 1 47
miljoen uitgegeven aan farmaceutische zorg. Met name de introductie van nieuwe 
anti-epileptica heeft geleid tot deze kostenstijging. Van de totale kostenstijging komt 
80% op rekening van de nieuwe anti-epileptica. Hiermee stijgt het marktaandeel van 
de nieuwe antiepileptica van 1 3,8 miljoen (17%) in 1995 naar 1 24,2 miljoen (52%) in 
2001.
In hoofdstuk 2.3 staat het verspreidingsproces (diffusie) van lamotrigine in de 
dagelijkse praktijk beschreven. In dit onderzoek wordt gebruik gemaakt van de GIP 
gegevens van 29.718 patiënten die lamotrigine of één van de oudere anti-epileptica 
carbamazepine, fenytoïne of valproïnezuur gebruiken. Centraal staat hoeveel patiënten 
met lamotrigine starten en hoe hun karakteristieken verschillen van die van patiënten 
die met de oudere anti-epileptica starten. Het marktaandeel van lamotrigine is 
gemiddeld minder dan 10% en daarmee beduidend lager dan dat van carbamazepine 
of valproïnezuur. In vergelijking met de oudere anti-epileptica wordt lamotrigine vaker 
voorgeschreven aan patiënten met een historie van andere anti-epileptica (OR 35,5; 
95%CI 31,6 – 39,9) en door neurologen (OR 2,8; 95%CI 2,6 – 3,0). Patiënten die met 
lamotrigine starten hebben minder vaak psychotropica gebruikt dan patiënten die met 
de oudere anti-epileptica starten (OR 0,35; 95%CI 0,31 – 0,39). Naarmate er meer tijd 
na de introductie van lamotrigine verstrijkt wordt lamotrigine meer voorgeschreven 
aan patiëntpopulaties die niet in de registratieonderzoeken zijn geïncludeerd. Het 
aandeel patiënten buiten de leeftijdscategorie 18-65 jaar stijgt van 14% in 1997 naar 
32% in 2000. Het aantal patiënten dat lamotrigine als eerste anti-epilepticum krijgt 
voorgeschreven stijgt van 3% in 1997 naar 16% in 2000. Ook worden er in de loop van 
de tijd meer psychotropica in de voorgeschiedenis van patiënten die met lamotrigine 
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starten gezien; dit zou kunnen duiden op een toenemend gebruik van lamotrigine voor 
andere indicaties dan epilepsie.
In hoofdstuk 2.4 worden gegevens van een landelijk cohort lamotrigine 
gebruikers beschreven. In dit hoofdstuk staan de wijze van gegevensverzameling en 
de patiëntkarakteristieken centraal. Geanonimiseerde prescriptiegegevens van 1.056
openbare apotheken in Nederland zijn gebruikt om een cohort van 3.598 patiënten 
die starten met lamotrigine te beschrijven. De karakteristieken van het landelijke 
cohort verschillen, qua leeftijd, medicatiehistorie en duur van follow-up, met die van de 
patiënten die geïncludeerd zijn in de registratieonderzoeken. In dit onderzoek wordt de 
retentietijd van lamotrigine als een grove maat voor de effectiviteit van dit geneesmiddel 
beschouwd. De retentietijdanalyse laat zien dat na een jaar 25% van de patiënten met 
lamotrigine is gestopt en na drie jaar follow-up 32%. Na drie jaar follow-up is bij meer 
dan de helft van de patiënten lamotrigine gestopt of is er een ander anti-epilepticum 
toegevoegd aan de therapie. 
De effectiviteit van lamotrigine in de dagelijkse praktijk wordt in hoofdstuk 3
beschreven. De onderzoeken in hoofdstuk 3 zijn gebaseerd op een landelijk cohort van 
patiënten met refractaire epilepsie. Hoofdstuk 3.1 beschrijft hoe de patiënten voor het 
onderzoek gerekruteerd zijn. In totaal zijn 466 openbare apotheken verzocht om 1.819
lamotrigine gebruikende patiënten aan te schrijven met het verzoek mee te doen 
met het statusonderzoek. In 183 gevallen heeft de openbare apotheker besloten het 
verzoek niet door te sturen. Van de resterende patiënten hebben 968 patiënten met 
het verzoek ingestemd (59%), 101 patiënten weigeren deelname aan het onderzoek 
(6%) en 567 patiënten hebben nooit gereageerd op het verzoek (35%). Uit de analyse 
van karakteristieken van de verschillende responsgroepen blijkt dat hogere leeftijd (HR 
1,49, 95% CI 1,22 – 1,81), het wonen in stedelijke regio’s (HR 1,23, 95% CI 1,05 – 1,43), 
een chronische ziektescore hoger dan zes (HR 1,42, 95% CI 1,20 – 1,96) en het gebruik 
van twee of meer anti-epileptica in de voorgeschiedenis gerelateerd zijn aan het niet 
verlenen van toestemming aan het onderzoek. Ook het stoppen van lamotrigine of het 
toevoegen van een ander anti-epilepticum zijn gerelateerd aan het niet verlenen van 
toestemming. De conclusie is dat via openbare apotheken een brede patiëntenpopulatie 
wordt bereikt, echter door het optreden van selectiebias kan vertekening van de 
uitkomstgegevens optreden.
In hoofdstuk 3.2 wordt een retrospectief follow-up onderzoek gepresenteerd. Bij 
368 patiënten zijn de statusgegevens geanalyseerd om een beeld te krijgen van de 
effectiviteit van lamotrigine bij patiënten met refractaire epilepsie. De effectiviteit van 
lamotrigine is bestudeerd gedurende het eerste jaar van gebruik, patiënten dienden 
hierbij als hun eigen controle. De effectiviteit van de lamotriginebehandeling is 
bepaald aan de hand van 1) reductie in de aanvalsfrequentie en 2) de retentietijd van 
lamotrigine. Door diverse redenen, waaronder de beperkte hoeveelheid informatie in 
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diverse medische dossiers, zijn uiteindelijk de gegevens van 165 patiënten geanalyseerd. 
Lamotrigine is effectief bij 40% van de patiënten die het geneesmiddel kregen vanwege 
onvoldoende aanvalscontrole met andere anti-epileptica (n=112) en 14% van deze 112
patiënten werd aanvalsvrij gedurende het eerste jaar van behandeling met lamotrigine. 
Lamotrigine is effectief bij 63% van de patiënten die het geneesmiddel kregen vanwege 
onacceptabele bijwerkingen van andere anti-epileptica (n=53). De uitkomst van de 
behandeling van lamotrigine is, bij de onvoldoende aanvalscontrole groep, gerelateerd 
aan bepaalde patiëntkenmerken. Zowel een langere ziektegeschiedenis van epilepsie (OR 
0,96, 95% CI: 0,94 – 0,99) en een hogere aanvalsfrequentie (OR 0,91, 95% CI: 0,84 – 0,97) 
zijn negatief gerelateerd aan de effectiviteit van lamotrigine. Het aantal anti-epileptica 
in de voorgeschiedenis is eveneens gerelateerd aan een succesvolle behandeling met 
lamotrigine; patiënten met slechts één anti-epilepticum in de voorgeschiedenis hebben 
een drie keer hogere kans op een effectieve behandeling met lamotrigine dan patiënten 
met drie anti-epileptica in hun voorgeschiedenis. Geconcludeerd wordt dat lamotrigine 
een anti-epilepticum is met een toegevoegde waarde bij patiënten met onvoldoende 
aanvalscontrole en bij patiënten met onacceptabele bijwerkingen op andere anti-
epileptica. 
Hoofdstuk 3.3 beschrijft een kosteneffectiviteitanalyse op basis van de gegevens van 
het patiëntencohort gepresenteerd in hoofdstuk 3.2. In dit hoofdstuk worden de directe 
medische kosten berekend in het jaar voor en na start van lamotrigine en gerelateerd 
aan de effectiviteit van lamotrigine. In het eerste jaar na de start van lamotrigine nemen 
de totale medische kosten toe met 1 453. Lamotrigine is bij 47% van de patiënten 
effectief, dit resulteert in een incrementele kosteneffectiviteit ratio van 1 954 per 
effectief behandelde patiënt per jaar.
Hoofdstuk 3.4 is een validatiestudie, hierin worden de prescriptiegegevens uit 
hoofdstuk 2.4 gekoppeld aan de statusgegevens uit hoofdstuk 3.2. De validiteit van de 
farmacoepidemiologische parameters van stoppen, add-on en retentietijd zijn in dit 
hoofdstuk geanalyseerd. Bij 29 van de 37 (sensitiviteit 78.4%) patiënten die stoppen met 
lamotrigine volgens de informatie in de medische status wordt dit ook geconcludeerd op 
basis van de analyse van de prescriptiegegevens. De sensitiviteit van de add-on parameter 
is 83.3%, bij 15 van de 18 patiënten die een ander anti-epilepticum toegevoegd krijgen 
na de start van lamotrigine (volgens de statusgegevens) wordt dit ook geconcludeerd op 
basis van een analyse van de prescriptiegegevens. Er is een goede correlatie tussen de 
retentietijd bepaald op basis van de prescriptiegegevens en de retentietijd bepaald uit 
de statusgegevens (Pearson r = 0.91). De conclusie is dat prescriptiegegevens een valide 
bron zijn om stoppen, toevoegen en retentietijd van geneesmiddelen te bepalen.
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Hoofdstuk 4 behandelt diverse aspecten van de klinische en gezondheidseconomische 
besliskunde. Hoofdstuk 4.1 beschrijft de resultaten van een vragenlijst gericht op de 
bekendheid van het College voor zorgverzekeringen (CVZ) protocol ‘Gebruik Lamotrigine’ 
onder de doelgroep van neurologen. De vragenlijst is gestuurd aan 490 neurologen en de 
vragenlijst is door 232 neurologen geretourneerd. Slechts 51 neurologen waren bekend 
met het protocol ‘Gebruik Lamotrigine’ en hiervan gaf 80% aan de strekking van het 
protocol te volgen. De noodzaak van een epilepsierichtlijn wordt door meer dan 90% 
van alle respondenten onderschreven. Zij spreken de voorkeur uit dat een dergelijke 
richtlijn wordt opgesteld en geëvalueerd door de beroepsgroep. In meerderheid 
(58%) zijn de respondenten positief over het opnemen van maatregelen betreffende 
kostenbeheersing in een dergelijk protocol.
Hoofdstuk 4.2 gaat nader in op de onbekendheid van het protocol ‘Gebruik 
Lamotrigine’ onder de beroepsgroep. In dit hoofdstuk worden de resultaten van een 
argumentatieve beleidsanalyse gepresenteerd aangaande het protocol. Kern van de 
argumentatieve beleidsanalyse is dat de kans op de gewenste gedragsverandering 
niet alleen bepaald wordt door de keuze en de kwaliteit van de inzet van een 
beleidsinstrument (het protocol ‘Gebruik Lamotrigine’), maar ook door de mate waarin 
de gevraagde handelswijze zinvol is in de ogen van de doelgroep, dat wil zeggen binnen 
de handelingstheorie van de doelgroep. De resultaten van onze analyse laten zien dat 
de beleidsmakers en neurologen vanuit een geheel andere, soms tegenovergestelde, 
invalshoek onderwerpen zoals de inzet van nieuwe anti-epileptica benaderen. Dit geeft 
aan dat de inzet van het protocol als beleidslijn weinig kans tot slagen heeft en dat 
beleidsmakers actiever moeten trachten hun handelingstheorie te laten overlappen met 
de handelingstheorie van de doelgroep.
Hoofdstuk 4.3 beschrijft een economische beslismodel naar de effectiviteit en de 
behandelkosten van zes verschillende behandelopties voor nieuwe patiënten met 
epilepsie. Modelleren in kosteneffectiviteitsonderzoek heeft tot doel gegevens uit 
verschillende bronnen bijeen te brengen. In dit model wordt de effectiviteit van de 
verschillende behandelopties gebaseerd op literatuurgegevens; de kosten worden 
gebaseerd op de gegevens uit de kostendagboeken van 71 patiënten met epilepsie. In 
het model worden behandelopties van carbamazepine, lamotrigine en valproïnezuur 
met elkaar vergeleken. De effectiviteit (aantal aanvalsvrije patiënten) varieerde van 
64% (valproïnezuur-carbamazepine strategie) tot 74% (lamotrigine- valproïnezuur 
strategie). De lamotrigine-valproïnezuur was effectiever dan de goedkoopste strategie 
carbamazepine-valproïnezuur, maar tegen zeer aanzienlijke extra kosten per extra 
effectief behandelde patiënt. Uit nadere analyses blijkt dat het model sterk kan worden 
beïnvloed door de beschikbare literatuurgegevens omtrent de effectiviteit van de diverse 
behandelopties. De conclusie uit het beslismodel is dat er geen aanwijzingen zijn die de 
doelmatigheid van lamotrigine als middel van eerste keuze onderschrijven. 
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Hoofdstuk 5 tracht de bevindingen van de individuele hoofdstukken aangaande 
de waardebepaling van lamotrigine in een breder perspectief te plaatsen. Er is een 
toenemende behoefte om de waarde van een geneesmiddel na de introductie in de 
dagelijkse praktijk goed te evalueren. Observationele onderzoeken, gebruikmakende van 
prescriptiedatabases of van statusgegevens kunnen een bijdrage leveren aan de kennis 
omtrent de effectiviteit, de veiligheid en de doelmatigheid van een nieuw geneesmiddel. 
In de afsluitende paragraaf van hoofdstuk 5 wordt hiertoe een aanzet gegeven. 
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